Pharmacokinetic O
properties O
of O
abacavir B-DRUG
were O
not O
altered O
by O
the O
addition O
of O
either O
lamivudine B-DRUG
or O
zidovudine B-DRUG
or O
the O
combination O
of O
lamivudine B-DRUG
and O
zidovudine B-DRUG
. O
No O
clinically O
significant O
changes O
to O
lamivudine B-DRUG
or O
zidovudine B-DRUG
pharmacokinetics O
were O
observed O
following O
concomitant O
administration O
of O
abacavir B-DRUG
. O
Abacavir B-DRUG
has O
no O
effect O
on O
the O
pharmacokinetic O
properties O
of O
ethanol B-DRUG
. O
Ethanol B-DRUG
decreases O
the O
elimination O
of O
abacavir B-DRUG
causing O
an O
increase O
in O
overall O
exposure O
. O
The O
addition O
of O
methadone B-DRUG
has O
no O
clinically O
significant O
effect O
on O
the O
pharmacokinetic O
properties O
of O
abacavir B-DRUG
. O
In O
a O
study O
of O
11 O
HIV O
- O
infected O
patients O
receiving O
methadone B-DRUG
- O
maintenance O
therapy O
( O
40 O
mg O
and O
90 O
mg O
daily O
) O
with O
600 O
mg O
of O
ZIAGEN B-BRAND
twice O
daily O
( O
twice O
the O
currently O
recommended O
dose O
) O
, O
oral O
methadone B-DRUG
clearance O
increased O
22 O
% O
( O
90 O
% O
CI O
6 O
% O
to O
42 O
% O
) O
. O
This O
alteration O
will O
not O
result O
in O
a O
methadone B-DRUG
dose O
modification O
in O
the O
majority O
of O
patients O
; O
however O
, O
an O
increased O
methadone B-DRUG
dose O
may O
be O
required O
in O
a O
small O
number O
of O
patients O
. O

Drug O
Interactions O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
- O
This O
medicine O
may O
be O
affected O
by O
the O
drug O
cholestyramine B-DRUG
and O
should O
not O
be O
taken O
with O
any O
form O
of O
estrogen O
therapy O
. O
Talk O
to O
your O
pharmacist O
for O
more O
information O
. O
Drugs O
that O
may O
decrease O
the O
effects O
of O
this O
medicine O
include O
: O
Rifampin B-DRUG
barbiturates B-GROUP
phenytoin B-DRUG
( O
Dilantin B-BRAND
) O
carbamazepine B-DRUG
( O
Tegretol B-BRAND
) O
Estrogens B-GROUP
may O
decrease O
the O
effects O
of O
benzodiazepines B-GROUP
( O
lorezepam B-DRUG
oxezepam B-DRUG
temezepam B-DRUG
) O
. O
If O
you O
are O
taking O
these O
medicines O
together O
or O
you O
have O
further O
questions O
about O
drug O
interactions O
talk O
to O
your O
doctor O
or O
pharmacist O
. O
Consult O
your O
doctor O
or O
pharmacist O
if O
you O
are O
taking O
any O
of O
the O
following O
: O
seizure O
medications O
antibiotics B-GROUP
warfarin B-DRUG
medications O
to O
help O
you O
sleep O

Cholestyramine B-DRUG
: O
Concomitant O
cholestyramine B-DRUG
administration O
decreased O
the O
mean O
AUC O
of O
total O
ezetimibe B-DRUG
approximately O
55 O
% O
. O
The O
incremental O
LDL O
- O
C O
reduction O
due O
to O
adding O
ezetimibe B-DRUG
to O
cholestyramine B-DRUG
may O
be O
reduced O
by O
this O
interaction O
. O
Fibrates B-GROUP
: O
The O
safety O
and O
effectiveness O
of O
ezetimibe B-DRUG
administered O
with O
fibrates B-GROUP
have O
not O
been O
established O
. O
Fibrates B-GROUP
may O
increase O
cholesterol O
excretion O
into O
the O
bile O
, O
leading O
to O
cholelithiasis O
. O
In O
a O
preclinical O
study O
in O
dogs O
, O
ezetimibe B-DRUG
increased O
cholesterol O
in O
the O
gallbladder O
bile O
. O
Co O
- O
administration O
of O
ZETIA B-BRAND
with O
fibrates B-GROUP
is O
not O
recommended O
until O
use O
in O
patients O
is O
studied O
. O
Fenofibrate B-DRUG
: O
In O
a O
pharmacokinetic O
study O
, O
concomitant O
fenofibrate B-DRUG
administration O
increased O
total O
ezetimibe B-DRUG
concentrations O
approximately O
1 O
. O
5 O
- O
fold O
. O
Gemfibrozil B-DRUG
: O
In O
a O
pharmacokinetic O
study O
, O
concomitant O
gemfibrozil B-DRUG
administration O
increased O
total O
ezetimibe B-DRUG
concentrations O
approximately O
1 O
. O
7 O
- O
fold O
. O
HMG B-GROUP
- I-GROUP
CoA I-GROUP
reductase I-GROUP
inhibitors I-GROUP
: O
No O
clinically O
significant O
pharmacokinetic O
interactions O
were O
seen O
when O
ezetimibe B-DRUG
was O
co O
- O
administered O
with O
atorvastatin B-DRUG
, O
simvastatin B-DRUG
, O
pravastatin B-DRUG
, O
lovastatin B-DRUG
, O
or O
fluvastatin B-DRUG
. O
Cyclosporine B-DRUG
: O
The O
total O
ezetimibe B-DRUG
level O
increased O
12 O
- O
fold O
in O
one O
renal O
transplant O
patient O
receiving O
multiple O
medications O
, O
including O
cyclosporine B-DRUG
. O
Patients O
who O
take O
both O
ezetimibe B-DRUG
and O
cyclosporine B-DRUG
should O
be O
carefully O
monitored O
. O
Carcinogenesis O
, O
Mutagenesis O
, O
Impairment O
of O
Fertility O
A O
104 O
- O
week O
dietary O
carcinogenicity O
study O
with O
ezetimibe B-DRUG
was O
conducted O
in O
rats O
at O
doses O
up O
to O
1500 O
mg O
/ O
kg O
/ O
day O
( O
males O
) O
and O
500 O
mg O
/ O
kg O
/ O
day O
( O
females O
) O
( O
~ O
20 O
times O
the O
human O
exposure O
at O
10 O
mg O
daily O
based O
on O
AUC0 O
- O
24hr O
for O
total O
ezetimibe B-DRUG
) O
. O
A O
104 O
- O
week O
dietary O
carcinogenicity O
study O
with O
ezetimibe B-DRUG
was O
also O
conducted O
in O
mice O
at O
doses O
up O
to O
500 O
mg O
/ O
kg O
/ O
day O
( O
> O
150 O
times O
the O
human O
exposure O
at O
10 O
mg O
daily O
based O
on O
AUC0 O
- O
24hr O
for O
total O

ezetimibe B-DRUG
) O
. O
There O
were O
no O
statistically O
significant O
increases O
in O
tumor O
incidences O
in O
drug O
- O
treated O
rats O
or O
mice O
. O
No O
evidence O
of O
mutagenicity O
was O
observed O
in O
vitro O
in O
a O
microbial O
mutagenicity O
( O
Ames O
) O
test O
with O
Salmonella O
typhimurium O
and O
Escherichia O
coli O
with O
or O
without O
metabolic O
activation O
. O
No O
evidence O
of O
clastogenicity O
was O
observed O
in O
vitro O
in O
a O
chromosomal O
aberration O
assay O
in O
human O
peripheral O
blood O
lymphocytes O
with O
or O
without O
metabolic O
activation O
. O
In O
addition O
, O
there O
was O
no O
evidence O
of O
genotoxicity O
in O
the O
in O
vivo O
mouse O
micronucleus O
test O
. O
In O
oral O
( O
gavage O
) O
fertility O
studies O
of O
ezetimibe B-DRUG
conducted O
in O
rats O
, O
there O
was O
no O
evidence O
of O
reproductive O
toxicity O
at O
doses O
up O
to O
1000 O
mg O
/ O
kg O
/ O
day O
in O
male O
or O
female O
rats O
( O
~ O
7 O
times O
the O
human O
exposure O
at O
10 O
mg O
daily O
based O
on O
AUC0 O
- O
24hr O
for O
total O
ezetimibe B-DRUG
) O
. O
Pregnancy O
Pregnancy O
Category O
: O
C O
There O
are O
no O
adequate O
and O
well O
- O
controlled O
studies O
of O
ezetimibe B-DRUG
in O
pregnant O
women O
. O
Ezetimibe B-DRUG
should O
be O
used O
during O
pregnancy O
only O
if O
the O
potential O
benefit O
justifies O
the O
risk O
to O
the O
fetus O
. O
In O
oral O
( O
gavage O
) O
embryo O
- O
fetal O
development O
studies O
of O
ezetimibe B-DRUG
conducted O
in O
rats O
and O
rabbits O
during O
organogenesis O
, O
there O
was O
no O
evidence O
of O
embryolethal O
effects O
at O
the O
doses O
tested O
( O
250 O
, O
500 O
, O
1000 O
mg O
/ O
kg O
/ O
day O
) O
. O
In O
rats O
, O
increased O
incidences O
of O
common O
fetal O
skeletal O
findings O
( O
extra O
pair O
of O
thoracic O
ribs O
, O
unossified O
cervical O
vertebral O
centra O
, O
shortened O
ribs O
) O
were O
observed O
at O
1000 O
mg O
/ O
kg O
/ O
day O
( O
~ O
10 O
times O
the O
human O
exposure O
at O
10 O
mg O
daily O
based O
on O
AUC0 O
- O
24hr O
for O
total O
ezetimibe B-DRUG
) O
. O
In O
rabbits O
treated O
with O
ezetimibe B-DRUG
, O
an O
increased O
incidence O
of O
extra O
thoracic O
ribs O
was O
observed O
at O
1000 O
mg O
/ O
kg O
/ O
day O
( O
150 O
times O
the O
human O
exposure O
at O
10 O
mg O
daily O
based O
on O
AUC0 O
- O
24hr O
for O
total O
ezetimibe B-DRUG
) O
. O
Ezetimibe B-DRUG
crossed O
the O
placenta O
when O
pregnant O
rats O
and O
rabbits O
were O
given O
multiple O
oral O
doses O
. O
Multiple O
dose O
studies O
of O
ezetimibe B-DRUG
given O
in O
combination O
with O
HMG B-GROUP
- I-GROUP
CoA I-GROUP
reductase I-GROUP
inhibitors I-GROUP
( O
statins B-GROUP
) O
in O
rats O
and O
rabbits O
during O
organogenesis O
result O
in O
higher O
ezetimibe B-DRUG

and O
statin O
exposures O
. O
Reproductive O
findings O
occur O
at O
lower O
doses O
in O
combination O
therapy O
compared O
to O
monotherapy O
. O
All O
HMG B-GROUP
- I-GROUP
CoA I-GROUP
reductase I-GROUP
inhibitors I-GROUP
are O
contraindicated O
in O
pregnant O
and O
nursing O
women O
. O
When O
ZETIA B-BRAND
is O
administered O
with O
an O
HMG B-GROUP
- I-GROUP
CoA I-GROUP
reductase I-GROUP
inhibitor I-GROUP
in O
a O
woman O
of O
childbearing O
potential O
, O
refer O
to O
the O
pregnancy O
category O
and O
package O
labeling O
for O
the O
HMG B-DRUG
- I-DRUG
CoA I-DRUG
reductase I-DRUG
inhibitor I-DRUG
. O
Labor O
and O
Delivery O
The O
effects O
of O
ZETIA B-BRAND
on O
labor O
and O
delivery O
in O
pregnant O
women O
are O
unknown O
. O
Nursing O
Mothers O
In O
rat O
studies O
, O
exposure O
to O
total O
ezetimibe B-DRUG
in O
nursing O
pups O
was O
up O
to O
half O
of O
that O
observed O
in O
maternal O
plasma O
. O
It O
is O
not O
known O
whether O
ezetimibe B-DRUG
is O
excreted O
into O
human O
breast O
milk O
; O
therefore O
, O
ZETIA B-BRAND
should O
not O
be O
used O
in O
nursing O
mothers O
unless O
the O
potential O
benefit O
justifies O
the O
potential O
risk O
to O
the O
infant O
. O
Pediatric O
Use O
The O
pharmacokinetics O
of O
ZETIA B-BRAND
in O
adolescents O
( O
10 O
to O
18 O
years O
) O
have O
been O
shown O
to O
be O
similar O
to O
that O
in O
adults O
. O
Treatment O
experience O
with O
ZETIA B-BRAND
in O
the O
pediatric O
population O
is O
limited O
to O
4 O
patients O
( O
9 O
to O
17 O
years O
) O
in O
the O
sitosterolemia O
study O
and O
5 O
patients O
( O
11 O
to O
17 O
years O
) O
in O
the O
HoFH O
study O
. O
Treatment O
with O
ZETIA B-BRAND
in O
children O
( O
< O
10 O
years O
) O
is O
not O
recommended O
. O
Geriatric O
Use O
Of O
the O
patients O
who O
received O
ZETIA B-BRAND
in O
clinical O
studies O
, O
948 O
were O
65 O
and O
older O
( O
this O
included O
206 O
who O
were O
75 O
and O
older O
) O
. O
The O
effectiveness O
and O
safety O
of O
ZETIA B-BRAND
were O
similar O
between O
these O
patients O
and O
younger O
subjects O
. O
Greater O
sensitivity O
of O
some O
older O
individuals O
cannot O
be O
ruled O
out O
. O

Clinically O
or O
potentially O
significant O
drug O
interactions O
between O
DIFLUCAN B-BRAND
and O
the O
following O
agents O
/ O
classes O
have O
been O
observed O
. O
These O
are O
described O
in O
greater O
detail O
below O
: O
DIFLUCAN B-BRAND
and O
the O
following O
agents O
/ O
classes O
have O
been O
observed O
. O
These O
are O
described O
in O
greater O
detail O
below O
: O
Oral O
hypoglycemics B-GROUP
, O
Coumarin B-GROUP
- I-GROUP
type I-GROUP
anticoagulants I-GROUP
, O
Phenytoin B-DRUG
, O
Cyclosporine B-DRUG
, O
Rifampin B-DRUG
, O
Theophylline B-DRUG
, O
Terfenadine B-DRUG
, O
Cisapride B-DRUG
, O
Astemizole B-DRUG
, O
Rifabutin B-DRUG
, O
Tacrolimus B-DRUG
, O
Short B-GROUP
- I-GROUP
acting I-GROUP
benzodiazepines I-GROUP
, O
Oral O
hypoglycemics B-GROUP
: O
Clinically O
significant O
hypoglycemia O
may O
be O
precipitated O
by O
the O
use O
of O
DIFLUCAN B-BRAND
with O
oral O
hypoglycemic B-GROUP
agents I-GROUP
; O
one O
fatality O
has O
been O
reported O
from O
hypoglycemia O
in O
association O
with O
combined O
DIFLUCAN B-BRAND
and O
glyburide B-DRUG
use O
. O
DIFLUCAN B-BRAND
reduces O
the O
metabolism O
of O
tolbutamide B-DRUG
, O
glyburide B-DRUG
, O
and O
glipizide B-DRUG
and O
increases O
the O
plasma O
concentration O
of O
these O
agents O
. O
When O
DIFLUCAN B-BRAND
is O
used O
concomitantly O
with O
these O
or O
other O
sulfonylurea B-GROUP
oral I-GROUP
hypoglycemic I-GROUP
agents I-GROUP
, O
blood O
glucose O
concentrations O
should O
be O
carefully O
monitored O
and O
the O
dose O
of O
the O
sulfonylurea B-GROUP
should O
be O
adjusted O
as O
necessary O
. O
Coumarin B-GROUP
- I-GROUP
type I-GROUP
anticoagulants I-GROUP
: O
Prothrombin O
time O
may O
be O
increased O
in O
patients O
receiving O
concomitant O
DIFLUCAN B-BRAND
and O
coumarin B-GROUP
- I-GROUP
type I-GROUP
anticoagulants I-GROUP
. O
In O
post O
- O
marketing O
experience O
, O
as O
with O
other O
azole B-GROUP
antifungals I-GROUP
, O
bleeding O
events O
( O
bruising O
, O
epistaxis O
, O
gastrointestinal O
bleeding O
, O
hematuria O
, O
and O
melena O
) O
have O
been O
reported O
in O
association O
with O
increases O
in O
prothrombin O
time O
in O
patients O
receiving O
fluconazole B-DRUG
concurrently O
with O
warfarin B-DRUG
. O
Careful O
monitoring O
of O
prothrombin O
time O
in O
patients O
receiving O
DIFLUCAN B-BRAND
and O
coumarin B-GROUP
- I-GROUP
type I-GROUP
anticoagulants I-GROUP
is O
recommended O
. O
( O
See O
< O
a O
href O
= O
" O
flucon O
_ O
cp O
. O
htm O
# O
CP O
" O
> O
CLINICAL O
PHARMACOLOGY O
: O
Drug O
Interaction O
Studies O
. O
) O
Phenytoin B-DRUG
: O
DIFLUCAN B-BRAND
increases O
the O
plasma O
concentrations O
of O
phenytoin B-DRUG
. O
Careful O
monitoring O
of O
phenytoin B-DRUG
concentrations O
in O
patients O
receiving O

DIFLUCAN B-BRAND
and O
phenytoin B-DRUG
is O
recommended O
. O
( O
See O
< O
a O
href O
= O
" O
flucon O
_ O
cp O
. O
htm O
# O
CP O
" O
> O
CLINICAL O
PHARMACOLOGY O
: O
Drug O
Interaction O
Studies O
. O
) O
Cyclosporine B-DRUG
: O
DIFLUCAN B-BRAND
may O
significantly O
increase O
cyclosporine B-DRUG
levels O
in O
renal O
transplant O
patients O
with O
or O
without O
renal O
impairment O
. O
Careful O
monitoring O
of O
cyclosporine B-DRUG
concentrations O
and O
serum O
creatinine O
is O
recommended O
in O
patients O
receiving O
DIFLUCAN B-BRAND
and O
cyclosporine B-DRUG
. O
( O
See O
CLINICAL O
PHARMACOLOGY O
: O
Drug O
Interaction O
Studies O
. O
) O
Rifampin B-DRUG
: O
Rifampin B-DRUG
enhances O
the O
metabolism O
of O
concurrently O
administered O
DIFLUCAN B-BRAND
. O
Depending O
on O
clinical O
circumstances O
, O
consideration O
should O
be O
given O
to O
increasing O
the O
dose O
of O
DIFLUCAN B-BRAND
when O
it O
is O
administered O
with O
rifampin B-DRUG
. O
Theophylline B-DRUG
: O
DIFLUCAN B-BRAND
increases O
the O
serum O
concentrations O
of O
theophylline B-DRUG
. O
Careful O
monitoring O
of O
serum O
theophylline B-DRUG
concentrations O
in O
patients O
receiving O
DIFLUCAN B-BRAND
and O
theophylline B-DRUG
is O
recommended O
. O
Terfenadine B-DRUG
: O
Because O
of O
the O
occurrence O
of O
serious O
cardiac O
dysrhythmias O
secondary O
to O
prolongation O
of O
the O
QTc O
interval O
in O
patients O
receiving O
azole B-GROUP
antifungals I-GROUP
in O
conjunction O
with O
terfenadine B-DRUG
, O
interaction O
studies O
have O
been O
performed O
. O
One O
study O
at O
a O
200 O
- O
mg O
daily O
dose O
of O
fluconazole B-DRUG
failed O
to O
demonstrate O
a O
prolongation O
in O
QTc O
interval O
. O
Another O
study O
at O
a O
400 O
- O
mg O
and O
800 O
- O
mg O
daily O
dose O
of O
fluconazole B-DRUG
demonstrated O
that O
DIFLUCAN B-BRAND
taken O
in O
doses O
of O
400 O
mg O
per O
day O
or O
greater O
significantly O
increases O
plasma O
levels O
of O
terfenadine B-DRUG
when O
taken O
concomitantly O
. O
The O
combined O
use O
of O
fluconazole B-DRUG
at O
doses O
of O
400 O
mg O
or O
greater O
with O
terfenadine B-DRUG
is O
contraindicated O
. O
The O
coadministration O
of O
fluconazole B-DRUG
at O
doses O
lower O
than O
400 O
mg O
/ O
day O
with O
terfenadine B-DRUG
should O
be O
carefully O
monitored O
. O
Cisapride B-DRUG
: O
There O
have O
been O
reports O
of O
cardiac O
events O
, O
including O
torsade O
de O
pointes O
in O
patients O
to O
whom O
fluconazole B-DRUG
and O
cisapride B-DRUG
were O
coadministered O
. O
A O
controlled O
study O
found O
that O
concomitant O
fluconazole B-DRUG
200 O
mg O
once O
daily O
and O
cisapride B-DRUG
20 O
mg O
four O
times O
a O
day O
yielded O
a O
significant O
increase O
in O

cisapride B-DRUG
plasma O
levels O
and O
prolongation O
of O
QTc O
interval O
. O
The O
combined O
use O
of O
fluconazole B-DRUG
with O
cisapride B-DRUG
is O
contraindicated O
. O
Astemizole B-DRUG
: O
The O
use O
of O
fluconazole B-DRUG
in O
patients O
concurrently O
taking O
astemizole B-DRUG
or O
other O
drugs O
metabolized O
by O
the O
cytochrome O
P450 O
system O
may O
be O
associated O
with O
elevations O
in O
serum O
levels O
of O
these O
drugs O
. O
In O
the O
absence O
of O
definitive O
information O
, O
caution O
should O
be O
used O
when O
coadministering O
fluconazole B-DRUG
. O
Patients O
should O
be O
carefully O
monitored O
. O
Rifabutin B-DRUG
: O
There O
have O
been O
reports O
of O
uveitis O
in O
patients O
to O
whom O
fluconazole B-DRUG
and O
rifabutin B-DRUG
were O
coadministered O
. O
Patients O
receiving O
rifabutin B-DRUG
and O
fluconazole B-DRUG
concomitantly O
should O
be O
carefully O
monitored O
. O
Tacrolimus B-DRUG
: O
There O
have O
been O
reports O
of O
nephrotoxicity O
in O
patients O
to O
whom O
fluconazole B-DRUG
and O
tacrolimus B-DRUG
were O
coadministered O
. O
Patients O
receiving O
tacrolimus B-DRUG
and O
fluconazole B-DRUG
concomitantly O
should O
be O
carefully O
monitored O
. O
Short B-GROUP
- I-GROUP
acting I-GROUP
Benzodiazepines I-GROUP
: O
Following O
oral O
administration O
of O
midazolam B-DRUG
, O
fluconazole B-DRUG
resulted O
in O
substantial O
increases O
in O
midazolam B-DRUG
concentrations O
and O
psychomotor O
effects O
. O
This O
effect O
on O
midazolam B-DRUG
appears O
to O
be O
more O
pronounced O
following O
oral O
administration O
of O
fluconazole B-DRUG
than O
with O
fluconazole B-DRUG
administered O
intravenously O
. O
If O
short B-GROUP
- I-GROUP
acting I-GROUP
benzodiazepines I-GROUP
, O
which O
are O
metabolized O
by O
the O
cytochrome O
P450 O
system O
, O
are O
concomitantly O
administered O
with O
fluconazole B-DRUG
, O
consideration O
should O
be O
given O
to O
decreasing O
the O
benzodiazepine B-GROUP
dosage O
, O
and O
the O
patients O
should O
be O
appropriately O
monitored O
. O
Fluconazole B-DRUG
tablets O
coadministered O
with O
ethinyl B-DRUG
estradiol I-DRUG
- O
and O
levonorgestrel B-DRUG
- O
containing O
oral O
contraceptives B-GROUP
produced O
an O
overall O
mean O
increase O
in O
ethinyl B-DRUG
estradiol I-DRUG
and O
levonorgestrel B-DRUG
levels O
; O
however O
, O
in O
some O
patients O
there O
were O
decreases O
up O
to O
47 O
% O
and O
33 O
% O
of O
ethinyl B-DRUG
estradiol I-DRUG
and O
levonorgestrel B-DRUG
levels O
. O
The O
data O
presently O
available O
indicate O
that O
the O
decreases O
in O
some O
individual O
ethinyl B-DRUG
estradiol I-DRUG
and O
levonorgestrel B-DRUG
AUC O
values O
with O
fluconazole B-DRUG
treatment O
are O
likely O
the O
result O
of O
random O
variation O
. O
While O
there O
is O
evidence O
that O
fluconazole B-DRUG
can O
inhibit O
the O
metabolism O
of O
ethinyl B-DRUG
estradiol I-DRUG
and O

levonorgestrel B-DRUG
, O
there O
is O
no O
evidence O
that O
fluconazole B-DRUG
is O
a O
net O
inducer O
of O
ethinyl B-DRUG
estradiol I-DRUG
or O
levonorgestrel B-DRUG
metabolism O
. O
The O
clinical O
significance O
of O
these O
effects O
is O
presently O
unknown O
. O
Physicians O
should O
be O
aware O
that O
interaction O
studies O
with O
medications O
other O
than O
those O
listed O
in O
the O
< O
a O
href O
= O
" O
flucon O
_ O
cp O
. O
htm O
# O
CP O
" O
> O
CLINICAL O
PHARMACOLOGY O
section O
have O
not O
been O
conducted O
, O
but O
such O
interactions O
may O
occur O
. O

No O
formal O
drug O
interaction O
studies O
have O
been O
conducted O
with O
Infergen B-BRAND
. O
Infergen B-BRAND
should O
be O
used O
cautiously O
in O
patients O
who O
are O
receiving O
agents O
that O
are O
known O
to O
cause O
myelosuppression O
or O
with O
agents O
known O
to O
be O
metabolized O
via O
the O
cytochrome O
P O
- O
450 O
pathway O
. O
9 O
Patients O
taking O
drugs O
that O
are O
metabolized O
by O
this O
pathway O
should O
be O
monitored O
closely O
for O
changes O
in O
the O
therapeutic O
and O
/ O
or O
toxic O
levels O
of O
concomitant O
drugs O
. O

Interactions O
for O
Dronabinol B-DRUG
: O
In O
studies O
involving O
patients O
with O
AIDS O
and O
/ O
or O
cancer O
, O
MARINOL B-BRAND
( O
Dronabinol B-DRUG
) O
Capsules O
has O
been O
co O
- O
administered O
with O
a O
variety O
of O
medications O
( O
e O
. O
g O
. O
, O
cytotoxic O
agents O
, O
anti B-DRUG
- I-DRUG
infective I-DRUG
agents O
, O
sedatives B-GROUP
, O
or O
opioid B-GROUP
analgesics I-GROUP
) O
without O
resulting O
in O
any O
clinically O
significant O
drug O
/ O
drug O
interactions O
. O
Although O
no O
drug O
/ O
drug O
interactions O
were O
discovered O
during O
the O
clinical O
trials O
of O
MARINOL B-BRAND
Capsules O
, O
cannabinoids B-GROUP
may O
interact O
with O
other O
medications O
through O
both O
metabolic O
and O
pharmacodynamic O
mechanisms O
. O
Dronabinol B-DRUG
is O
highly O
protein O
bound O
to O
plasma O
proteins O
, O
and O
therefore O
, O
might O
displace O
other O
protein O
- O
bound O
drugs O
. O
Although O
this O
displacement O
has O
not O
been O
confirmed O
in O
vivo O
, O
practitioners O
should O
monitor O
patients O
for O
a O
change O
in O
dosage O
requirements O
when O
administering O
dronabinol B-DRUG
to O
patients O
receiving O
other O
highly O
protein O
- O
bound O
drugs O
. O

No O
specific O
interactions O
are O
known O
at O
this O
time O
. O

You O
cannot O
take O
mazindol B-DRUG
if O
you O
have O
taken O
a O
monoamine B-GROUP
oxidase I-GROUP
inhibitor I-GROUP
( O
MAOI B-GROUP
) O
such O
as O
isocarboxazid B-DRUG
( O
Marplan B-BRAND
) O
, O
tranylcypromine B-DRUG
( O
Parnate B-BRAND
) O
, O
or O
phenelzine B-DRUG
( O
Nardil B-BRAND
) O
in O
the O
last O
14 O
days O
. O
Changes O
in O
insulin B-DRUG
and O
other O
diabetes O
drug O
therapies O
may O
be O
necessary O
during O
treatment O
with O
mazindol B-DRUG
. O
Mazindol B-DRUG
may O
reduce O
the O
effects O
of O
guanethidine B-DRUG
( O
Ismelin B-BRAND
) O
. O
This O
could O
lead O
to O
an O
increase O
in O
blood O
pressure O
. O
Tell O
your O
doctor O
if O
you O
are O
taking O
guanethidine B-DRUG
. O
Before O
taking O
this O
medication O
, O
tell O
your O
doctor O
if O
you O
are O
taking O
a O
tricyclic B-GROUP
antidepressant I-GROUP
such O
as O
amitriptyline B-DRUG
( O
Elavil B-BRAND
) O
, O
amoxapine B-DRUG
( O
Asendin B-BRAND
) O
, O
doxepin B-DRUG
( O
Sinequan B-BRAND
) O
, O
nortriptyline B-DRUG
( O
Pamelor B-BRAND
) O
, O
imipramine B-DRUG
( O
Tofranil B-BRAND
) O
, O
clomipramine B-DRUG
( O
Anafranil B-BRAND
) O
, O
protriptyline B-DRUG
( O
Vivactil B-BRAND
) O
, O
or O
desipramine B-DRUG
( O
Norpramin B-BRAND
) O
. O
These O
drugs O
may O
decrease O
the O
effects O
of O
mazindol B-DRUG
. O

Preliminary O
evidence O
suggests O
that O
cimetidine B-DRUG
inhibits O
mebendazole B-DRUG
metabolism O
and O
may O
result O
in O
an O
increase O
in O
plasma O
concentrations O
of O
mebendazole B-DRUG
. O

Patients O
receiving O
antibiotics B-GROUP
and O
sulfonamides B-GROUP
generally O
should O
not O
be O
treated O
with O
ganglion B-GROUP
blockers I-GROUP
. O
The O
action O
of O
Mecamylamine B-DRUG
may O
be O
potentiated O
by O
anesthesia O
, O
other O
antihypertensive B-GROUP
drugs I-GROUP
and O
alcohol B-DRUG
. O

No O
drug O
- O
drug O
interaction O
studies O
have O
been O
conducted O
with O
depo B-BRAND
- I-BRAND
subQ I-BRAND
provera I-BRAND
104 I-BRAND
. O
Aminoglutethimide B-DRUG
administered O
concomitantly O
with O
depo B-BRAND
- I-BRAND
subQ I-BRAND
provera I-BRAND
104 I-BRAND
may O
significantly O
decrease O
the O
serum O
concentrations O
of O
MPA B-DRUG
. O
Laboratory O
Tests O
The O
pathologist O
should O
be O
advised O
of O
progestin O
therapy O
when O
relevant O
specimens O
are O
submitted O
. O
The O
physician O
should O
be O
informed O
that O
certain O
endocrine O
and O
liver O
function O
tests O
, O
and O
blood O
components O
may O
be O
affected O
by O
progestin O
therapy O
: O
( O
a O
) O
Plasma O
and O
urinary O
steroid O
levels O
are O
decreased O
( O
e O
. O
g O
. O
, O
progesterone O
, O
estradiol O
, O
pregnanediol O
, O
testosterone O
, O
cortisol O
) O
. O
( O
b O
) O
Plasma O
and O
urinary O
gonadotropin O
levels O
are O
decreased O
( O
e O
. O
g O
. O
, O
LH O
, O
FSH O
) O
. O
( O
c O
) O
SHBG O
concentrations O
are O
decreased O
. O
( O
d O
) O
T3 O
- O
uptake O
values O
may O
decrease O
. O
( O
e O
) O
There O
may O
be O
small O
changes O
in O
coagulation O
factors O
. O
( O
f O
) O
Sulfobromophthalein O
and O
other O
liver O
function O
test O
values O
may O
be O
increased O
slightly O
. O
( O
g O
) O
There O
may O
be O
small O
changes O
in O
lipid O
profiles O
. O

Pharmacokinetic O
studies O
show O
that O
there O
are O
no O
significant O
alterations O
in O
pharmacokinetic O
parameters O
of O
zidovudine B-DRUG
or O
rifabutin B-DRUG
to O
warrant O
dosage O
adjustment O
when O
megestrol B-DRUG
acetate I-DRUG
is O
administered O
with O
these O
drugs O
. O
A O
pharmacokinetic O
study O
demonstrated O
that O
coadministration O
of O
megestrol B-DRUG
acetate I-DRUG
and O
indinavir B-DRUG
results O
in O
a O
significant O
decrease O
in O
the O
pharmacokinetic O
parameters O
( O
~ O
36 O
% O
for O
Cmax O
and O
~ O
28 O
% O
for O
AUC O
) O
of O
indinavir B-DRUG
. O
Administration O
of O
a O
higher O
dose O
of O
indinavir B-DRUG
should O
be O
considered O
when O
coadministering O
with O
megestrol B-DRUG
acetate I-DRUG
. O
The O
effects O
of O
indinavir B-DRUG
, O
zidovudine B-DRUG
or O
rifabutin B-DRUG
on O
the O
pharmacokinetics O
of O
megestrol B-DRUG
acetate I-DRUG
were O
not O
studied O
. O

Melatonin B-DRUG
may O
interact O
with O
the O
following O
drugs O
: O
aspirin B-BRAND
and O
other O
NSAIDs B-GROUP
( O
may O
lower O
melatonin B-DRUG
levels O
) O
, O
fluvoxamine B-DRUG
( O
bioavailability O
of O
oral O
melatonin B-DRUG
is O
increased O
with O
coadministration O
) O
, O
beta B-GROUP
blockers I-GROUP
( O
may O
decrease O
melatonin B-DRUG
levels O
) O
, O
fluoxetine B-DRUG
( O
reports O
of O
psychotic O
episodes O
when O
coadministered O
) O
, O
progestin B-GROUP
( O
coadministration O
of O
melatonin B-DRUG
with O
progestin B-GROUP
can O
inhibit O
ovarian O
function O
in O
women O
) O
, O
benzodiazepenes B-GROUP
and O
other O
sedating O
drugs O
( O
may O
result O
in O
additive O
sedation O
and O
an O
increased O
incidence O
of O
adverse O
effects O
) O
, O
and O
corticosteroids B-GROUP
( O
coadministration O
of O
melatonin B-DRUG
and O
corticosteroids B-GROUP
may O
interfere O
with O
the O
efficacy O
of O
the O
corticosteroids B-GROUP
) O
. O

ACE B-GROUP
inhibitors I-GROUP
Reports O
suggest O
that O
NSAIDs B-GROUP
may O
diminish O
the O
antihypertensive O
effect O
of O
angiotensin B-GROUP
- I-GROUP
converting I-GROUP
enzyme I-GROUP
( I-GROUP
ACE I-GROUP
) I-GROUP
inhibitors I-GROUP
. O
This O
interaction O
should O
be O
given O
consideration O
in O
patients O
taking O
NSAIDs B-GROUP
concomitantly O
with O
ACE B-GROUP
inhibitors I-GROUP
. O
Aspirin B-BRAND
: O
Concomitant O
administration O
of O
aspirin B-BRAND
( O
1000 O
mg O
TID O
) O
to O
healthy O
volunteers O
tended O
to O
increase O
the O
AUC O
( O
10 O
% O
) O
and O
Cmax O
( O
24 O
% O
) O
of O
meloxicam B-DRUG
. O
The O
clinical O
significance O
of O
this O
interaction O
is O
not O
known O
; O
however O
, O
as O
with O
other O
NSAIDs B-GROUP
, O
concomitant O
administration O
of O
meloxicam B-DRUG
and O
aspirin B-BRAND
is O
not O
generally O
recommended O
because O
of O
the O
potential O
for O
increased O
adverse O
effects O
. O
Concomitant O
administration O
of O
low O
- O
dose O
aspirin B-BRAND
with O
MOBIC B-BRAND
may O
result O
in O
an O
increased O
rate O
of O
GI O
ulceration O
or O
other O
complications O
, O
compared O
to O
use O
of O
MOBIC B-BRAND
alone O
. O
MOBIC B-BRAND
is O
not O
a O
substitute O
for O
aspirin B-BRAND
for O
cardiovascular O
prophylaxis O
. O
Cholestyramine B-DRUG
: O
Pretreatment O
for O
four O
days O
with O
cholestyramine B-DRUG
significantly O
increased O
the O
clearance O
of O
meloxicam B-DRUG
by O
50 O
% O
. O
This O
resulted O
in O
a O
decrease O
in O
t1 O
/ O
2 O
, O
from O
19 O
. O
2 O
hours O
to O
12 O
. O
5 O
hours O
, O
and O
a O
35 O
% O
reduction O
in O
AUC O
. O
This O
suggests O
the O
existence O
of O
a O
recirculation O
pathway O
for O
meloxicam B-DRUG
in O
the O
gastrointestinal O
tract O
. O
The O
clinical O
relevance O
of O
this O
interaction O
has O
not O
been O
established O
. O
Cimetidine B-DRUG
: O
Concomitant O
administration O
of O
200 O
mg O
cimetidine B-DRUG
QID O
did O
not O
alter O
the O
single O
- O
dose O
pharmacokinetics O
of O
30 O
mg O
meloxicam B-DRUG
. O
Digoxin B-DRUG
: O
Meloxicam B-DRUG
15 O
mg O
once O
daily O
for O
7 O
days O
did O
not O
alter O
the O
plasma O
concentration O
profile O
of O
digoxin B-DRUG
after O
b O
- O
acetyldigoxin O
administration O
for O
7 O
days O
at O
clinical O
doses O
. O
In O
vitro O
testing O
found O
no O
protein O
binding O
drug O
interaction O
between O
digoxin B-DRUG
and O
meloxicam B-DRUG
. O
Furosemide B-DRUG
: O
Clinical O
studies O
, O
as O
well O
as O
post O
- O
marketing O
observations O
, O
have O
shown O
that O
NSAIDs B-GROUP
can O
reduce O
the O
natriuretic O
effect O
of O
furosemide B-DRUG
and O
thiazide B-GROUP
diuretics I-GROUP
in O
some O
patients O
. O
This O
effect O
has O
been O
attributed O
to O
inhibition O
of O
renal O
prostaglandin O
synthesis O
. O
Studies O
with O
furosemide B-DRUG
agents O
and O
meloxicam B-DRUG
have O
not O
demonstrated O
a O
reduction O
in O
natriuretic O
effect O
. O
Furosemide B-DRUG
: O
single O
and O

multiple O
dose O
pharmacodynamics O
and O
pharmacokinetics O
are O
not O
affected O
by O
multiple O
doses O
of O
meloxicam B-DRUG
. O
Nevertheless O
, O
during O
concomitant O
therapy O
with O
furosemide B-DRUG
and O
MOBIC B-BRAND
, O
patients O
should O
be O
observed O
closely O
for O
signs O
of O
declining O
renal O
function O
, O
as O
well O
as O
to O
assure O
diuretic O
efficacy O
. O
Lithium B-DRUG
: O
In O
clinical O
trials O
, O
NSAIDs B-GROUP
have O
produced O
an O
elevation O
of O
plasma O
lithium B-DRUG
levels O
and O
a O
reduction O
in O
renal O
lithium B-DRUG
clearance O
. O
In O
a O
study O
conducted O
in O
healthy O
subjects O
, O
mean O
pre O
- O
dose O
lithium B-DRUG
concentration O
and O
AUC O
were O
increased O
by O
21 O
% O
in O
subjects O
receiving O
lithium B-DRUG
doses O
ranging O
from O
804 O
to O
1072 O
mg O
BID O
with O
meloxicam B-DRUG
15 O
mg O
QD O
as O
compared O
to O
subjects O
receiving O
lithium B-DRUG
alone O
. O
These O
effects O
have O
been O
attributed O
to O
inhibition O
of O
renal O
prostaglandin O
synthesis O
by O
MOBIC B-BRAND
. O
Patients O
on O
lithium B-DRUG
treatment O
should O
be O
closely O
monitored O
when O
MOBIC B-BRAND
is O
introduced O
or O
withdrawn O
. O
Methotrexate B-DRUG
: O
A O
study O
in O
13 O
rheumatoid O
arthritis O
( O
RA O
) O
patients O
evaluated O
the O
effects O
of O
multiple O
doses O
of O
meloxicam B-DRUG
on O
the O
pharmacokinetics O
of O
methotrexate B-DRUG
taken O
once O
weekly O
. O
Meloxicam B-DRUG
did O
not O
have O
a O
significant O
effect O
on O
the O
pharmacokinetics O
of O
single O
doses O
of O
methotrexate B-DRUG
. O
In O
vitro O
, O
methotrexate B-DRUG
did O
not O
displace O
meloxicam B-DRUG
from O
its O
human O
serum O
binding O
sites O
. O
Warfarin B-DRUG
: O
Anticoagulant O
activity O
should O
be O
monitored O
, O
particularly O
in O
the O
first O
few O
days O
after O
initiating O
or O
changing O
MOBIC B-BRAND
therapy O
in O
patients O
receiving O
warfarin B-DRUG
or O
similar O
agents O
, O
since O
these O
patients O
are O
at O
an O
increased O
risk O
of O
bleeding O
. O
The O
effect O
of O
meloxicam B-DRUG
on O
the O
anticoagulant O
effect O
of O
warfarin B-DRUG
was O
studied O
in O
a O
group O
of O
healthy O
subjects O
receiving O
daily O
doses O
of O
warfarin B-DRUG
that O
produced O
an O
INR O
( O
International O
Normalized O
Ratio O
) O
between O
1 O
. O
2 O
and O
1 O
. O
8 O
. O
In O
these O
subjects O
, O
meloxicam B-DRUG
did O
not O
alter O
warfarin B-DRUG
pharmacokinetics O
and O
the O
average O
anticoagulant O
effect O
of O
warfarin B-DRUG
as O
determined O
by O
prothrombin O
time O
. O
However O
, O
one O
subject O
showed O
an O
increase O
in O
INR O
from O
1 O
. O
5 O
to O
2 O
. O
1 O
. O
Caution O
should O
be O
used O
when O
administering O
MOBIC B-BRAND
with O
warfarin B-DRUG
since O
patients O
on O
warfarin B-DRUG
may O
experience O
changes O
in O
INR O
and O
an O
increased O
risk O
of O
bleeding O
complications O
when O
a O
new O
medication O
is O

introduced O
. O

DRUG O
INTERACTIONS O
There O
are O
no O
known O
drug O
/ O
drug O
interactions O
with O
oral O
ALKERAN B-BRAND
Vaccinations O
with O
live B-GROUP
organism I-GROUP
vaccines I-GROUP
are O
not O
recommended O
in O
immunocompromised O
individuals O
Nalidixic B-DRUG
acid I-DRUG
together O
with O
high O
- O
dose O
intravenous O
melphalan B-DRUG
has O
caused O
deaths O
in O
children O
due O
to O
haemorrhagic O
enterocolitis O
. O
Impaired O
renal O
function O
has O
been O
described O
in O
bone O
marrow O
transplant O
patients O
who O
were O
conditioned O
with O
high O
- O
dose O
intravenous O
melphalan B-DRUG
and O
who O
subsequently O
received O
cyclosporin B-DRUG
to O
prevent O
graft O
- O
versus O
- O
host O
disease O

The O
following O
agents O
may O
increase O
certain O
actions O
or O
side O
effects O
of O
anticholinergic B-GROUP
drugs I-GROUP
: O
amantadine B-DRUG
, O
antiarrhythmic B-GROUP
agents I-GROUP
of I-GROUP
class I-GROUP
I I-GROUP
( O
e O
. O
g O
. O
, O
quinidine B-DRUG
) O
, O
antihistamines B-GROUP
, O
antipsychotic B-GROUP
agents I-GROUP
( O
e O
. O
g O
. O
, O
phenothiazines B-GROUP
) O
, O
benzodiazepines B-GROUP
, O
MAO B-GROUP
inhibitors I-GROUP
, O
narcotic B-GROUP
analgesics I-GROUP
( O
e O
. O
g O
. O
, O
meperidine B-DRUG
) O
, O
nitrates B-GROUP
and O
nitrites B-GROUP
, O
sympathomimetic B-GROUP
agents I-GROUP
, O
tricyclic B-GROUP
antidepressants I-GROUP
, O
and O
other O
drugs O
having O
anticholinergic O
activity O
. O
Anticholinergics B-GROUP
antagonize O
the O
effects O
of O
antiglaucoma B-GROUP
agents I-GROUP
. O
Anticholinergic B-GROUP
drugs I-GROUP
in O
the O
presence O
of O
increased O
intraocular O
pressure O
may O
be O
hazardous O
when O
taken O
concurrently O
with O
agents O
such O
as O
corticosteroids B-GROUP
. O
Anticholinergic B-GROUP
agents I-GROUP
may O
affect O
gastrointestinal O
absorption O
of O
various O
drugs O
, O
such O
as O
slowly O
dissolving O
dosage O
forms O
of O
digoxin B-DRUG
; O
increased O
serum O
digoxin B-DRUG
concentrations O
may O
result O
. O
Anticholinergic B-GROUP
drugs I-GROUP
may O
antagonize O
the O
effects O
of O
drugs O
that O
alter O
gastrointestinal O
motility O
, O
such O
as O
metoclopramide B-DRUG
. O
Because O
antacids B-GROUP
may O
interfere O
with O
the O
absorption O
of O
anticholinergic B-GROUP
agents I-GROUP
, O
simultaneous O
use O
of O
these O
drugs O
should O
be O
avoided O
. O
The O
inhibiting O
effects O
of O
anticholinergic B-GROUP
drugs I-GROUP
on O
gastric O
hydrochloric O
acid O
secretion O
are O
antagonized O
by O
agents O
used O
to O
treat O
achlorhydria O
and O
those O
used O
to O
test O
gastric O
secretion O
. O

Interaction O
with O
Other O
Central B-GROUP
Nervous I-GROUP
System I-GROUP
Depressants I-GROUP
: O
MEPERIDINE B-DRUG
SHOULD O
BE O
USED O
WITH O
GREAT O
CAUTION O
AND O
IN O
REDUCED O
DOSAGE O
IN O
PATIENTS O
WHO O
ARE O
CONCURRENTLY O
RECEIVING O
OTHER O
NARCOTIC B-GROUP
ANALGESICS I-GROUP
, O
GENERAL O
ANESTHETICS B-GROUP
, O
PHENOTHIAZINES B-GROUP
, O
OTHER O
TRANQUILIZERS B-GROUP
, O
SEDATIVE B-GROUP
- I-GROUP
HYPNOTICS I-GROUP
( O
INCLUDING O
BARBITURATES B-GROUP
) O
, O
TRICYCLIC B-GROUP
ANTIDEPRESSANTS I-GROUP
AND O
OTHER O
CNS B-GROUP
DEPRESSANTS I-GROUP
( O
INCLUDING O
ALCOHOL B-DRUG
) O
. O
RESPIRATORY O
DEPRESSION O
, O
HYPOTENSION O
, O
AND O
PROFOUND O
SEDATION O
OR O
COMA O
MAY O
RESULT O
. O

Some O
anticonvulsants B-GROUP
may O
interact O
with O
Mephenytoin B-DRUG
. O
They O
can O
either O
increase O
or O
decrease O
the O
effect O
of O
Mephenytoin B-DRUG
. O
Those O
anticonvulsants B-GROUP
include O
divalproex B-DRUG
sodium I-DRUG
, O
valproic B-DRUG
acid I-DRUG
, O
and O
phenobarbital B-DRUG
. O
Mephenytoin B-DRUG
may O
also O
affect O
the O
effects O
of O
other O
drugs O
, O
which O
include O
some O
steroid B-GROUP
medications I-GROUP
, O
warfarin B-DRUG
, O
certain O
heart O
medicines O
, O
birth O
control O
pills O
, O
anti B-GROUP
- I-GROUP
infective I-GROUP
medicines I-GROUP
, O
furosemide B-DRUG
and O
theophylline B-DRUG
Please O
note O
that O
Mephenytoin B-DRUG
may O
interact O
with O
other O
drugs O
that O
are O
not O
listed O
here O
. O

Mequitazine B-DRUG
can O
interact O
with O
CNS B-GROUP
depressant I-GROUP
, O
antichlolinergic B-GROUP
, O
TCA B-GROUP
, O
MAOIs B-GROUP
, O
and O
alcohol B-DRUG
. O

Probenecid B-DRUG
competes O
with O
meropenem B-DRUG
for O
active O
tubular O
secretion O
and O
thus O
inhibits O
the O
renal O
excretion O
of O
meropenem B-DRUG
. O
This O
led O
to O
statistically O
significant O
increases O
in O
the O
elimination O
half O
- O
life O
( O
38 O
% O
) O
and O
in O
the O
extent O
of O
systemic O
exposure O
( O
56 O
% O
) O
. O
Therefore O
, O
the O
coadministration O
of O
probenecid B-DRUG
with O
meropenem B-DRUG
is O
not O
recommended O
. O
There O
is O
evidence O
that O
meropenem B-DRUG
may O
reduce O
serum O
levels O
of O
valproic B-DRUG
acid I-DRUG
to O
subtherapeutic O
levels O
( O
therapeutic O
range O
considered O
to O
be O
50 O
to O
100 O
g O
/ O
mL O
total O
valproate B-DRUG
) O
. O

ARAMINE B-BRAND
should O
be O
used O
with O
caution O
in O
digitalized O
patients O
, O
since O
the O
combination O
of O
digitalis B-GROUP
and O
sympathomimetic B-GROUP
amines I-GROUP
may O
cause O
ectopic O
arrhythmias O
. O
Monoamine B-GROUP
oxidase I-GROUP
inhibitors I-GROUP
or O
tricyclic B-GROUP
antidepressants I-GROUP
may O
potentiate O
the O
action O
of O
sympathomimetic B-GROUP
amines I-GROUP
. O
Therefore O
, O
when O
initiating O
pressor O
therapy O
in O
patients O
receiving O
these O
drugs O
, O
the O
initial O
dose O
should O
be O
small O
and O
given O
with O
caution O
. O

SKELAXIN B-BRAND
may O
enhance O
the O
effects O
of O
alcohol B-DRUG
, O
barbiturates B-GROUP
and O
other O
CNS B-GROUP
depressants I-GROUP
. O

Methazolamide B-DRUG
should O
be O
used O
with O
caution O
in O
patients O
on O
steroid O
therapy O
because O
of O
the O
potential O
for O
developing O
hypokalemia O
. O
Caution O
is O
advised O
for O
patients O
receiving O
high O
- O
dose O
aspirin B-BRAND
and O
methazolamide B-DRUG
concomitantly O
, O
as O
anorexia O
, O
tachypnea O
, O
lethargy O
, O
coma O
and O
death O
have O
been O
reported O
with O
concomitant O
use O
of O
high O
- O
dose O
aspirin B-BRAND
and O
carbonic B-GROUP
anhydrase I-GROUP
inhibitors I-GROUP
. O

Anticoagulants B-GROUP
( O
oral O
) O
: O
The O
activity O
of O
oral O
anticoagulants B-GROUP
may O
be O
potentiated O
by O
anti O
- O
vitamin O
- O
K O
activity O
attributed O
to O
methimazole B-DRUG
. O
- O
adrenergic B-GROUP
blocking I-GROUP
agents I-GROUP
: O
Hyperthyroidism O
may O
cause O
an O
increased O
clearance O
of O
beta O
ratio O
. O
A O
dose O
reduction O
of O
beta B-GROUP
- I-GROUP
adrenergic I-GROUP
blockers I-GROUP
may O
be O
needed O
when O
a O
hyperthyroid O
patient O
becomes O
euthyroid O
. O
Digitalis B-GROUP
glycosides I-GROUP
: O
Serum O
digitalis O
levels O
may O
be O
increased O
when O
hyperthyroid O
patients O
on O
a O
stable O
digitalis B-GROUP
glycoside I-GROUP
regimen O
become O
euthyroid O
; O
reduced O
dosage O
of O
digitalis B-GROUP
glycosides I-GROUP
may O
be O
required O
. O
Theophylline B-DRUG
: O
Theophylline B-DRUG
clearance O
may O
decrease O
when O
hyperthyroid O
patients O
on O
a O
stable O
theophylline B-DRUG
regimen O
become O
euthyroid O
; O
a O
reduced O
dose O
of O
theophylline B-DRUG
may O
be O
needed O
. O

Dosages O
of O
concomitantly O
administered O
opioids B-GROUP
should O
be O
reduced O
by O
approximately O
half O
, O
because O
levomepromazine B-DRUG
amplifies O
the O
therapeutic O
actions O
and O
side O
- O
effects O
of O
opioids B-GROUP
. O
Combination O
with O
tramadol B-DRUG
( O
Ultram B-BRAND
) O
is O
associated O
with O
increased O
risk O
of O
seizures O
. O
Additive O
sedative O
effects O
and O
confusional O
states O
may O
emerge O
if O
levomepromazine B-DRUG
is O
given O
with O
benzodiazepines B-GROUP
or O
barbiturates B-GROUP
. O
This O
may O
be O
avoided O
by O
using O
the O
lowest O
dose O
possible O
with O
the O
substances O
in O
question O
. O
Exert O
particular O
caution O
in O
combining O
levomepromazine B-DRUG
with O
other O
anticholinergic B-GROUP
drugs I-GROUP
( O
tricyclic B-GROUP
antidepressants I-GROUP
and O
antiparkinsonian B-GROUP
- I-GROUP
agents I-GROUP
) O
: O
Particularly O
the O
elderly O
may O
develop O
delirium O
, O
high O
fever O
, O
severe O
obstipation O
, O
even O
ileus O
and O
glaucoma O
. O
Reduce O
both O
the O
dose O
of O
levomepromazine B-DRUG
and O
the O
dose O
of O
the O
other O
drug O
. O
If O
possible O
, O
avoid O
such O
combinations O
. O
Caffeine B-DRUG
and O
/ O
or O
stimulantes O
of O
the O
ephedrine B-DRUG
/ O
amphetamine B-DRUG
type O
may O
counteract O
the O
specific O
actions O
of O
levomepromazine B-DRUG
. O
Concomitant O
use O
of O
these O
substances O
should O
be O
avoided O
. O
Coffee O
and O
black O
tea O
should O
be O
avoided O
because O
they O
decrease O
the O
absorption O
of O
levomepromazine B-DRUG
considerably O
. O
The O
same O
is O
true O
for O
antacids B-GROUP
; O
these O
should O
be O
given O
1 O
to O
2 O
hours O
before O
or O
after O
oral O
administration O
of O
leveomepromazine B-DRUG
. O

Concomitant O
Therapy O
Special O
care O
should O
be O
exercised O
in O
treating O
patients O
who O
are O
receiving O
concomitant O
therapy O
( O
either O
topically O
or O
systemically O
) O
with O
known O
photosensitizing O
agents O
such O
as O
anthralin B-DRUG
, O
coal B-DRUG_N
tar I-DRUG_N
or O
coal B-DRUG_N
tar I-DRUG_N
derivatives I-DRUG_N
, O
griseofulvin B-DRUG
, O
phenothiazines B-GROUP
, O
nalidixic B-DRUG
acid I-DRUG
, O
halogenated B-GROUP
salicylanilides I-GROUP
( O
bacteriostatic O
soaps O
) O
, O
sulfonamides B-DRUG
, O
tetracyclines B-GROUP
, O
thiazides B-GROUP
, O
and O
certain O
organic O
staining O
dyes O
such O
as O
methylene B-DRUG_N
blue I-DRUG_N
, O
toluidine B-DRUG_N
blue I-DRUG_N
, O
rose O
bengal O
and O
methyl O
orange O
. O

Since O
Celontin B-BRAND
( O
methsuximide B-DRUG
) O
may O
interact O
with O
concurrently O
administered O
antiepileptic B-GROUP
drugs I-GROUP
, O
periodic O
serum O
level O
determinations O
of O
these O
drugs O
may O
be O
necessary O
( O
eg O
methsuximide B-DRUG
may O
increase O
the O
plasma O
concentrations O
of O
phenytoin B-DRUG
and O
phenobarbital B-DRUG
) O
. O

Hypokalemia O
can O
sensitize O
or O
exaggerate O
the O
response O
of O
the O
heart O
to O
the O
toxic O
effects O
of O
digitalis B-GROUP
( O
e O
. O
g O
. O
, O
increased O
ventricular O
irritability O
) O
. O
Hypokalemia O
may O
develop O
during O
concomitant O
use O
of O
steroids B-GROUP
or O
ACTH B-DRUG
. O
Insulin B-DRUG
requirements O
in O
diabetic O
patients O
may O
be O
increased O
, O
decreased O
, O
or O
unchanged O
. O
Thiazides B-GROUP
may O
decrease O
arterial O
responsiveness O
to O
norepinephrine B-DRUG
. O
This O
diminution O
is O
not O
sufficient O
to O
preclude O
effectiveness O
of O
the O
pressor O
agent O
for O
therapeutic O
use O
. O
Thiazide B-GROUP
drugs I-GROUP
may O
increase O
the O
responsiveness O
of O
tubocurarine B-DRUG
. O
Lithium B-DRUG
renal O
clearance O
is O
reduced O
by O
thiazides B-GROUP
, O
increasing O
the O
risk O
of O
lithium B-DRUG
toxicity O
. O
Thiazides B-GROUP
may O
add O
to O
or O
potentiate O
the O
action O
of O
other O
antihypertensive B-GROUP
drugs I-GROUP
. O
Potentiation O
occurs O
with O
ganglionic B-GROUP
or I-GROUP
peripheral I-GROUP
adrenergic I-GROUP
blocking I-GROUP
drugs I-GROUP
. O

There O
have O
been O
no O
studies O
of O
the O
interaction O
of O
methyl B-DRUG
aminolevulinate I-DRUG
cream O
with O
any O
other O
drugs O
, O
including O
local O
anesthetics B-GROUP
. O
It O
is O
possible O
that O
concomitant O
use O
of O
other O
known O
photosensitizing O
agents O
might O
increase O
the O
photosensitivity O
reaction O
of O
actinic O
keratoses O
treated O
with O
methyl B-DRUG
aminolevulinate I-DRUG
cream O
. O

When O
methyldopa B-DRUG
is O
used O
with O
other O
antihypertensive B-GROUP
drugs I-GROUP
, O
potentiation O
of O
antihypertensive O
effect O
may O
occur O
. O
Patients O
should O
be O
followed O
carefully O
to O
detect O
side O
reactions O
or O
unusual O
manifestations O
of O
drug O
idiosyncrasy O
. O
Patients O
may O
require O
reduced O
doses O
of O
anesthetics B-GROUP
when O
on O
methyldopa B-DRUG
. O
If O
hypotension O
does O
occur O
during O
anesthesia O
, O
it O
usually O
can O
be O
controlled O
by O
vasopressors B-GROUP
. O
The O
adrenergic O
receptors O
remain O
sensitive O
during O
treatment O
with O
methyldopa B-DRUG
. O
When O
methyldopa B-DRUG
and O
lithium B-DRUG
are O
given O
concomitantly O
the O
patient O
should O
be O
carefully O
monitored O
for O
symptoms O
of O
lithium B-DRUG
toxicity O
. O
Read O
the O
circular O
for O
lithium B-DRUG
preparations O
. O
Several O
studies O
demonstrate O
a O
decrease O
in O
the O
bioavailability O
of O
methyldopa B-DRUG
when O
it O
is O
ingested O
with O
ferrous B-DRUG
sulfate I-DRUG
or O
ferrous B-DRUG
gluconate I-DRUG
. O
This O
may O
adversely O
affect O
blood O
pressure O
control O
in O
patients O
treated O
with O
methyldopa B-DRUG
. O
Coadministration O
of O
methyldopa B-DRUG
with O
ferrous B-DRUG
sulfate I-DRUG
or O
ferrous B-DRUG
gluconate I-DRUG
is O
not O
recommended O
. O
Monoamine B-GROUP
oxidase I-GROUP
( I-GROUP
MAO I-GROUP
) I-GROUP
inhibitors I-GROUP
: O
See O
CONTRAINDICATIONS O
. O
Drug O
/ O
Laboratory O
Test O
Interactions O
Methyldopa B-DRUG
may O
interfere O
with O
measurement O
of O
: O
urinary O
uric O
acid O
by O
the O
phosphotungstate O
method O
, O
serum O
creatinine O
by O
the O
alkaline O
picrate O
method O
, O
and O
SGOT O
by O
colorimetric O
methods O
. O
Interference O
with O
spectrophotometric O
methods O
for O
SGOT O
analysis O
has O
not O
been O
reported O
. O
Since O
methyldopa B-DRUG
causes O
fluorescence O
in O
urine O
samples O
at O
the O
same O
wave O
lengths O
as O
catecholamines O
, O
falsely O
high O
levels O
of O
urinary O
catecholamines O
may O
be O
reported O
. O
This O
will O
interfere O
with O
the O
diagnosis O
of O
pheochromocytoma O
. O
It O
is O
important O
to O
recognize O
this O
phenomenon O
before O
a O
patient O
with O
a O
possible O
pheochromocytoma O
is O
subjected O
to O
surgery O
. O
Methyldopa B-DRUG
does O
not O
interfere O
with O
measurement O
of O
VMA B-DRUG_N
( O
vanillylmandelic B-DRUG_N
acid I-DRUG_N
) O
, O
a O
test O
for O
pheochromocytoma O
, O
by O
those O
methods O
which O
convert O
VMA B-DRUG_N
to O
vanillin B-DRUG_N
. O
Methyldopa B-DRUG
is O
not O
recommended O
for O
the O
treatment O
of O
patients O
with O
pheochromocytoma O
. O
Rarely O
, O
when O
urine O
is O
exposed O
to O
air O
after O
voiding O
, O
it O
may O
darken O
because O
of O
breakdown O
of O
methyldopa B-DRUG
or O
its O
metabolites O
. O

CYP O
3A4 O
Inhibitors O
( O
e O
. O
g O
. O
Macrolide B-GROUP
Antibiotics I-GROUP
and O
Protease B-GROUP
Inhibitors I-GROUP
) O
There O
have O
been O
rare O
reports O
of O
serious O
adverse O
events O
in O
connection O
with O
the O
coadministration O
of O
certain O
ergot B-GROUP
alkaloid I-GROUP
drugs I-GROUP
( O
e O
. O
g O
. O
dihydroergotamine B-DRUG
and O
ergotamine B-DRUG
) O
and O
potent O
CYP O
3A4 O
inhibitors O
, O
resulting O
in O
vasospasm O
leading O
to O
cerebral O
ischemia O
and O
/ O
or O
ischemia O
of O
the O
extremities O
. O
Although O
there O
have O
been O
no O
reports O
of O
such O
interactions O
with O
methylergonovine B-DRUG
alone O
, O
potent O
CYP O
3A4 O
inhibitors O
should O
not O
be O
coadministered O
with O
methylergonovine O
. O
Examples O
of O
some O
of O
the O
more O
potent O
CYP O
3A4 O
inhibitors O
include O
macrolide B-GROUP
antibiotics I-GROUP
( O
e O
. O
g O
. O
, O
erythromycin B-DRUG
, O
troleandomycin B-DRUG
, O
clarithromycin B-DRUG
) O
, O
HIV B-GROUP
protease I-GROUP
or I-GROUP
reverse I-GROUP
transcriptase I-GROUP
inhibitors I-GROUP
( O
e O
. O
g O
. O
, O
ritonavir B-DRUG
, O
indinavir B-DRUG
, O
nelfinavir B-DRUG
, O
delavirdine B-DRUG
) O
or O
azole B-GROUP
antifungals I-GROUP
( O
e O
. O
g O
. O
, O
ketoconazole B-DRUG
, O
itraconazole B-DRUG
, O
voriconazole B-DRUG
) O
. O
Less O
potent O
CYP O
3A4 O
inhibitors O
should O
be O
administered O
with O
caution O
. O
Less O
potent O
inhibitors O
include O
saquinavir B-DRUG
, O
nefazodone B-DRUG
, O
fluconazole B-DRUG
, O
grapefruit O
juice O
, O
fluoxetine B-DRUG
, O
fluvoxamine B-DRUG
, O
zileuton B-DRUG
, O
and O
clotrimazole B-DRUG
. O
These O
lists O
are O
not O
exhaustive O
, O
and O
the O
prescriber O
should O
consider O
the O
effects O
on O
CYP O
3A4 O
of O
other O
agents O
being O
considered O
for O
concomitant O
use O
with O
methylergonovine B-DRUG
. O
No O
pharmacokinetic O
interactions O
involving O
other O
cytochrome O
P450 O
isoenzymes O
are O
known O
. O
Caution O
should O
be O
exercised O
when O
Methergine B-BRAND
( O
methylergonovine B-DRUG
maleate I-DRUG
) O
is O
used O
concurrently O
with O
other O
vasoconstrictors B-GROUP
or O
ergot B-GROUP
alkaloids I-GROUP
. O

Ritalin B-BRAND
may O
decrease O
the O
hypotensive O
effect O
of O
guanethidine B-DRUG
. O
Use O
cautiously O
with O
pressor O
agents O
. O
Human O
pharmacologic O
studies O
have O
shown O
that O
Ritalin B-BRAND
may O
inhibit O
the O
metabolism O
of O
coumarin B-GROUP
anticoagulants I-GROUP
, O
anticonvulsants B-GROUP
( O
phenobarbital B-DRUG
, O
diphenylhydantoin B-DRUG
, O
primidone B-DRUG
) O
, O
phenylbutazone B-DRUG
, O
and O
tricyclic B-GROUP
drugs I-GROUP
( O
imipramine B-DRUG
, O
clomipramine B-DRUG
, O
desipramine B-DRUG
) O
. O
Downward O
dosage O
adjustments O
of O
these O
drugs O
may O
be O
required O
when O
given O
concomitantly O
with O
Ritalin B-BRAND
. O
Serious O
adverse O
events O
have O
been O
reported O
in O
concomitant O
use O
with O
clonidine B-DRUG
, O
although O
no O
causality O
for O
the O
combination O
has O
been O
established O
. O
The O
safety O
of O
using O
methylphenidate B-DRUG
in O
combination O
with O
clonidine B-DRUG
or O
other O
centrally O
acting O
alpha B-GROUP
- I-GROUP
2 I-GROUP
agonists I-GROUP
has O
not O
been O
systemically O
evaluated O
. O

The O
pharmacokinetic O
interactions O
listed O
below O
are O
potentially O
clinically O
important O
. O
Mutual O
inhibition O
of O
metabolism O
occurs O
with O
concurrent O
use O
of O
cyclosporin B-DRUG
and O
methylprednisolone B-DRUG
; O
therefore O
, O
it O
is O
possible O
that O
adverse O
events O
associated O
with O
the O
individual O
use O
of O
either O
drug O
may O
be O
more O
apt O
to O
occur O
. O
convulsions O
have O
been O
reported O
with O
concurrent O
use O
of O
methylprednisolone B-DRUG
and O
cyclosporin B-DRUG
. O
Drugs O
that O
induce O
hepatic O
enzymes O
such O
as O
phenobarbital B-DRUG
, O
phenytoin B-DRUG
, O
and O
rifampin B-DRUG
may O
increase O
the O
clearance O
of O
methylprednisolone B-DRUG
and O
may O
require O
increased O
in O
methylprednisolone B-DRUG
dose O
to O
achieve O
the O
desired O
response O
. O
Drugs O
such O
as O
troleandomycin B-DRUG
and O
ketoconazole B-DRUG
may O
inhibit O
the O
metabolism O
of O
methylprednisolone B-DRUG
and O
thus O
decrease O
its O
clearance O
. O
Therefore O
, O
the O
dose O
of O
methylprednisolone B-DRUG
should O
be O
titrated O
to O
avoid O
steroid O
toxicity O
. O
Methylprednisolone B-DRUG
may O
increase O
the O
clearance O
of O
chronic O
high O
dose O
aspirin B-BRAND
. O
This O
could O
lead O
to O
decreased O
salicylate B-GROUP
serum O
levels O
or O
increase O
the O
risk O
of O
salicylate B-GROUP
toxicity O
when O
methylprednisolone B-DRUG
is O
withdrawn O
. O
Aspirin B-BRAND
should O
be O
used O
cautiously O
in O
conjunction O
with O
corticosteroids B-GROUP
in O
patients O
suffering O
from O
hypoprothrombinemia O
. O
The O
effect O
of O
methylprednisolone B-DRUG
on O
oral O
anticoagulants B-GROUP
is O
variable O
. O
There O
are O
reports O
of O
enhanced O
as O
well O
as O
diminished O
effects O
of O
anticoagulant B-GROUP
when O
given O
concurrently O
with O
corticosteroids B-GROUP
. O
Therefore O
, O
coagulation O
indices O
should O
be O
monitored O
to O
maintain O
the O
desired O
anticoagulant O
effect O
. O

Methscopolamine B-DRUG
may O
interact O
with O
antidepressants B-GROUP
( O
tricyclic B-GROUP
type O
) O
, O
MAO B-GROUP
inhibitors I-GROUP
( O
e O
. O
g O
. O
, O
phenelzine B-DRUG
, O
linezolid B-DRUG
, O
tranylcypromine B-DRUG
, O
isocarboxazid B-DRUG
, O
selegiline B-DRUG
, O
furazolidone B-DRUG
) O
, O
quinidine B-DRUG
, O
amantadine B-DRUG
, O
antihistamines B-GROUP
( O
e O
. O
g O
. O
, O
diphenhydramine B-DRUG
) O
, O
other O
anticholinergics B-GROUP
, O
potassium B-DRUG
chloride I-DRUG
supplements O
, O
antacids B-GROUP
, O
absorbent B-GROUP
- I-GROUP
type I-GROUP
anti I-GROUP
- I-GROUP
diarrhea I-GROUP
medicines I-GROUP
( O
e O
. O
g O
. O
, O
kaolin B-DRUG
- O
pectin B-DRUG
) O
, O
phenothiazines B-GROUP
( O
e O
. O
g O
. O
, O
chlorpromazine B-DRUG
, O
promethazine B-DRUG
) O
. O

Methyprylon B-DRUG
may O
interact O
with O
other O
addictive O
medications O
, O
in O
that O
it O
may O
increase O
the O
likelyhood O
of O
addiction O
and O
abuse O
. O
Concurrent O
use O
of O
alcohol B-DRUG
and O
other O
CNS B-GROUP
depression I-GROUP
- I-GROUP
producing I-GROUP
drugs I-GROUP
may O
increase O
the O
CNS O
depressant O
effects O
of O
methyprylon B-DRUG
or O
these O
other O
medications O
. O

Methysergide B-DRUG
may O
reverse O
the O
analgesic O
activity O
of O
narcotic B-GROUP
analgesics I-GROUP
. O
Concurrent O
use O
with O
vasoconstrictor B-GROUP
agents I-GROUP
including O
ergot B-GROUP
alkaloids I-GROUP
, O
sumatriptan B-DRUG
, O
and O
nicotine B-DRUG
( O
e O
. O
g O
. O
smoking O
) O
may O
result O
in O
enhanced O
vasoconstriction O
. O

The O
effects O
of O
metoclopramide B-DRUG
on O
gastrointestinal O
motility O
are O
antagonized O
by O
anticholinergic B-GROUP
drugs I-GROUP
and O
narcotic B-GROUP
analgesics I-GROUP
. O
Additive O
sedative O
effects O
can O
occur O
when O
metoclopramide B-DRUG
is O
given O
with O
alcohol B-DRUG
, O
sedatives B-GROUP
, O
hypnotics B-GROUP
, O
narcotics B-GROUP
, O
or O
tranquilizers B-GROUP
. O
The O
finding O
that O
metoclopramide B-DRUG
releases O
catecholamines O
in O
patients O
with O
essential O
hypertension O
suggests O
that O
it O
should O
be O
used O
cautiously O
, O
if O
at O
all O
, O
in O
patients O
receiving O
monoamine B-GROUP
oxi I-GROUP
- I-GROUP
dase I-GROUP
inhibitors I-GROUP
. O
Absorption O
of O
drugs O
from O
the O
stomach O
may O
be O
diminished O
( O
e O
. O
g O
. O
, O
digoxin B-DRUG
) O
by O
metoclopramide B-DRUG
, O
whereas O
the O
rate O
and O
/ O
or O
extent O
of O
absorption O
of O
drugs O
from O
the O
small O
bowel O
may O
be O
increased O
( O
e O
. O
g O
. O
, O
acetaminophen B-DRUG
, O
tetracycline B-DRUG
, O
levodopa B-DRUG
, O
ethanol B-DRUG
, O
cyclosporine B-DRUG
) O
. O
Gastroparesis O
( O
gastric O
stasis O
) O
may O
be O
responsible O
for O
poor O
diabetic O
control O
in O
some O
patients O
. O
Exogenously O
administered O
insulin B-DRUG
may O
begin O
to O
act O
before O
food O
has O
left O
the O
stomach O
and O
lead O
to O
hypoglycemia O
. O
Because O
the O
action O
of O
metoclopramide B-DRUG
will O
influence O
the O
delivery O
of O
food O
to O
the O
intestines O
and O
thus O
the O
rate O
of O
absorption O
, O
insulin B-DRUG
dosage O
or O
timing O
of O
dosage O
may O
require O
adjustment O
. O

Diuretics B-GROUP
: O
Furosemide B-DRUG
and O
probably O
other O
loop B-GROUP
diuretics I-GROUP
given O
concomitantly O
with O
metolazone B-DRUG
can O
cause O
unusually O
large O
or O
prolonged O
losses O
of O
fluid O
and O
electrolytes O
. O
Other O
Antihypertensives B-GROUP
: O
When O
MYKROX B-BRAND
Tablets O
are O
used O
with O
other O
antihypertensive B-GROUP
drugs I-GROUP
, O
care O
must O
be O
taken O
, O
especially O
during O
initial O
therapy O
. O
Dosage O
adjustments O
of O
other O
antihypertensives B-GROUP
may O
be O
necessary O
. O
Alcohol B-DRUG
, O
Barbiturates B-GROUP
, O
and O
Narcotics B-GROUP
: O
The O
hypotensive O
effects O
of O
these O
drugs O
may O
be O
potentiated O
by O
the O
volume O
contraction O
that O
may O
be O
associated O
with O
metolazone B-DRUG
therapy O
. O
Digitalis B-GROUP
Glycosides I-GROUP
: O
Diuretic B-GROUP
- O
induced O
hypokalemia O
can O
increase O
the O
sensitivity O
of O
the O
myocardium O
to O
digitalis B-GROUP
. O
Serious O
arrhythmias O
can O
result O
. O
Corticosteroids B-GROUP
or O
ACTH B-DRUG
: O
May O
increase O
the O
risk O
of O
hypokalemia O
and O
increase O
salt O
and O
water O
retention O
. O
Lithium B-DRUG
: O
Serum O
lithium B-DRUG
levels O
may O
increase O
. O
Curariform B-GROUP
Drugs I-GROUP
: O
Diuretic B-GROUP
- O
induced O
hypokalemia O
may O
enhance O
neuromuscular O
blocking O
effects O
of O
curariform B-GROUP
drugs I-GROUP
( O
such O
as O
tubocurarine B-DRUG
) O
the O
most O
serious O
effect O
would O
be O
respiratory O
depression O
which O
could O
proceed O
to O
apnea O
. O
Accordingly O
, O
it O
may O
be O
advisable O
to O
discontinue O
MYKROX B-BRAND
Tablets O
three O
days O
before O
elective O
surgery O
. O
Salicylates B-GROUP
and O
Other O
Non B-GROUP
- I-GROUP
Steroidal I-GROUP
Anti I-GROUP
- I-GROUP
Inflammatory I-GROUP
Drugs I-GROUP
: O
May O
decrease O
the O
antihypertensive O
effects O
of O
MYKROX B-BRAND
Tablets O
. O
Sympathomimetics B-GROUP
: O
Metolazone B-DRUG
may O
decrease O
arterial O
responsiveness O
to O
norepinephrine B-DRUG
, O
but O
this O
diminution O
is O
not O
sufficient O
to O
preclude O
effectiveness O
of O
the O
pressor O
agent O
for O
therapeutic O
use O
. O
Methenamine B-DRUG
: O
Efficacy O
may O
be O
decreased O
due O
to O
urinary O
alkalizing O
effect O
of O
metolazone B-DRUG
. O
Anticoagulants B-GROUP
: O
Metolazone B-DRUG
, O
as O
well O
as O
other O
thiazide B-GROUP
- I-GROUP
like I-GROUP
diuretics I-GROUP
, O
may O
affect O
the O
hypoprothrombinemic O
response O
to O
anticoagulants B-GROUP
; O
dosage O
adjustments O
may O
be O
necessary O
. O

Catecholamine O
- O
depleting O
drugs O
( O
e O
. O
g O
. O
, O
reserpine B-DRUG
) O
may O
have O
an O
additive O
effect O
when O
given O
with O
beta B-GROUP
- I-GROUP
blocking I-GROUP
agents I-GROUP
. O
Patients O
treated O
with O
extended O
release O
metoprolol B-DRUG
succinate I-DRUG
plus O
a O
catecholamine O
depletor O
should O
therefore O
be O
closely O
observed O
for O
evidence O
of O
hypotension O
or O
marked O
bradycardia O
, O
which O
may O
produce O
vertigo O
, O
syncope O
, O
or O
postural O
hypotension O
. O

Oral O
metronidazole B-DRUG
has O
been O
reported O
to O
potentiate O
the O
anticoagulant O
effect O
of O
coumarin B-GROUP
and O
warfarin B-DRUG
, O
resulting O
in O
a O
prolongation O
of O
prothrombin O
time O
. O
Drug O
interactions O
should O
be O
kept O
in O
mind O
when O
METROGEL B-BRAND
( O
metronidazole B-DRUG
gel O
) O
, O
1 O
% O
is O
prescribed O
for O
patients O
who O
are O
receiving O
anticoagulant O
treatment O
, O
although O
they O
are O
less O
likely O
to O
occur O
with O
topical O
metronidazole B-DRUG
administration O
because O
of O
low O
absorption O
. O

Drugs O
affecting O
pituitary O
or O
adrenocortical O
function O
, O
including O
all O
corticosteroid O
therapy O
, O
must O
be O
discontinued O
prior O
to O
and O
during O
testing O
with O
Metopirone B-BRAND
. O
The O
metabolism O
of O
Metopirone B-BRAND
is O
accelerated O
by O
phenytoin B-DRUG
; O
therefore O
, O
results O
of O
the O
test O
may O
be O
inaccurate O
in O
patients O
taking O
phenytoin B-DRUG
within O
two O
weeks O
before O
. O
Asubnormal O
response O
may O
occur O
in O
patients O
on O
estrogen O
therapy O
. O
Metopirone B-BRAND
inhibits O
the O
glucuronidation O
of O
acetaminophen B-DRUG
and O
could O
possibly O
potentiate O
acetaminophen B-DRUG
toxicity O
. O

Caution O
should O
be O
observed O
in O
administering O
DEMSER B-BRAND
to O
patients O
receiving O
phenothiazines B-GROUP
or O
haloperidol B-DRUG
because O
the O
extrapyramidal O
effects O
of O
these O
drugs O
can O
be O
expected O
to O
be O
potentiated O
by O
inhibition O
of O
catecholamine O
synthesis O
. O
Concurrent O
use O
of O
DEMSER B-BRAND
with O
alcohol B-DRUG
or O
other O
CNS B-DRUG
depressants I-DRUG
can O
increase O
their O
sedative O
effects O
. O

Since O
MEXITIL B-BRAND
is O
a O
substrate O
for O
the O
metabolic O
pathways O
involving O
CYP2D6 O
and O
CYP1A2 O
enzymes O
, O
inhibition O
or O
induction O
of O
either O
of O
these O
enzymes O
would O
be O
expected O
to O
alter O
mexiletine B-DRUG
plasma O
concentrations O
. O
In O
a O
formal O
, O
single O
- O
dose O
interaction O
study O
( O
n O
= O
6 O
males O
) O
the O
clearance O
of O
mexiletine B-DRUG
was O
decreased O
by O
38 O
% O
following O
the O
coadministration O
of O
fluvoxamine B-DRUG
, O
an O
inhibitor O
of O
CYP1A2 O
. O
In O
another O
formal O
study O
( O
n O
= O
8 O
extensive O
and O
n O
= O
7 O
poor O
metabolizers O
of O
CYP2D6 O
) O
, O
coadministration O
of O
propafenone B-DRUG
did O
not O
alter O
the O
kinetics O
of O
mexiletine B-DRUG
in O
the O
poor O
CYP2D6 O
metabolizer O
group O
. O
However O
, O
the O
metabolic O
clearance O
of O
mexiletine B-DRUG
in O
the O
extensive O
metabolizer O
phenotype O
decreased O
by O
about O
70 O
% O
making O
the O
poor O
and O
extensive O
metabolizer O
groups O
indistinguishable O
. O
In O
this O
crossover O
steady O
state O
study O
, O
the O
pharmacokinetics O
of O
propafenone B-DRUG
were O
unaffected O
in O
either O
phenotype O
by O
the O
coadministration O
of O
mexiletine B-DRUG
. O
Addition O
of O
mexiletine B-DRUG
to O
propafenone B-DRUG
did O
not O
lead O
to O
further O
electrocardiographic O
parameters O
changes O
of O
QRS O
, O
QTc O
, O
RR O
, O
and O
PR O
intervals O
than O
propafenone B-DRUG
alone O
. O
When O
concomitant O
administration O
of O
either O
of O
these O
two O
drugs O
with O
mexiletine B-DRUG
is O
initiated O
, O
the O
dose O
of O
mexiletine B-DRUG
should O
be O
slowly O
titrated O
to O
desired O
effect O
. O
In O
a O
large O
compassionate O
use O
program O
Mexitil B-BRAND
has O
been O
used O
concurrently O
with O
commonly O
employed O
antianginal O
, O
antihypertensive B-GROUP
, O
and O
anticoagulant B-GROUP
drugs I-GROUP
without O
observed O
interactions O
. O
A O
variety O
of O
antiarrhythmics B-GROUP
such O
as O
quinidine B-DRUG
or O
propranolol B-DRUG
were O
also O
added O
, O
sometimes O
with O
improved O
control O
of O
ventricular O
ectopy O
. O
When O
phenytoin B-DRUG
or O
other O
hepatic O
enzyme O
inducers O
such O
as O
rifampin B-DRUG
and O
phenobarbital B-DRUG
have O
been O
taken O
concurrently O
with O
Mexitil B-BRAND
, O
lowered O
Mexitil B-BRAND
plasma O
levels O
have O
been O
reported O
. O
Monitoring O
of O
Mexitil B-BRAND
plasma O
levels O
is O
recommended O
during O
such O
concurrent O
use O
to O
avoid O
ineffective O
therapy O
. O
In O
a O
formal O
study O
, O
benzodiazepines B-GROUP
were O
shown O
not O
to O
affect O
Mexitil B-BRAND
plasma O
concentrations O
. O
ECG O
intervals O
( O
PR O
, O
QRS O
, O
and O
QT O
) O
were O
not O
affected O
by O
concurrent O
Mexitil B-BRAND
and O
digoxin B-DRUG
, O
diuretics B-GROUP
, O
or O

propranolol B-DRUG
. O
Concurrent O
administration O
of O
cimetidine B-DRUG
and O
Mexitil B-BRAND
has O
been O
reported O
to O
increase O
, O
decrease O
, O
or O
leave O
unchanged O
Mexitil B-BRAND
plasma O
levels O
; O
therefore O
patients O
should O
be O
followed O
carefully O
during O
concurrent O
therapy O
. O
Mexitil B-BRAND
does O
not O
alter O
serum O
digoxin B-DRUG
levels O
but O
magnesium B-DRUG
- I-DRUG
aluminum I-DRUG
hydroxide I-DRUG
, O
when O
used O
to O
treat O
gastrointestinal O
symptoms O
due O
to O
Mexitil B-BRAND
, O
has O
been O
reported O
to O
lower O
serum O
digoxin B-DRUG
levels O
. O
Concurrent O
use O
of O
Mexitil B-BRAND
and O
theophylline B-DRUG
may O
lead O
to O
increased O
plasma O
theophylline B-DRUG
levels O
. O
One O
controlled O
study O
in O
eight O
normal O
subjects O
showed O
a O
72 O
% O
mean O
increase O
( O
range O
35 O
- O
136 O
% O
) O
in O
plasma O
theophylline B-DRUG
levels O
. O
This O
increase O
was O
observed O
at O
the O
first O
test O
point O
which O
was O
the O
second O
day O
after O
starting O
Mexitil B-BRAND
. O
Theophylline B-DRUG
plasma O
levels O
returned O
to O
pre O
- O
Mexitil B-BRAND
values O
within O
48 O
hours O
after O
discontinuing O
Mexitil B-BRAND
. O
If O
Mexitil B-BRAND
and O
theophylline B-DRUG
are O
to O
be O
used O
concurrently O
, O
theophylline B-DRUG
blood O
levels O
should O
be O
monitored O
, O
particularly O
when O
the O
Mexitil B-BRAND
dose O
is O
changed O
. O
An O
appropriate O
adjustment O
in O
theophylline B-DRUG
dose O
should O
be O
considered O
. O
Additionally O
, O
in O
one O
controlled O
study O
in O
five O
normal O
subjects O
and O
seven O
patients O
, O
the O
clearance O
of O
caffeine B-DRUG
was O
decreased O
50 O
% O
following O
the O
administration O
of O
Mexitil B-BRAND
. O

Posicor B-BRAND
inhibits O
some O
of O
the O
liver O
' O
s O
ability O
to O
metabolize O
some O
other O
drugs O
- O
terfenadine B-DRUG
, O
astemizole B-DRUG
, O
cisapride B-DRUG
, O
cyclosporine B-DRUG
, O
and O
tricyclic B-GROUP
antidepressants I-GROUP
. O
Thus O
the O
concentrations O
of O
these O
drugs O
would O
increase O
meaning O
side O
effects O
may O
be O
seen O
. O
A O
dose O
adjustment O
may O
be O
required O
. O

A O
total O
of O
11 O
clinical O
drug O
- O
drug O
interaction O
studies O
were O
conducted O
in O
healthy O
volunteers O
to O
evaluate O
the O
potential O
for O
interaction O
between O
MYCAMINE B-BRAND
and O
mycophenolate B-DRUG
mofetil I-DRUG
, O
cyclosporine B-DRUG
, O
tacrolimus B-DRUG
, O
prednisolone B-DRUG
, O
sirolimus B-DRUG
, O
nifedipine B-DRUG
, O
fluconazole B-DRUG
, O
ritonavir B-DRUG
, O
and O
rifampin B-DRUG
. O
In O
these O
studies O
, O
no O
interaction O
that O
altered O
the O
pharmacokinetics O
of O
micafungin B-DRUG
was O
observed O
. O
There O
was O
no O
effect O
of O
a O
single O
dose O
or O
multiple O
doses O
of O
MYCAMINE B-BRAND
on O
mycophenolate B-DRUG
mofetil I-DRUG
, O
cyclosporine B-DRUG
, O
tacrolimus B-DRUG
, O
prednisolone B-DRUG
, O
and O
fluconazole B-DRUG
pharmacokinetics O
. O
Sirolimus B-DRUG
AUC O
was O
increased O
by O
21 O
% O
with O
no O
effect O
on O
Cmax O
in O
the O
presence O
of O
steady O
- O
state O
MYCAMINE B-BRAND
compared O
with O
sirolimus B-DRUG
alone O
. O
Nifedipine B-DRUG
AUC O
and O
Cmax O
were O
increased O
by O
18 O
% O
and O
42 O
% O
, O
respectively O
, O
in O
the O
presence O
of O
steady O
- O
state O
MYCAMINE B-BRAND
compared O
with O
nifedipine B-DRUG
alone O
. O
Patients O
receiving O
sirolimus B-DRUG
or O
nifedipine B-DRUG
in O
combination O
with O
MYCAMINE B-BRAND
should O
be O
monitored O
for O
sirolimus B-DRUG
or O
nifedipine B-DRUG
toxicity O
and O
sirolimus B-DRUG
or O
nifedipine B-DRUG
dosage O
should O
be O
reduced O
if O
necessary O
. O
Micafungin B-DRUG
is O
not O
an O
inhibitor O
of O
P O
- O
glycoprotein O
and O
, O
therefore O
, O
would O
not O
be O
expected O
to O
alter O
P O
- O
glycoprotein O
- O
mediated O
drug O
transport O
activity O
. O

Drug O
Interactions O
: O
Inhibitors O
of O
CYP3A4 O
Isozymes O
: O
Caution O
is O
advised O
when O
midazolam B-DRUG
is O
administered O
concomitantly O
with O
drugs O
that O
are O
known O
to O
inhibit O
the O
cytochrome O
P450 O
3A4 O
enzyme O
system O
( O
ie O
, O
some O
drugs O
in O
the O
drug O
classes O
of O
azole B-GROUP
antimycotics I-GROUP
, O
protease B-GROUP
inhibitors I-GROUP
, O
calcium B-GROUP
channel I-GROUP
antagonists I-GROUP
, O
and O
macrolide B-GROUP
antibiotics I-GROUP
) O
. O
Drugs O
such O
as O
erythromycin B-DRUG
, O
diltiazem B-DRUG
, O
verapamil B-DRUG
, O
ketoconazole B-DRUG
, O
fluconazole B-DRUG
and O
itraconazole B-DRUG
were O
shown O
to O
significantly O
increase O
the O
C O
max O
and O
AUC O
of O
orally O
administered O
midazolam B-DRUG
. O
These O
drug O
interactions O
may O
result O
in O
increased O
and O
prolonged O
sedation O
due O
to O
a O
decrease O
in O
plasma O
clearance O
of O
midazolam B-DRUG
. O
Although O
not O
studied O
, O
the O
potent O
cytochrome O
P450 O
3A4 O
inhibitors O
ritonavir B-DRUG
and O
nelfinavir B-DRUG
may O
cause O
intense O
and O
prolonged O
sedation O
and O
respiratory O
depression O
due O
to O
a O
decrease O
in O
plasma O
clearance O
of O
midazolam B-DRUG
. O
Caution O
is O
advised O
when O
VERSED B-BRAND
Syrup I-BRAND
is O
used O
concomitantly O
with O
these O
drugs O
. O
Dose O
adjustments O
should O
be O
considered O
and O
possible O
prolongation O
and O
intensity O
of O
effect O
should O
be O
anticipated O
. O
Inducers O
of O
CYP3A4 O
Isozymes O
: O
Cytochrome O
P450 O
inducers O
, O
such O
as O
rifampin B-DRUG
, O
carbamazepine B-DRUG
, O
and O
phenytoin B-DRUG
, O
induce O
metabolism O
and O
caused O
a O
markedly O
decreased O
C O
max O
and O
AUC O
of O
oral O
midazolam B-DRUG
in O
adult O
studies O
. O
Although O
clinical O
studies O
have O
not O
been O
performed O
, O
phenobarbital B-DRUG
is O
expected O
to O
have O
the O
same O
effect O
. O
Caution O
is O
advised O
when O
administering O
VERSED B-BRAND
Syrup I-BRAND
to O
patients O
receiving O
these O
medications O
and O
if O
necessary O
dose O
adjustments O
should O
be O
considered O
. O
The O
difficulty O
in O
achieving O
adequate O
sedation O
may O
have O
been O
the O
result O
of O
decreased O
absorption O
of O
the O
sedatives B-GROUP
due O
to O
both O
the O
gastrointestinal O
effects O
and O
stimulant O
effects O
of O
methylphenidate B-DRUG
. O
The O
sedative O
effect O
of O
VERSED B-BRAND
Syrup I-BRAND
is O
accentuated O
by O
any O
concomitantly O
administered O
medication O
which O
depresses O
the O
central O
nervous O
system O
, O
particularly O
narcotics B-GROUP
( O
eg O
, O
morphine B-DRUG
, O
meperidine B-DRUG
and O
fentanyl B-DRUG
) O
, O
propofol B-DRUG
, O
ketamine B-DRUG
, O
nitrous B-DRUG
oxide I-DRUG
, O
secobarbital B-DRUG
and O
droperidol B-DRUG
. O
Consequently O

, O
the O
dose O
of O
VERSED B-BRAND
Syrup I-BRAND
should O
be O
adjusted O
according O
to O
the O
type O
and O
amount O
of O
concomitant O
medications O
administered O
and O
the O
desired O
clinical O
response O
. O
No O
significant O
adverse O
interactions O
with O
common O
premedications O
( O
such O
as O
atropine B-DRUG
, O
scopolamine B-DRUG
, O
glycopyrrolate B-DRUG
, O
diazepam B-DRUG
, O
hydroxyzine B-DRUG
, O
and O
other O
muscle B-GROUP
relaxants I-GROUP
) O
or O
local O
anesthetics B-GROUP
have O
been O
observed O
. O

When O
administered O
concomitantly O
with O
ProAmatine B-BRAND
, O
cardiac B-GROUP
glycosides I-GROUP
may O
enhance O
or O
precipitate O
bradycardia O
, O
A O
. O
V O
. O
block O
or O
arrhythmia O
. O
The O
use O
of O
drugs O
that O
stimulate O
alpha O
- O
adrenergic O
receptors O
( O
e O
. O
g O
. O
, O
phenylephrine B-DRUG
, O
pseudoephedrine B-DRUG
, O
ephedrine B-DRUG
, O
phenylpropanolamine B-DRUG
or O
dihydroergotamine B-DRUG
) O
may O
enhance O
or O
potentiate O
the O
pressor O
effects O
of O
ProAmatine B-BRAND
. O
Therefore O
, O
caution O
should O
be O
used O
when O
ProAmatine B-BRAND
is O
administered O
concomitantly O
with O
agents O
that O
cause O
vasoconstriction O
. O
ProAmatine B-BRAND
has O
been O
used O
in O
patients O
concomitantly O
treated O
with O
salt O
- O
retaining O
steroid O
therapy O
( O
i O
. O
e O
. O
, O
fludrocortisone B-DRUG
acetate I-DRUG
) O
, O
with O
or O
without O
salt O
supplementation O
. O
The O
potential O
for O
supine O
hypertension O
should O
be O
carefully O
monitored O
in O
these O
patients O
and O
may O
be O
minimized O
by O
either O
reducing O
the O
dose O
of O
fludrocortisone B-DRUG
acetate I-DRUG
or O
decreasing O
the O
salt O
intake O
prior O
to O
initiation O
of O
treatment O
with O
. O
ProAmatine B-BRAND
. O
Alpha B-GROUP
- I-GROUP
adrenergic I-GROUP
blocking I-GROUP
agents I-GROUP
, O
such O
as O
prazosin B-DRUG
, O
terazosin B-DRUG
, O
and O
doxazosin B-DRUG
, O
can O
antagonize O
the O
effects O
of O
ProAmatine B-BRAND
. O
Potential O
for O
Drug O
Interactions O
: O
It O
appears O
possible O
, O
although O
there O
is O
no O
supporting O
experimental O
evidence O
, O
that O
the O
high O
renal O
clearance O
of O
desglymidodrine B-DRUG_N
( O
a O
base O
) O
is O
due O
to O
active O
tubular O
secretion O
by O
the O
base O
- O
secreting O
system O
also O
responsible O
for O
the O
secretion O
of O
such O
drugs O
as O
metformin B-DRUG
, O
cimetidine B-DRUG
, O
ranitidine B-DRUG
, O
procainamide B-DRUG
, O
triamterene B-DRUG
, O
flecainide B-DRUG
, O
and O
quinidine B-DRUG
. O
Thus O
there O
may O
be O
a O
potential O
for O
drug O
- O
drug O
interactions O
with O
these O
drugs O
. O

Although O
specific O
drug O
or O
food O
interactions O
with O
mifepristone B-DRUG
have O
not O
been O
studied O
, O
on O
the O
basis O
of O
this O
drug O
s O
metabolism O
by O
CYP O
3A4 O
, O
it O
is O
possible O
that O
ketoconazole B-DRUG
, O
itraconazole B-DRUG
, O
erythromycin B-DRUG
, O
and O
grapefruit O
juice O
may O
inhibit O
its O
metabolism O
( O
increasing O
serum O
levels O
of O
mifepristone B-DRUG
) O
. O
Furthermore O
, O
rifampin B-DRUG
, O
dexamethasone B-DRUG
, O
St O
. O
John O
s O
Wort O
, O
and O
certain O
anticonvulsants B-GROUP
( O
phenytoin B-DRUG
, O
phenobarbital B-DRUG
, O
carbamazepine B-DRUG
) O
may O
induce O
mifepristone B-DRUG
metabolism O
( O
lowering O
serum O
levels O
of O
mifepristone B-DRUG
) O
. O
Based O
on O
in O
vitro O
inhibition O
information O
, O
coadministration O
of O
mifepristone B-DRUG
may O
lead O
to O
an O
increase O
in O
serum O
levels O
of O
drugs O
that O
are O
CYP O
3A4 O
substrates O
. O
Due O
to O
the O
slow O
elimination O
of O
mifepristone B-DRUG
from O
the O
body O
, O
such O
interaction O
may O
be O
observed O
for O
a O
prolonged O
period O
after O
its O
administration O
. O
Therefore O
, O
caution O
should O
be O
exercised O
when O
mifepristone B-DRUG
is O
administered O
with O
drugs O
that O
are O
CYP O
3A4 O
substrates O
and O
have O
narrow O
therapeutic O
range O
, O
including O
some O
agents O
used O
during O
general O
anesthesia O
. O

While O
co O
- O
administration O
of O
ZAVESCA B-BRAND
appeared O
to O
increase O
the O
clearance O
of O
Cerezyme B-BRAND
by O
70 O
% O
, O
these O
results O
are O
not O
conclusive O
because O
of O
the O
small O
number O
of O
subjects O
studied O
and O
because O
patients O
took O
variable O
doses O
of O
Cerezyme B-BRAND
. O
Combination O
therapy O
with O
Cerezyme B-BRAND
( O
imiglucerase B-DRUG
) O
and O
ZAVESCA B-BRAND
is O
not O
indicated O
. O

No O
untoward O
clinical O
manifestations O
have O
been O
observed O
in O
limited O
experience O
with O
patients O
in O
whom O
PRIMACOR B-BRAND
was O
used O
concurrently O
with O
the O
following O
drugs O
: O
digitalis B-GROUP
glycosides I-GROUP
; O
lidocaine B-DRUG
, O
quinidine B-DRUG
; O
hydralazine B-DRUG
, O
prazosin B-DRUG
; O
isosorbide B-DRUG
dinitrate I-DRUG
, O
nitroglycerin B-DRUG
; O
chlorthalidone B-DRUG
, O
furosemide B-DRUG
, O
hydrochlorothiazide B-DRUG
, O
spironolactone B-DRUG
; O
captopril B-DRUG
; O
heparin B-DRUG
, O
warfarin B-DRUG
, O
diazepam B-DRUG
, O
insulin B-DRUG
; O
and O
potassium B-DRUG
supplements O
. O
Chemical O
Interactions O
There O
is O
an O
immediate O
chemical O
interaction O
which O
is O
evidenced O
by O
the O
formation O
of O
a O
precipitate O
when O
furosemide B-DRUG
is O
injected O
into O
an O
intravenous O
line O
of O
an O
infusion O
of O
PRIMACOR B-BRAND
. O
Therefore O
, O
furosemide B-DRUG
should O
not O
be O
administered O
in O
intravenous O
lines O
containing O
PRIMACOR B-BRAND
. O

Because O
tetracyclines B-GROUP
have O
been O
shown O
to O
depress O
plasma O
prothrombin O
activity O
, O
patients O
who O
are O
on O
anticoagulant B-GROUP
therapy O
may O
require O
downward O
adjustment O
of O
their O
anticoagulant B-GROUP
dosage O
. O
Since O
bacteriostatic O
drugs O
may O
interfere O
with O
the O
bactericidal O
action O
of O
penicillin B-DRUG
, O
it O
is O
advisable O
to O
avoid O
giving O
tetracycline B-GROUP
class I-GROUP
drugs I-GROUP
in O
conjunction O
with O
penicillin B-DRUG
. O
Absorption O
of O
tetracyclines B-GROUP
is O
impaired O
by O
antacids B-GROUP
containing O
aluminum B-DRUG
, O
calcium B-DRUG
or O
magnesium B-DRUG
, O
and O
iron B-DRUG
- O
containing O
preparations O
. O
The O
concurrent O
use O
of O
tetracycline B-GROUP
and O
methoxyflurane B-DRUG
has O
been O
reported O
to O
result O
in O
fatal O
renal O
toxicity O
. O
Concurrent O
use O
of O
tetracyclines B-GROUP
with O
oral O
contraceptives B-GROUP
may O
render O
oral O
contraceptives B-GROUP
less O
effective O
. O

Interaction O
with O
Guanethidine B-DRUG
: O
Although O
minoxidil B-DRUG
does O
not O
itself O
cause O
orthostatic O
hypotension O
, O
its O
administration O
to O
patients O
already O
receiving O
guanethidine B-DRUG
can O
result O
in O
profound O
orthostatic O
effects O
. O
If O
at O
all O
possible O
guanethidine B-DRUG
should O
be O
discontinued O
well O
before O
minoxidil B-DRUG
is O
begun O
. O
Where O
this O
is O
not O
possible O
, O
minoxidil B-DRUG
therapy O
should O
be O
started O
in O
the O
hospital O
and O
the O
patient O
should O
remain O
institutionalized O
until O
severe O
orthostatic O
effects O
are O
no O
longer O
present O
or O
the O
patient O
has O
learned O
to O
avoid O
activities O
that O
provoke O
them O
. O

As O
with O
other O
drugs O
, O
the O
potential O
for O
interaction O
by O
a O
variety O
of O
mechanisms O
( O
e O
. O
g O
. O
, O
pharmacodynamic O
, O
pharmacokinetic O
inhibition O
or O
enhancement O
, O
etc O
. O
) O
is O
a O
possibility O
. O
Drugs O
Affecting O
Hepatic O
Metabolism O
The O
metabolism O
and O
pharmacokinetics O
of O
REMERON B-BRAND
SolTab I-BRAND
( O
mirtazapine B-DRUG
) O
Orally O
Disintegrating O
Tablets O
may O
be O
affected O
by O
the O
induction O
or O
inhibition O
of O
drug O
- O
metab O
- O
olizing O
enzymes O
. O
Drugs O
that O
are O
Metabolized O
by O
and O
/ O
or O
Inhibit O
Cytochrome O
P450 O
Enzymes O
Many O
drugs O
are O
metabolized O
by O
and O
/ O
or O
inhibit O
various O
cytochrome O
P450 O
enzymes O
, O
e O
. O
g O
. O
, O
2D6 O
, O
1A2 O
, O
3A4 O
, O
etc O
. O
In O
vitro O
studies O
have O
shown O
that O
mirtazapine B-DRUG
is O
a O
substrate O
for O
several O
of O
these O
enzymes O
, O
including O
2D6 O
, O
1A2 O
, O
and O
3A4 O
. O
While O
in O
vitro O
studies O
have O
shown O
that O
mirtazapine B-DRUG
is O
not O
a O
potent O
inhibitor O
of O
any O
of O
these O
enzymes O
, O
an O
indication O
that O
mirtazapine B-DRUG
is O
not O
likely O
to O
have O
a O
clinically O
significant O
inhibitory O
effect O
on O
the O
metabolism O
of O
other O
drugs O
that O
are O
substrates O
for O
these O
cytochrome O
P450 O
enzymes O
, O
the O
concomitant O
use O
of O
REMERON B-BRAND
SolTab I-BRAND
with O
most O
other O
drugs O
metabolized O
by O
these O
enzymes O
has O
not O
been O
formally O
studied O
. O
Consequently O
, O
it O
is O
not O
possible O
to O
make O
any O
definitive O
statements O
about O
the O
risks O
of O
coadministration O
of O
REMERON B-BRAND
SolTab I-BRAND
with O
such O
drugs O
. O
Alcohol B-DRUG
: O
Concomitant O
administration O
of O
alcohol B-DRUG
( O
equivalent O
to O
60 O
g O
) O
had O
a O
minimal O
effect O
on O
plasma O
levels O
of O
mirtazapine B-DRUG
( O
15 O
mg O
) O
in O
6 O
healthy O
male O
subjects O
. O
However O
, O
the O
impairment O
of O
cognitive O
and O
motor O
skills O
produced O
by O
REMERON B-BRAND
were O
shown O
to O
be O
additive O
with O
those O
produced O
by O
alcohol B-DRUG
. O
Accordingly O
, O
patients O
should O
be O
advised O
to O
avoid O
alcohol B-DRUG
while O
taking O
REMERON B-BRAND
SolTab I-BRAND
. O
Diazepam B-DRUG
: O
Concomitant O
administration O
of O
diazepam B-DRUG
( O
15 O
mg O
) O
had O
a O
minimal O
effect O
on O
plasma O
levels O
of O
mirtazapine B-DRUG
( O
15 O
mg O
) O
in O
12 O
healthy O
subjects O
. O
However O
, O
the O
impairment O
of O
motor O
skills O
produced O
by O
REMERON B-BRAND
has O
been O
shown O
to O
be O
additive O
with O
those O
caused O
by O
diazepam B-DRUG
. O
Accordingly O
, O
patients O
should O
be O
advised O
to O
avoid O
diazepam B-DRUG
and O
other O
similar O
drugs O
while O
taking O
REMERON B-BRAND
SolTab I-BRAND
. O

Misoprostol B-DRUG
has O
not O
been O
shown O
to O
interfere O
with O
the O
beneficial O
effects O
of O
aspirin B-BRAND
on O
signs O
and O
symptoms O
of O
rheumatoid O
arthritis O
. O
Misoprostol B-DRUG
does O
not O
exert O
clinically O
significant O
effects O
on O
the O
absorption O
, O
blood O
levels O
, O
and O
anti O
- O
platelet O
effects O
of O
therapeutic O
doses O
of O
aspirin B-BRAND
. O
Misoprostol B-DRUG
has O
no O
clinically O
significant O
effect O
on O
the O
kinetics O
of O
diclofenac B-DRUG
or O
ibuprofen B-DRUG
. O

Mitotane B-DRUG
has O
been O
reported O
to O
accelerate O
the O
metabolism O
of O
warfarin B-DRUG
by O
the O
mechanism O
of O
hepatic O
microsomal O
enzyme O
induction O
, O
leading O
to O
an O
increase O
in O
dosage O
requirements O
for O
warfarin B-DRUG
. O
Therefore O
, O
physicians O
should O
closely O
monitor O
patients O
for O
a O
change O
in O
anticoagulant B-GROUP
dosage O
requirements O
when O
administering O
Mitotane B-DRUG
to O
patients O
on O
coumarin B-GROUP
- I-GROUP
type I-GROUP
anticoagulants I-GROUP
. O
In O
addition O
, O
Mitotane B-DRUG
should O
be O
given O
with O
caution O
to O
patients O
receiving O
other O
drugs O
susceptible O
to O
the O
influence O
of O
hepatic O
enzyme O
induction O
. O

Mitoxantrone B-DRUG
and O
its O
metabolites O
are O
excreted O
in O
bile O
and O
urine O
, O
but O
it O
is O
not O
known O
whether O
the O
metabolic O
or O
excretory O
pathways O
are O
saturable O
, O
may O
be O
inhibited O
or O
induced O
, O
or O
if O
mitoxantrone B-DRUG
and O
its O
metabolites O
undergo O
enterohepatic O
circulation O
. O
To O
date O
, O
post O
- O
marketing O
experience O
has O
not O
revealed O
any O
significant O
drug O
interactions O
in O
patients O
who O
have O
received O
NOVANTRONE B-BRAND
for O
treatment O
of O
cancer O
. O
Information O
on O
drug O
interactions O
in O
patients O
with O
multiple O
sclerosis O
is O
limited O
. O
Following O
concurrent O
administration O
of O
NOVANTRONE B-BRAND
with O
corticosteroids B-GROUP
, O
no O
evidence O
of O
drug O
interactions O
has O
been O
observed O
. O

Although O
MIVACRON B-BRAND
( O
a O
mixture O
of O
three O
stereoisomers O
) O
has O
been O
administered O
safely O
following O
succinylcholine O
- O
facilitated O
tracheal O
intubation O
, O
the O
interaction O
between O
MIVACRON B-BRAND
and O
succinylcholine B-DRUG
has O
not O
been O
systematically O
studied O
. O
Prior O
administration O
of O
succinylcholine B-DRUG
can O
potentiate O
the O
neuromuscular O
blocking O
effects O
of O
nondepolarizing B-GROUP
agents I-GROUP
. O
Evidence O
of O
spontaneous O
recovery O
from O
succinylcholine B-DRUG
should O
be O
observed O
before O
the O
administration O
of O
MIVACRON B-BRAND
. O
The O
use O
of O
MIVACRON B-BRAND
before O
succinylcholine B-DRUG
to O
attenuate O
some O
of O
the O
side O
effects O
of O
succinylcholine B-DRUG
has O
not O
been O
studied O
. O
There O
are O
no O
clinical O
data O
on O
the O
use O
of O
MIVACRON B-BRAND
with O
other O
nondepolarizing B-GROUP
neuromuscular I-GROUP
blocking I-GROUP
agents I-GROUP
. O
Isoflurane B-DRUG
and O
enflurane B-DRUG
( O
administered O
with O
nitrous B-DRUG
oxide I-DRUG
/ O
oxygen B-DRUG
to O
achieve O
1 O
. O
25 O
M O
. O
C O
. O
decrease O
the O
ED50 O
of O
MIVACRON B-BRAND
by O
as O
much O
as O
25 O
% O
( O
see O
CLINICAL O
PHARMACOLOGY O
: O
Pharmacodynamics O
and O
Individualization O
of O
Dosages O
) O
. O
These O
agents O
may O
also O
prolong O
the O
clinically O
effective O
duration O
of O
action O
and O
decrease O
the O
average O
infusion O
requirement O
of O
MIVACRON B-BRAND
by O
as O
much O
as O
35 O
% O
to O
40 O
% O
. O
A O
greater O
potentiation O
of O
the O
neuromuscular O
blocking O
effects O
of O
MIVACRON B-BRAND
may O
be O
expected O
with O
higher O
concentrations O
of O
enflurane B-DRUG
or O
isoflurane B-DRUG
. O
Halothane B-DRUG
has O
little O
or O
no O
effect O
on O
the O
ED50 O
, O
but O
may O
prolong O
the O
duration O
of O
action O
and O
decrease O
the O
average O
infusion O
requirement O
by O
as O
much O
as O
20 O
% O
. O
Other O
drugs O
which O
may O
enhance O
the O
neuromuscular O
blocking O
action O
of O
nondepolarizing B-DRUG
agents I-DRUG
such O
as O
MIVACRON B-BRAND
include O
certain O
antibiotics B-GROUP
( O
e O
. O
g O
. O
, O
aminoglycosides B-GROUP
, O
tetracyclines B-GROUP
, O
bacitracin B-DRUG
, O
polymyxins B-GROUP
, O
lincomycin B-DRUG
, O
clindamycin B-DRUG
, O
colistin B-DRUG
, O
and O
sodium B-DRUG
colistimethate I-DRUG
) O
, O
magnesium B-GROUP
salts O
, O
lithium B-DRUG
, O
local O
anesthetics B-GROUP
, O
procainamide B-DRUG
, O
and O
quinidine B-DRUG
. O
The O
neuromuscular O
blocking O
effect O
of O
MIVACRON B-BRAND
may O
be O
enhanced O
by O
drugs O
that O
reduce O
plasma O
cholinesterase O
activity O
( O
e O
. O
g O
. O
, O
chronically O
administered O
oral O
contraceptives B-GROUP
, O
glucocorticoids B-GROUP
, O
or O
certain O
monoamine B-GROUP

oxidase I-GROUP
inhibitors I-GROUP
) O
or O
by O
drugs O
that O
irreversibly O
inhibit O
plasma O
cholinesterase O
. O
Resistance O
to O
the O
neuromuscular O
blocking O
action O
of O
nondepolarizing O
neuromuscular B-GROUP
blocking I-GROUP
agents I-GROUP
has O
been O
demonstrated O
in O
patients O
chronically O
administered O
phenytoin B-DRUG
or O
carbamazepine B-DRUG
. O
While O
the O
effects O
of O
chronic O
phenytoin B-DRUG
or O
carbamazepine B-DRUG
therapy O
on O
the O
action O
of O
MIVACRON B-BRAND
are O
unknown O
, O
slightly O
shorter O
durations O
of O
neuromuscular O
block O
may O
be O
anticipated O
and O
infusion O
rate O
requirements O
may O
be O
higher O
. O
Some O
drug O
interactions O
are O
: O
- O
birth O
control O
pills O
- O
corticosteroids B-GROUP
- O
medicines O
for O
angina O
or O
high O
blood O
pressure O
- O
medicines O
for O
pain O
- O
medicines O
to O
control O
seizures O
such O
as O
phenytoin B-DRUG
or O
carbamazepine B-DRUG
- O
certain O
antibiotics B-GROUP
given O
by O
injection O
- O
cisplatin B-DRUG
- O
edrophonium B-DRUG
- O
neostigmine B-DRUG
- O
polymyxin B-DRUG
B I-DRUG
or O
bacitracin B-DRUG
- O
local O
anesthetics B-GROUP
such O
as O
procaine B-DRUG
- O
general O
anesthetics B-GROUP
- O
succinylcholine B-DRUG
or O
other O
muscle B-GROUP
relaxants I-GROUP

Diuretics B-GROUP
: O
Excessive O
reductions O
in O
blood O
pressure O
may O
occur O
in O
patients O
on O
diuretic O
therapy O
when O
ACE B-GROUP
inhibitors I-GROUP
are O
started O
. O
The O
possibility O
of O
hypotensive O
effects O
with O
UNIVASC B-BRAND
can O
be O
minimized O
by O
discontinuing O
diuretic O
therapy O
for O
several O
days O
or O
cautiously O
increasing O
salt O
intake O
before O
initiation O
of O
treatment O
with O
UNIVASC B-BRAND
. O
If O
this O
is O
not O
possible O
, O
the O
starting O
dose O
of O
moexpril B-DRUG
should O
be O
reduced O
. O
. O
Potassium B-DRUG
Supplements O
and O
Potassium B-GROUP
- I-GROUP
Sparing I-GROUP
Diuretics I-GROUP
: O
UNIVASC B-BRAND
can O
increase O
serum O
potassium O
because O
it O
decreases O
aldosterone O
secretion O
. O
Use O
of O
potassium B-GROUP
- I-GROUP
sparing I-GROUP
diuretics I-GROUP
( O
spironolactone B-DRUG
, O
triamterene B-DRUG
, O
amiloride B-DRUG
) O
or O
potassium B-DRUG
supplements O
concomitantly O
with O
ACE B-GROUP
inhibitors I-GROUP
can O
increase O
the O
risk O
of O
hyperkalemia O
. O
Therefore O
, O
if O
concomitant O
use O
of O
such O
agents O
is O
indicated O
, O
they O
should O
be O
given O
with O
caution O
and O
the O
patient O
' O
s O
serum O
potassium O
should O
be O
monitored O
. O
Oral O
Anticoagulants B-GROUP
: O
Interaction O
studies O
with O
warfarin B-DRUG
failed O
to O
identify O
any O
clinically O
important O
effect O
on O
the O
serum O
concentrations O
of O
the O
anticoagulant B-GROUP
or O
on O
its O
anticoagulant O
effect O
. O
Lithium B-DRUG
: O
Increased O
serum O
lithium B-DRUG
levels O
and O
symptoms O
of O
lithium B-DRUG
toxicity O
have O
been O
reported O
in O
patients O
receiving O
ACE B-GROUP
inhibitors I-GROUP
during O
therapy O
with O
lithium B-DRUG
. O
These O
drugs O
should O
be O
coadministered O
with O
caution O
, O
and O
frequent O
monitoring O
of O
serum O
lithium B-DRUG
levels O
is O
recommended O
. O
If O
a O
diuretic B-GROUP
is O
also O
used O
, O
the O
risk O
of O
lithium B-DRUG
toxicity O
may O
be O
increased O
. O
Other O
Agents O
: O
No O
clinically O
important O
pharmacokinetic O
interactions O
occurred O
when O
UNIVASC B-BRAND
was O
administered O
concomitantly O
with O
hydrochlorothiazide B-DRUG
, O
digoxin B-DRUG
, O
or O
cimetidine B-DRUG
. O
UNIVASC B-BRAND
has O
been O
used O
in O
clinical O
trials O
concomitantly O
with O
calcium B-GROUP
- I-GROUP
channel I-GROUP
- I-GROUP
blocking I-GROUP
agents I-GROUP
, O
diuretics B-GROUP
, O
H2 B-GROUP
blockers I-GROUP
, O
digoxin B-DRUG
, O
oral O
hypoglycemic B-GROUP
agents I-GROUP
, O
and O
cholesterol O
- O
lowering O
agents O
. O
There O
was O
no O
evidence O
of O
clinically O
important O
adverse O
interactions O
. O

In O
clinical O
studies O
, O
the O
concurrent O
administration O
of O
the O
ASMANEX B-BRAND
TWISTHALER I-BRAND
inhaler O
and O
other O
drugs O
commonly O
used O
in O
the O
treatment O
of O
asthma O
was O
not O
associated O
with O
any O
unusual O
adverse O
events O
. O
However O
, O
ketoconazole B-DRUG
, O
a O
potent O
inhibitor O
of O
cytochrome O
P450 O
3A4 O
, O
may O
increase O
plasma O
levels O
of O
mometasone B-DRUG
furoate I-DRUG
during O
concomitant O
dosing O
. O

Montelukast B-DRUG
at O
a O
Dose O
of O
10 O
mg O
Once O
Daily O
Dosed O
to O
Pharmacokinetic O
Steady O
State O
- O
did O
not O
cause O
clinically O
significant O
changes O
in O
the O
kinetics O
of O
a O
single O
intravenous O
dose O
of O
theophylline B-DRUG
( O
predominantly O
a O
cytochrome O
P450 O
1A2 O
substrate O
) O
. O
- O
did O
not O
change O
the O
pharmacokinetic O
profile O
of O
warfarin B-DRUG
( O
a O
substrate O
of O
cytochromes O
P450 O
2A6 O
and O
2C9 O
) O
or O
influence O
the O
effect O
of O
a O
single O
30 O
- O
mg O
oral O
dose O
of O
warfarin B-DRUG
on O
prothrombin O
time O
or O
the O
INR O
( O
International O
Normalized O
Ratio O
) O
. O
- O
did O
not O
change O
the O
pharmacokinetic O
profile O
or O
urinary O
excretion O
of O
immunoreactive O
digoxin B-DRUG
. O
- O
did O
not O
change O
the O
plasma O
concentration O
profile O
of O
terfenadine B-DRUG
( O
a O
substrate O
of O
cytochrome O
P450 O
3A4 O
) O
or O
fexofenadine B-DRUG
, O
its O
carboxylated O
metabolite O
, O
and O
did O
not O
prolong O
the O
QTc O
interval O
following O
co O
- O
administration O
with O
terfenadine B-DRUG
60 O
mg O
twice O
daily O
. O
Montelukast B-DRUG
at O
Doses O
of O
100 O
mg O
Daily O
Dosed O
to O
Pharmacokinetic O
Steady O
State O
: O
- O
did O
not O
significantly O
alter O
the O
plasma O
concentrations O
of O
either O
component O
of O
an O
oral O
contraceptive B-GROUP
containing O
norethindrone B-DRUG
1 O
mg O
/ O
ethinyl O
estradiol B-DRUG
35 O
mcg O
. O
- O
did O
not O
cause O
any O
clinically O
significant O
change O
in O
plasma O
profiles O
of O
prednisone B-DRUG
or O
prednisolone B-DRUG
following O
administration O
of O
either O
oral O
prednisone B-DRUG
or O
intravenous O
prednisolone B-DRUG
. O
Phenobarbital B-DRUG
, O
which O
induces O
hepatic O
metabolism O
, O
decreased O
the O
AUC O
of O
montelukast B-DRUG
approximately O
40 O
% O
following O
a O
single O
10 O
- O
mg O
dose O
of O
montelukast B-DRUG
. O
No O
dosage O
adjustment O
for O
montelukast B-DRUG
is O
recommended O
. O
It O
is O
reasonable O
to O
employ O
appropriate O
clinical O
monitoring O
when O
potent O
cytochrome O
P450 O
enzyme O
inducers O
, O
such O
as O
phenobarbital B-DRUG
or O
rifampin B-DRUG
, O
are O
co O
- O
administered O
with O
montelukast B-DRUG
. O
Montelukast B-DRUG
has O
been O
administered O
with O
other O
therapies O
routinely O
used O
in O
the O
prophylaxis O
and O
chronic O
treatment O
of O
asthma O
with O
no O
apparent O
increase O
in O
adverse O
reactions O
. O
In O
drug O
- O
interaction O
studies O
, O
the O
recommended O
clinical O
dose O
of O
montelukast B-DRUG
did O
not O
have O
clinically O
important O
effects O
on O
the O
pharmacokinetics O
of O
the O
following O
drugs O
: O
theophylline B-DRUG
, O
prednisone B-DRUG
, O

prednisolone B-DRUG
, O
oral O
contraceptives B-GROUP
( O
norethindrone B-DRUG
1 O
mg O
/ O
ethinyl B-DRUG
estradiol I-DRUG
35 O
mcg O
) O
, O
terfenadine B-DRUG
, O
digoxin B-DRUG
, O
and O
warfarin B-DRUG
. O
Although O
additional O
specific O
interaction O
studies O
were O
not O
performed O
, O
montelukast B-DRUG
was O
used O
concomitantly O
with O
a O
wide O
range O
of O
commonly O
prescribed O
drugs O
in O
clinical O
studies O
without O
evidence O
of O
clinical O
adverse O
interactions O
. O
These O
medications O
included O
thyroid B-GROUP
hormones I-GROUP
, O
sedative B-GROUP
hypnotics I-GROUP
, O
non B-GROUP
- I-GROUP
steroidal I-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
agents I-GROUP
, O
benzodiazepines B-GROUP
, O
and O
decongestants B-GROUP
. O
Phenobarbital B-DRUG
, O
which O
induces O
hepatic O
metabolism O
, O
decreased O
the O
AUC O
of O
montelukast B-DRUG
approximately O
40 O
% O
following O
a O
single O
10 O
- O
mg O
dose O
of O
montelukast B-DRUG
. O
No O
dosage O
adjustment O
for O
montelukast B-DRUG
is O
recommended O
. O
It O
is O
reasonable O
to O
employ O
appropriate O
clinical O
monitoring O
when O
potent O
cytochrome O
P450 O
enzyme O
inducers O
, O
such O
as O
phenobarbital B-DRUG
or O
rifampin B-DRUG
, O
are O
co O
- O
administered O
with O
montelukast B-DRUG
. O

May O
interact O
with O
cimetidine B-DRUG
, O
digoxin B-DRUG
, O
medicines O
to O
control O
heart O
rhythm O
, O
sevelamer B-DRUG
, O
and O
theophylline B-DRUG
. O

Use O
with O
Other O
Central B-GROUP
Nervous I-GROUP
System I-GROUP
Depressants I-GROUP
: O
The O
depressant O
effects O
of O
morphine B-DRUG
are O
potentiated O
by O
the O
presence O
of O
other O
CNS B-GROUP
depressants I-GROUP
such O
as O
alcohol B-DRUG
, O
sedatives B-GROUP
, O
antihistaminics B-GROUP
, O
or O
psychotropic B-GROUP
drugs I-GROUP
. O
Use O
of O
neuroleptics B-GROUP
in O
conjunction O
with O
oral O
morphine B-DRUG
may O
increase O
the O
risk O
of O
respiratory O
depression O
, O
hypotension O
and O
profound O
sedation O
or O
coma O
. O
Interaction O
with O
Mixed B-GROUP
Agonist I-GROUP
/ I-GROUP
Antagonist I-GROUP
Opioid I-GROUP
Analgesics I-GROUP
: O
Agonist B-GROUP
/ I-GROUP
antagonist I-GROUP
analgesics I-GROUP
( O
i O
. O
e O
. O
, O
pentazocine B-DRUG
, O
nalbuphine B-DRUG
, O
butorphanol B-DRUG
, O
or O
buprenorphine B-DRUG
) O
should O
NOT O
be O
administered O
to O
patients O
who O
have O
received O
or O
are O
receiving O
a O
course O
of O
therapy O
with O
a O
proof O
opioid B-GROUP
agonist I-GROUP
analgesic I-GROUP
. O
In O
these O
patients O
, O
the O
mixed O
agonist O
/ O
antagonist O
may O
alter O
the O
analgesic O
effect O
or O
may O
precipitate O
withdrawal O
symptoms O
. O

Drug O
- O
drug O
interaction O
studies O
have O
not O
been O
conducted O
with O
VIGAMOX B-BRAND
solution O
. O
In O
vitro O
studies O
indicate O
that O
moxifloxacin B-DRUG
does O
not O
inhibit O
CYP3A4 O
, O
CYP2D6 O
, O
CYP2C9 O
, O
CYP2C19 O
, O
or O
CYP1A2 O
indicating O
that O
moxifloxacin B-DRUG
is O
unlikely O
to O
alter O
the O
pharmacokinetics O
of O
drugs O
metabolized O
by O
these O
cytochrome O
P450 O
isozymes O
. O

Antacids B-GROUP
: O
Absorption O
of O
a O
single O
dose O
of O
Myfortic B-BRAND
was O
decreased O
when O
administered O
to O
12 O
stable O
renal O
transplant O
patients O
also O
taking O
magnesium B-DRUG
- O
aluminum B-DRUG
containing O
antacids B-GROUP
( O
30 O
mL O
) O
: O
the O
mean O
Cmax O
and O
AUC O
( O
0 O
- O
t O
) O
values O
for O
MPA O
were O
25 O
% O
and O
37 O
% O
lower O
, O
respectively O
, O
than O
when O
Myfortic B-BRAND
was O
administered O
alone O
under O
fasting O
conditions O
. O
It O
is O
recommended O
that O
Myfortic B-DRUG
and O
antacids B-GROUP
not O
be O
administered O
simultaneously O
. O
Cyclosporine B-DRUG
: O
When O
studied O
in O
stable O
renal O
transplant O
patients O
, O
cyclosporine B-DRUG
, O
USP O
( O
MODIFIED O
) O
pharmacokinetics O
were O
unaffected O
by O
steady O
state O
dosing O
of O
Myfortic B-BRAND
. O
Acyclovir B-DRUG
/ O
Ganciclovir B-DRUG
: O
may O
be O
taken O
with O
Myfortic B-BRAND
; O
however O
, O
during O
the O
period O
of O
treatment O
, O
physicians O
should O
monitor O
blood O
cell O
counts O
. O
Both O
acyclovir B-DRUG
/ O
ganciclovir B-DRUG
and O
MPAG B-DRUG_N
concentrations O
are O
increased O
in O
the O
presence O
of O
renal O
impairment O
, O
their O
coexistence O
may O
compete O
for O
tubular O
secretion O
and O
further O
increase O
in O
the O
concentrations O
of O
the O
two O
. O
Azathioprine B-DRUG
/ O
Mycophenolate B-DRUG
Mofetil I-DRUG
: O
Given O
that O
azathioprine B-DRUG
and O
mycophenolate B-DRUG
mofetil I-DRUG
inhibit O
purine O
metabolism O
, O
it O
is O
recommended O
that O
Myfortic B-BRAND
not O
be O
administered O
concomitantly O
with O
azathioprine B-DRUG
or O
mycophenolate B-DRUG
mofetil I-DRUG
. O
Cholestyramine B-DRUG
and O
Drugs O
that O
Bind O
Bile O
Acids O
: O
These O
drugs O
interrupt O
enterohepatic O
recirculation O
and O
reduce O
MPA B-DRUG_N
exposure O
when O
coadministered O
with O
mycophenolate B-DRUG
mofetil I-DRUG
. O
Therefore O
, O
do O
not O
administer O
Myfortic B-DRUG
with O
cholestyramine B-DRUG
or O
other O
agents O
that O
may O
interfere O
with O
enterohepatic O
recirculation O
or O
drugs O
that O
may O
bind O
bile O
acids O
, O
for O
example O
bile O
acid O
sequestrates O
or O
oral O
activated B-DRUG
charcoal I-DRUG
, O
because O
of O
the O
potential O
to O
reduce O
the O
efficacy O
of O
Myfortic B-BRAND
. O
Oral O
Contraceptives B-GROUP
: O
Given O
the O
different O
metabolism O
of O
Myfortic B-BRAND
and O
oral O
contraceptives B-GROUP
, O
no O
drug O
interaction O
between O
these O
two O
classes O
of O
drug O
is O
expected O
. O
However O
, O
in O
a O
drug O
- O
drug O
interaction O
study O
, O
mean O
levonorgesterol B-DRUG
AUC O
was O
decreased O
by O
15 O
% O
when O
coadministered O
with O
mycophenolate B-DRUG
mofetil I-DRUG
. O
Therefore O
, O
it O
is O
recommended O
that O
oral O
contraceptives B-GROUP
are O
co O
- O
administered O
with O
Myfortic B-BRAND

with O
caution O
and O
additional O
birth O
control O
methods O
be O
considered O
. O
Live B-GROUP
Vaccines I-GROUP
: O
During O
treatment O
with O
Myfortic B-DRUG
, O
the O
use O
of O
live B-GROUP
attenuated I-GROUP
vaccines I-GROUP
should O
be O
avoided O
and O
patients O
should O
be O
advised O
that O
vaccinations O
may O
be O
less O
effective O
. O
Influenza O
vaccination O
may O
be O
of O
value O
. O
Prescribers O
should O
refer O
to O
national O
guidelines O
for O
influenza O
vaccination O
. O
Drugs O
that O
alter O
the O
gastrointestinal O
flora O
may O
interact O
with O
Myfortic B-BRAND
by O
disrupting O
enterohepatic O
recirculation O
. O
Interference O
of O
MPAG B-DRUG_N
hydrolysis O
may O
lead O
to O
less O
MPA B-DRUG_N
available O
for O
absorption O
. O

No O
significant O
drug O
interactions O
were O
reported O
in O
studies O
in O
which O
olmesartan B-DRUG
medoxomil I-DRUG
was O
co O
- O
administered O
with O
digoxin B-DRUG
or O
warfarin B-DRUG
in O
healthy O
volunteers O
. O
The O
bioavailability O
of O
olmesartan B-DRUG
was O
not O
significantly O
altered O
by O
the O
co O
- O
administration O
of O
antacids B-GROUP
[ O
Al O
( O
OH O
) O
3 O
/ O
Mg O
( O
OH O
) O
2 O
] O
. O
Olmesartan B-DRUG
medoxomil I-DRUG
is O
not O
metabolized O
by O
the O
cytochrome O
P450 O
system O
and O
has O
no O
effects O
on O
P450 O
enzymes O
; O
thus O
, O
interactions O
with O
drugs O
that O
inhibit O
, O
induce O
or O
are O
metabolized O
by O
those O
enzymes O
are O
not O
expected O
. O

Ondansetron B-DRUG
does O
not O
itself O
appear O
to O
induce O
or O
inhibit O
the O
cytochrome O
P O
- O
450 O
drug O
- O
metabolizing O
enzyme O
system O
of O
the O
liver O
. O
Because O
ondansetron B-DRUG
is O
metabolized O
by O
hepatic O
cytochrome O
P O
- O
450 O
drug O
- O
metabolizing O
enzymes O
( O
CYP3A4 O
, O
CYP2D6 O
, O
CYP1A2 O
) O
, O
inducers O
or O
inhibitors O
of O
these O
enzymes O
may O
change O
the O
clearance O
and O
, O
hence O
, O
the O
half O
- O
life O
of O
ondansetron B-DRUG
. O
On O
the O
basis O
of O
limited O
available O
data O
, O
no O
dosage O
adjustment O
is O
recommended O
for O
patients O
on O
these O
drugs O
. O
Phenytoin B-DRUG
, O
Carbamazepine B-DRUG
, O
and O
Rifampicin B-DRUG
: O
In O
patients O
treated O
with O
potent O
inducers O
of O
CYP3A4 O
( O
i O
. O
e O
. O
, O
phenytoin B-DRUG
, O
carbamazepine B-DRUG
, O
and O
rifampicin B-DRUG
) O
, O
the O
clearance O
of O
ondansetron B-DRUG
was O
significantly O
increased O
and O
ondansetron B-DRUG
blood O
concentrations O
were O
decreased O
. O
However O
, O
on O
the O
basis O
of O
available O
data O
, O
no O
dosage O
adjustment O
for O
ondansetron B-DRUG
is O
recommended O
for O
patients O
on O
these O
drugs O
. O
1 O
, O
3 O
Tramadol B-DRUG
: O
Although O
no O
pharmacokinetic O
drug O
interaction O
between O
ondansetron B-DRUG
and O
tramadol B-DRUG
has O
been O
observed O
, O
data O
from O
2 O
small O
studies O
indicate O
that O
ondansetron B-DRUG
may O
be O
associated O
with O
an O
increase O
in O
patient O
controlled O
administration O
of O
tramadol B-DRUG
. O
4 O
, O
5 O
Chemotherapy O
: O
Tumor O
response O
to O
chemotherapy O
in O
the O
P O
388 O
mouse O
leukemia O
model O
is O
not O
affected O
by O
ondansetron B-DRUG
. O
In O
humans O
, O
carmustine B-DRUG
, O
etoposide B-DRUG
, O
and O
cisplatin B-DRUG
do O
not O
affect O
the O
pharmacokinetics O
of O
ondansetron B-DRUG
. O
In O
a O
crossover O
study O
in O
76 O
pediatric O
patients O
, O
I O
. O
V O
. O
ondansetron B-DRUG
did O
not O
increase O
blood O
levels O
of O
high O
- O
dose O
methotrexate B-DRUG
. O

Other O
beta B-GROUP
adrenergic I-GROUP
aerosol I-GROUP
bronchodilators I-GROUP
should O
not O
be O
used O
concomitantly O
with O
Alupent B-BRAND
( O
metaproterenol B-DRUG
sulfate I-DRUG
USP O
) O
because O
they O
may O
have O
additive O
effects O
. O
Beta B-GROUP
adrenergic I-GROUP
agonists I-GROUP
should O
be O
administered O
with O
caution O
to O
patients O
being O
treated O
with O
monoamine B-GROUP
oxidase I-GROUP
inhibitors I-GROUP
or O
tricyclic B-GROUP
antidepressants I-GROUP
, O
since O
the O
action O
of O
beta B-GROUP
adrenergic I-GROUP
agonists I-GROUP
on O
the O
vascular O
system O
may O
be O
potentiated O
. O

Alcohol B-DRUG
: O
In O
a O
multiple O
- O
dose O
study O
in O
30 O
normal O
weight O
subjects O
, O
coadministration O
of O
XENICAL B-BRAND
and O
40 O
grams O
of O
alcohol B-DRUG
( O
e O
. O
g O
. O
, O
approximately O
3 O
glasses O
of O
wine O
) O
did O
not O
result O
in O
alteration O
of O
alcohol B-DRUG
pharmacokinetics O
, O
orlistat B-DRUG
pharmacodynamics O
( O
fecal O
fat O
excretion O
) O
, O
or O
systemic O
exposure O
to O
orlistat B-DRUG
. O
Cyclosporine B-DRUG
: O
Preliminary O
data O
from O
a O
XENICAL B-BRAND
and O
cyclosporine B-DRUG
drug O
interaction O
study O
indicate O
a O
reduction O
in O
cyclosporine B-DRUG
plasma O
levels O
when O
XENICAL B-BRAND
was O
coadministered O
with O
cyclosporine B-DRUG
. O
Digoxin B-DRUG
: O
In O
12 O
normal O
- O
weight O
subjects O
receiving O
XENICAL B-BRAND
120 O
mg O
three O
times O
a O
day O
for O
6 O
days O
, O
XENICAL B-BRAND
did O
not O
alter O
the O
pharmacokinetics O
of O
a O
single O
dose O
of O
digoxin B-DRUG
. O
Fat B-GROUP
- I-GROUP
soluble I-GROUP
Vitamin I-GROUP
Supplements I-GROUP
and O
Analogues O
: O
A O
pharmacokinetic O
interaction O
study O
showed O
a O
30 O
% O
reduction O
in O
beta B-DRUG
- I-DRUG
carotene I-DRUG
supplement O
absorption O
when O
concomitantly O
administered O
with O
XENICAL B-BRAND
. O
XENICAL B-BRAND
inhibited O
absorption O
of O
a O
vitamin B-DRUG
E I-DRUG
acetate I-DRUG
supplement O
by O
approximately O
60 O
% O
. O
The O
effect O
of O
orlistat B-DRUG
on O
the O
absorption O
of O
supplemental O
vitamin B-GROUP
D I-GROUP
, O
vitamin B-GROUP
A I-GROUP
, O
and O
nutritionally O
- O
derived O
vitamin B-GROUP
K I-GROUP
is O
not O
known O
at O
this O
time O
. O
Glyburide B-DRUG
: O
In O
12 O
normal O
- O
weight O
subjects O
receiving O
orlistat B-DRUG
80 O
mg O
three O
times O
a O
day O
for O
5 O
days O
, O
orlistat B-DRUG
did O
not O
alter O
the O
pharmacokinetics O
or O
pharmacodynamics O
( O
blood O
glucose O
- O
lowering O
) O
of O
glyburide B-DRUG
. O
Nifedipine B-DRUG
( O
extended O
- O
release O
tablets O
) O
: O
In O
17 O
normal O
- O
weight O
subjects O
receiving O
XENICAL B-BRAND
120 O
mg O
three O
times O
a O
day O
for O
6 O
days O
, O
XENICAL B-BRAND
did O
not O
alter O
the O
bioavailability O
of O
nifedipine B-DRUG
( O
extended O
- O
release O
tablets O
) O
. O
Oral O
Contraceptives B-GROUP
: O
In O
20 O
normal O
- O
weight O
female O
subjects O
, O
the O
treatment O
of O
XENICAL B-BRAND
120 O
mg O
three O
times O
a O
day O
for O
23 O
days O
resulted O
in O
no O
changes O
in O
the O
ovulation O
- O
suppressing O
action O
of O
oral O
contraceptives B-GROUP
. O
Phenytoin B-DRUG
: O
In O
12 O
normal O
- O
weight O
subjects O
receiving O
XENICAL B-BRAND
120 O
mg O
three O
times O
a O
day O
for O
7 O
days O
, O
XENICAL B-BRAND
did O
not O
alter O
the O
pharmacokinetics O
of O
a O
single O
300 O
- O
mg O
dose O
of O
phenytoin B-DRUG
. O
Pravastatin B-DRUG

: O
In O
a O
2 O
- O
way O
crossover O
study O
of O
24 O
normal O
- O
weight O
, O
mildly O
hypercholesterolemic O
patients O
receiving O
XENICAL B-BRAND
120 O
mg O
three O
times O
a O
day O
for O
6 O
days O
, O
XENICAL B-BRAND
did O
not O
affect O
the O
pharmacokinetics O
of O
pravastatin B-DRUG
. O
Warfarin B-DRUG
: O
In O
12 O
normal O
- O
weight O
subjects O
, O
administration O
of O
XENICAL B-BRAND
120 O
mg O
three O
times O
a O
day O
for O
16 O
days O
did O
not O
result O
in O
any O
change O
in O
either O
warfarin B-DRUG
pharmacokinetics O
( O
both O
R O
- O
and O
S O
- O
enantiomers O
) O
or O
pharmacodynamics O
( O
prothrombin O
time O
and O
serum O
Factor O
VII O
) O
. O
Although O
undercarboxylated O
osteocalcin O
, O
a O
marker O
of O
vitamin O
K O
nutritional O
status O
, O
was O
unaltered O
with O
XENICAL B-BRAND
administration O
, O
vitamin O
K O
levels O
tended O
to O
decline O
in O
subjects O
taking O
XENICAL B-BRAND
. O
Therefore O
, O
as O
vitamin B-GROUP
K I-GROUP
absorption O
may O
be O
decreased O
with O
XENICAL B-BRAND
, O
patients O
on O
chronic O
stable O
doses O
of O
warfarin B-DRUG
who O
are O
prescribed O
XENICAL B-BRAND
should O
be O
monitored O
closely O
for O
changes O
in O
coagulation O
parameters O
. O

Tetracycline B-GROUP
, O
a O
bacteriostatic O
antibiotic B-GROUP
, O
may O
antagonize O
the O
bactericidal O
effect O
of O
penicillin B-DRUG
and O
concurrent O
use O
of O
these O
drugs O
should O
be O
avoided O
. O

No O
specific O
cytochrome O
P450 O
- O
based O
drug O
interaction O
studies O
have O
been O
conducted O
. O
No O
pharmacokinetic O
interaction O
between O
85 O
mg O
/ O
m2 O
ELOXATIN B-BRAND
and O
infusional O
5 B-DRUG
- I-DRUG
FU I-DRUG
has O
been O
observed O
in O
patients O
treated O
every O
2 O
weeks O
. O
Increases O
of O
5 B-DRUG
- I-DRUG
FU I-DRUG
plasma O
concentrations O
by O
approximately O
20 O
% O
have O
been O
observed O
with O
doses O
of O
130 O
mg O
/ O
m2 O
ELOXATIN B-BRAND
dosed O
every O
3 O
weeks O
. O
Since O
platinum O
containing O
species O
are O
eliminated O
primarily O
through O
the O
kidney O
, O
clearance O
of O
these O
products O
may O
be O
decreased O
by O
coadministration O
of O
potentially O
nephrotoxic O
compounds O
; O
although O
, O
this O
has O
not O
been O
specifically O
studied O
. O

Anticoagulants B-GROUP
Anabolic B-GROUP
steroids I-GROUP
may O
increase O
sensitivity O
to O
oral O
anticoagulants B-GROUP
. O
Dosage O
of O
the O
anticoagulant B-GROUP
may O
have O
to O
be O
decreased O
in O
order O
to O
maintain O
desired O
prothrombin O
time O
. O
Patients O
receiving O
oral O
anticoagulant O
therapy O
require O
close O
monitoring O
, O
especially O
when O
anabolic B-GROUP
steroids I-GROUP
are O
started O
or O
stopped O
. O
Warfarin B-DRUG
: O
A O
multidose O
study O
of O
oxandrolone B-DRUG
, O
given O
as O
5 O
or O
10 O
mg O
BID O
in O
15 O
healthy O
subjects O
concurrently O
treated O
with O
warfarin B-DRUG
, O
resulted O
in O
a O
mean O
increase O
in O
S B-DRUG
- I-DRUG
warfarin I-DRUG
half O
- O
life O
from O
26 O
to O
48 O
hours O
and O
AUC O
from O
4 O
. O
55 O
to O
12 O
. O
08 O
ng O
* O
hr O
/ O
mL O
: O
similar O
increases O
in O
R B-DRUG
- I-DRUG
warfarin I-DRUG
half O
- O
life O
and O
AUC O
were O
also O
detected O
. O
Microscopic O
hematuria O
( O
9 O
/ O
15 O
) O
and O
gingival O
bleeding O
( O
1 O
/ O
15 O
) O
were O
also O
observed O
. O
A O
5 O
. O
5 O
- O
fold O
decrease O
in O
the O
mean O
warfarin B-DRUG
dose O
from O
6 O
. O
13 O
mg O
/ O
day O
to O
1 O
. O
13 O
mg O
/ O
day O
( O
approximately O
80 O
- O
85 O
% O
reduction O
of O
warfarin B-DRUG
dose O
) O
, O
was O
necessary O
to O
maintain O
a O
target O
INR O
of O
1 O
. O
5 O
. O
When O
oxandrolone B-DRUG
therapy O
is O
initiated O
in O
a O
patient O
already O
receiving O
treatment O
with O
warfarin B-DRUG
, O
the O
INR O
or O
prothrombin O
time O
( O
PT O
) O
should O
be O
monitored O
closely O
and O
the O
dose O
of O
warfarin B-DRUG
adjusted O
as O
necessary O
until O
a O
stable O
target O
INR O
or O
PT O
has O
been O
achieved O
. O
Furthermore O
, O
in O
patients O
receiving O
both O
drugs O
, O
careful O
monitoring O
of O
the O
INR O
or O
PT O
, O
and O
adjustment O
of O
the O
warfarin B-DRUG
dosage O
if O
indicated O
are O
recommended O
when O
the O
oxandrolone B-DRUG
dose O
is O
changed O
or O
discontinued O
. O
Patients O
should O
be O
closely O
monitored O
for O
signs O
and O
symptoms O
of O
occult O
bleeding O
. O
Oral O
hypoglycemic B-GROUP
agents I-GROUP
Oxandrolone B-DRUG
may O
inhibit O
the O
metabolism O
of O
oral O
hypoglycemic B-GROUP
agents I-GROUP
. O
Adrenal B-GROUP
steroids I-GROUP
or O
ACTH B-DRUG
In O
patients O
with O
edema O
, O
concomitant O
administration O
with O
adrenal B-GROUP
cortical I-GROUP
steroids I-GROUP
or O
ACTH B-DRUG
may O
increase O
the O
edema O
. O
Drug O
/ O
Laboratory O
test O
interactions O
Anabolic B-DRUG
steroids I-DRUG
may O
decrease O
levels O
of O
thyroxine O
- O
binding O
globulin O
, O
resulting O
in O
decreased O
total O
T4 O
serum O
levels O
and O
increased O
resin O
uptake O
of O
T3 O
and O
T4 O
. O
Free O
thyroid O
hormone O
levels O
remain O
unchanged O
. O
In O
addition O
, O
a O
decrease O
in O
PBI O
and O
radioactive O
iodine O
uptake O
may O
occur O
. O

Potential O
drug O
interactions O
between O
OXISTAT B-BRAND
and O
other O
drugs O
have O
not O
been O
systematically O
evaluated O
. O

No O
reported O
significant O
interactions O

The O
concomitant O
use O
of O
oxybutynin B-DRUG
with O
other O
anticholinergic B-GROUP
drugs I-GROUP
or O
with O
other O
agents O
which O
produce O
dry O
mouth O
, O
constipation O
, O
somnolence O
( O
drowsiness O
) O
, O
and O
/ O
or O
other O
anticholinergic O
- O
like O
effects O
may O
increase O
the O
frequency O
and O
/ O
or O
severity O
of O
such O
effects O
. O
Anticholinergic B-GROUP
agents I-GROUP
may O
potentially O
alter O
the O
absorption O
of O
some O
concomitantly O
administered O
drugs O
due O
to O
anticholinergic O
effects O
on O
gastrointestinal O
motility O
. O
This O
may O
be O
of O
concern O
for O
drugs O
with O
a O
narrow O
therapeutic O
index O
. O
Mean O
oxybutynin B-DRUG
chloride I-DRUG
plasma O
concentrations O
were O
approximately O
2 O
fold O
higher O
when O
DITROPAN B-BRAND
XL I-BRAND
was O
administered O
with O
ketoconazole B-DRUG
, O
a O
potent O
CYP3A4 O
inhibitor O
. O
Other O
inhibitors O
of O
the O
cytochrome O
P450 O
3A4 O
enzyme O
system O
, O
such O
as O
antimycotic B-GROUP
agents I-GROUP
( O
e O
. O
g O
. O
, O
itraconazole B-DRUG
and O
miconazole B-DRUG
) O
or O
macrolide B-GROUP
antibiotics I-GROUP
( O
e O
. O
g O
. O
, O
erythromycin B-DRUG
and O
clarithromycin B-DRUG
) O
, O
may O
alter O
oxybutynin B-DRUG
mean O
pharmacokinetic O
parameters O
( O
i O
. O
e O
. O
, O
Cmax O
and O
AUC O
) O
. O
The O
clinical O
relevance O
of O
such O
potential O
interactions O
is O
not O
known O
. O
Caution O
should O
be O
used O
when O
such O
drugs O
are O
co O
- O
administered O
. O
Concurrent O
ingestion O
of O
antacid B-GROUP
( O
20 O
mL O
of O
antacid B-GROUP
containing O
aluminum B-DRUG
hydroxide I-DRUG
, O
magnesium B-DRUG
hydroxide I-DRUG
, O
and O
simethicone B-DRUG
) O
did O
not O
significantly O
affect O
the O
exposure O
of O
oxybutynin B-DRUG
or O
desethyloxybutynin B-DRUG_N
. O

The O
CNS O
depressant O
effects O
of O
oxycodone B-DRUG
hydrochloride I-DRUG
may O
be O
additive O
with O
that O
of O
other O
CNS B-GROUP
depressants I-GROUP
. O
. O

The O
concomitant O
use O
of O
other O
CNS B-GROUP
depressants I-GROUP
including O
sedatives B-GROUP
, O
hypnotics B-GROUP
, O
tranquilizers B-GROUP
, O
general O
anesthetics B-GROUP
, O
phenothiazines B-GROUP
, O
other O
opioids B-GROUP
, O
tricyclic B-GROUP
antidepressants I-GROUP
, O
monoamine B-GROUP
oxidase I-GROUP
( I-GROUP
MAO I-GROUP
) I-GROUP
inhibitors I-GROUP
, O
and O
alcohol B-DRUG
may O
produce O
additive O
CNS O
depressant O
effects O
. O
When O
such O
combined O
therapy O
is O
contemplated O
, O
the O
dose O
of O
one O
or O
both O
agents O
should O
be O
reduced O
. O
Anticholinergics B-GROUP
or O
other O
medications O
with O
anticholinergic O
activity O
when O
used O
concurrently O
with O
opioid B-GROUP
analgesics I-GROUP
may O
result O
in O
increased O
risk O
of O
urinary O
retention O
and O
/ O
or O
severe O
constipation O
, O
which O
may O
lead O
to O
paralytic O
ileus O
. O
It O
has O
been O
reported O
that O
the O
incidence O
of O
bradycardia O
was O
increased O
when O
oxymorphone B-DRUG
was O
combined O
with O
propofol B-DRUG
for O
induction O
of O
anesthesia O
. O
In O
addition O
, O
CNS O
toxicity O
has O
been O
reported O
( O
confusion O
, O
disorientation O
, O
respiratory O
depression O
, O
apnea O
, O
seizures O
) O
following O
coadministration O
of O
cimetidine B-DRUG
with O
opioid B-GROUP
analgesics I-GROUP
; O
no O
clear O
- O
cut O
cause O
and O
effect O
relationship O
was O
established O
. O

Severe O
hypertension O
has O
been O
reported O
when O
oxytocin B-DRUG
was O
given O
three O
to O
four O
hours O
following O
prophylactic O
administration O
of O
a O
vasoconstrictor B-GROUP
in O
conjunction O
with O
caudal O
block O
anesthesia O
. O
Cyclopropane O
anesthesia O
may O
modify O
oxytocin B-DRUG
s O
cardiovascular O
effects O
, O
so O
as O
to O
produce O
unexpected O
results O
such O
as O
hypotension O
. O
Maternal O
sinus O
bradycardia O
with O
abnormal O
atrioventricular O
rhythms O
has O
also O
been O
noted O
when O
oxytocin B-DRUG
was O
used O
concomitantly O
with O
cyclopropane O
anesthesia O
. O

Potential O
for O
INVEGA B-BRAND
to O
Affect O
Other O
Drugs O
Paliperidone B-DRUG
is O
not O
expected O
to O
cause O
clinically O
important O
pharmacokinetic O
interactions O
with O
drugs O
that O
are O
metabolized O
by O
cytochrome O
P450 O
isozymes O
. O
In O
vitro O
studies O
in O
human O
liver O
microsomes O
showed O
that O
paliperidone B-DRUG
does O
not O
substantially O
inhibit O
the O
metabolism O
of O
drugs O
metabolized O
by O
cytochrome O
P450 O
isozymes O
, O
including O
CYP1A2 O
, O
CYP2A6 O
, O
CYP2C8 O
/ O
9 O
/ O
10 O
, O
CYP2D6 O
, O
CYP2E1 O
, O
CYP3A4 O
, O
and O
CYP3A5 O
. O
Therefore O
, O
paliperidone B-DRUG
is O
not O
expected O
to O
inhibit O
clearance O
of O
drugs O
that O
are O
metabolized O
by O
these O
metabolic O
pathways O
in O
a O
clinically O
relevant O
manner O
. O
Paliperidone B-DRUG
is O
also O
not O
expected O
to O
have O
enzyme O
inducing O
properties O
. O
At O
therapeutic O
concentrations O
, O
paliperidone B-DRUG
did O
not O
inhibit O
P O
- O
glycoprotein O
. O
Paliperidone B-DRUG
is O
therefore O
not O
expected O
to O
inhibit O
P O
- O
glycoprotein O
- O
mediated O
transport O
of O
other O
drugs O
in O
a O
clinically O
relevant O
manner O
. O
Given O
the O
primary O
CNS O
effects O
of O
paliperidone B-DRUG
, O
INVEGA B-BRAND
should O
be O
used O
with O
caution O
in O
combination O
with O
other O
centrally B-GROUP
acting I-GROUP
drugs I-GROUP
and O
alcohol B-DRUG
. O
Paliperidone B-DRUG
may O
antagonize O
the O
effect O
of O
levodopa B-DRUG
and O
other O
dopamine B-GROUP
agonists I-GROUP
. O
Because O
of O
its O
potential O
for O
inducing O
orthostatic O
hypotension O
, O
an O
additive O
effect O
may O
be O
observed O
when O
INVEGA B-BRAND
is O
administered O
with O
other O
therapeutic O
agents O
that O
have O
this O
potential O
. O
Potential O
for O
Other O
Drugs O
to O
Affect O
INVEGA B-BRAND
Paliperidone B-DRUG
is O
not O
a O
substrate O
of O
CYP1A2 O
, O
CYP2A6 O
, O
CYP2C9 O
, O
and O
CYP2C19 O
, O
so O
that O
an O
interaction O
with O
inhibitors O
or O
inducers O
of O
these O
isozymes O
is O
unlikely O
. O
While O
in O
vitro O
studies O
indicate O
that O
CYP2D6 O
and O
CYP3A4 O
may O
be O
minimally O
involved O
in O
paliperidone B-DRUG
metabolism O
, O
in O
vivo O
studies O
do O
not O
show O
decreased O
elimination O
by O
these O
isozymes O
and O
they O
contribute O
to O
only O
a O
small O
fraction O
of O
total O
body O
clearance O
. O

No O
formal O
drug O
- O
drug O
interaction O
studies O
were O
conducted O
. O
In O
Trial O
1 O
, O
the O
proportions O
of O
patients O
in O
the O
placebo O
and O
Synagis B-BRAND
groups O
who O
received O
routine O
childhood O
vaccines B-GROUP
, O
influenza B-GROUP
vaccine I-GROUP
, O
bronchodilators B-GROUP
or O
corticosteroids B-GROUP
were O
similar O
and O
no O
incremental O
increase O
in O
adverse O
reactions O
was O
observed O
among O
patients O
receiving O
these O
agents O
. O

Palonosetron B-DRUG
is O
eliminated O
from O
the O
body O
through O
both O
renal O
excretion O
and O
metabolic O
pathways O
with O
the O
latter O
mediated O
via O
multiple O
CYP O
enzymes O
. O
In O
vitro O
studies O
indicated O
that O
palonosetron B-DRUG
is O
not O
an O
inhibitor O
of O
CYP1A2 O
, O
CYP2A6 O
, O
CYP2B6 O
, O
CYP2C9 O
, O
CYP2D6 O
, O
CYP2E1 O
and O
CYP3A4 O
/ O
5 O
( O
CYP2C19 O
was O
not O
investigated O
) O
nor O
does O
it O
induce O
the O
activity O
of O
CYP1A2 O
, O
CYP2D6 O
, O
or O
CYP3A4 O
/ O
5 O
. O
Therefore O
, O
the O
potential O
for O
clinically O
significant O
drug O
interactions O
with O
palonosetron B-DRUG
appears O
to O
be O
low O
. O
A O
study O
in O
healthy O
volunteers O
involving O
single O
- O
dose O
IV O
palonosetron B-DRUG
( O
0 O
. O
75 O
mg O
) O
and O
steady O
state O
oral O
metoclopramide B-DRUG
( O
10 O
mg O
four O
times O
daily O
) O
demonstrated O
no O
significant O
pharmacokinetic O
interaction O
. O
In O
controlled O
clinical O
trials O
, O
ALOXI B-BRAND
injection O
has O
been O
safely O
administered O
with O
corticosteroids B-GROUP
, O
analgesics B-GROUP
, O
antiemetics B-GROUP
/ O
antinauseants B-GROUP
, O
antispasmodics B-GROUP
and O
anticholinergic B-GROUP
agents I-GROUP
. O
Palonosetron B-DRUG
did O
not O
inhibit O
the O
antitumor O
activity O
of O
the O
five O
chemotherapeutic B-GROUP
agents I-GROUP
tested O
( O
cisplatin B-DRUG
, O
cyclophosphamide B-DRUG
, O
cytarabine B-DRUG
, O
doxorubicin B-DRUG
and O
mitomycin B-DRUG
C I-DRUG
) O
in O
murine O
tumor O
models O
. O

Concomitant O
administration O
of O
a O
loop B-GROUP
diuretic I-GROUP
had O
no O
effect O
on O
the O
calcium O
- O
lowering O
action O
of O
Aredia B-BRAND
. O
Caution O
is O
indicated O
when O
Aredia B-BRAND
is O
used O
with O
other O
potentially O
nephrotoxic O
drugs O
. O
Also O
see O
CLINICAL O
PHARMACOLOGY O

No O
formal O
drug O
- O
drug O
interaction O
studies O
have O
been O
conducted O
with O
Vectibix B-BRAND
. O

Pantoprazole B-DRUG
is O
metabolized O
through O
the O
cytochrome O
P450 O
system O
, O
primarily O
the O
CYP2C19 O
and O
CYP3A4 O
isozymes O
, O
and O
subsequently O
undergoes O
Phase O
II O
conjugation O
. O
Based O
on O
studies O
evaluating O
possible O
interactions O
of O
pantoprazole B-DRUG
with O
other O
drugs O
, O
no O
dosage O
adjustment O
is O
needed O
with O
concomitant O
use O
of O
the O
following O
: O
theophylline B-DRUG
, O
cisapride B-DRUG
, O
antipyrine B-DRUG
, O
caffeine B-DRUG
, O
carbamazepine B-DRUG
, O
diazepam B-DRUG
( O
and O
its O
active O
metabolite O
, O
desmethyldiazepam B-DRUG_N
) O
, O
diclofenac B-DRUG
, O
naproxen B-DRUG
, O
piroxicam B-DRUG
, O
digoxin B-DRUG
, O
ethanol B-DRUG
, O
glyburide B-DRUG
, O
an O
oral O
contraceptive B-GROUP
( O
levonorgestrel B-DRUG
/ O
ethinyl B-DRUG
estradiol I-DRUG
) O
, O
metoprolol B-DRUG
, O
nifedipine B-DRUG
, O
phenytoin B-DRUG
, O
warfarin B-DRUG
, O
midazolam B-DRUG
, O
clarithromycin B-DRUG
, O
metronidazole B-DRUG
, O
or O
amoxicillin B-DRUG
. O
Clinically O
relevant O
interactions O
of O
pantoprazole B-DRUG
with O
other O
drugs O
with O
the O
same O
metabolic O
pathways O
are O
not O
expected O
. O
Therefore O
, O
when O
coadministered O
with O
pantoprazole B-DRUG
, O
adjustment O
of O
the O
dosage O
of O
pantoprazole B-DRUG
or O
of O
such O
drugs O
may O
not O
be O
necessary O
. O
There O
was O
also O
no O
interaction O
with O
concomitantly O
administered O
antacids B-GROUP
. O
There O
have O
been O
postmarketing O
reports O
of O
increased O
INR O
and O
prothrombin O
time O
in O
patients O
receiving O
proton B-GROUP
pump I-GROUP
inhibitors I-GROUP
, O
including O
pantoprazole B-DRUG
, O
and O
warfarin B-DRUG
concomitantly O
. O
Increases O
in O
INR O
and O
prothrombin O
time O
may O
lead O
to O
abnormal O
bleeding O
and O
even O
death O
. O
Patients O
treated O
with O
proton B-GROUP
pump I-GROUP
inhibitors I-GROUP
and O
warfarin B-DRUG
concomitantly O
should O
be O
monitored O
for O
increases O
in O
INR O
and O
prothrombin O
time O
. O
Because O
of O
profound O
and O
long O
lasting O
inhibition O
of O
gastric O
acid O
secretion O
, O
pantoprazole B-DRUG
may O
interfere O
with O
absorption O
of O
drugs O
where O
gastric O
pH O
is O
an O
important O
determinant O
of O
their O
bioavailability O
( O
eg O
, O
ketoconazole B-DRUG
, O
ampicillin B-DRUG
esters O
, O
and O
iron B-DRUG
salts O
) O
. O
Laboratory O
Tests O
There O
have O
been O
reports O
of O
false O
- O
positive O
urine O
screening O
tests O
for O
tetrahydrocannabinol B-DRUG
( O
THC B-DRUG
) O
in O
patients O
receiving O
most O
proton B-GROUP
pump I-GROUP
inhibitors I-GROUP
, O
including O
pantoprazole B-DRUG
. O
An O
alternative O
confirmatory O
method O
should O
be O
considered O
to O
verify O
positive O
results O
. O

Not O
compatible O
with O
CNS B-GROUP
depressants I-GROUP
or O
trycyclic B-GROUP
antidepressants I-GROUP

Paricalcitol B-DRUG_N
is O
not O
expected O
to O
inhibit O
the O
clearance O
of O
drugs O
metabolized O
by O
cytochrome O
P450 O
enzymes O
CYP1A2 O
, O
CYP2A6 O
, O
CYP2B6 O
, O
CYP2C8 O
, O
CYP2C9 O
, O
CYP2C19 O
, O
CYP2D6 O
CYP2E1 O
or O
CYP3A O
nor O
induce O
the O
clearance O
of O
drugs O
metabolized O
by O
CYP2B6 O
, O
CYP2C9 O
or O
CYP3A O
. O
A O
multiple O
dose O
drug O
- O
drug O
interaction O
study O
demonstrated O
that O
ketoconazole B-DRUG
approximately O
doubled O
paricalcitol B-DRUG
AUC0 O
- O
. O
Since O
paricalcitol B-DRUG
is O
partially O
metabolized O
by O
CYP3A O
and O
ketoconazole B-DRUG
le O
is O
known O
to O
be O
a O
strong O
inhibitor O
of O
cytochrome O
P450 O
3A O
enzyme O
, O
care O
should O
be O
taken O
while O
dosing O
paricalcitol B-DRUG
with O
ketoconazole B-DRUG
and O
other O
strong O
P450 O
3A O
inhibitors O
including O
atazanavir B-DRUG
, O
clarithromycin B-DRUG
, O
indinavir B-DRUG
, O
itraconazole B-DRUG
, O
nefazodone B-DRUG
, O
nelfinavir B-DRUG
, O
ritonavir B-DRUG
, O
saquinavir B-DRUG
, O
telithromycin B-DRUG
or O
voriconazole B-DRUG
. O
Dose O
adjustment O
of O
Zemplar B-BRAND
Capsules O
may O
be O
required O
, O
and O
iPTH O
and O
serum O
calcium O
concentrations O
should O
be O
closely O
monitored O
if O
a O
patient O
initiates O
or O
discontinues O
therapy O
with O
a O
strong O
CYP3A4 O
inhibitor O
such O
as O
ketoconazole B-DRUG
. O
Drugs O
that O
impair O
intestinal O
absorption O
of O
fat B-GROUP
- I-GROUP
soluble I-GROUP
vitamins I-GROUP
, O
such O
as O
cholestyramine B-DRUG
, O
may O
interfere O
with O
the O
absorption O
of O
Zemplar B-BRAND
Capsules O
. O

Drug O
interaction O
studies O
have O
not O
been O
conducted O
with O
Macugen B-BRAND
. O
Pegaptanib B-DRUG
is O
metabolized O
by O
nucleases O
and O
is O
generally O
not O
affected O
by O
the O
cytochrome O
P450 O
system O
. O
Two O
early O
clinical O
studies O
conducted O
in O
patients O
who O
received O
Macugen B-BRAND
alone O
and O
in O
combination O
with O
PDT O
revealed O
no O
apparent O
difference O
in O
the O
plasma O
pharmacokinetics O
of O
pegaptanib B-DRUG
. O

No O
formal O
drug O
interaction O
studies O
between O
Neulasta B-BRAND
and O
other O
drugs O
have O
been O
performed O
. O
Drugs O
such O
as O
lithium B-DRUG
may O
potentiate O
the O
release O
of O
neutrophils O
; O
patients O
receiving O
lithium B-DRUG
and O
Neulasta B-BRAND
should O
have O
more O
frequent O
monitoring O
of O
neutrophil O
counts O
. O

In O
a O
pharmacokinetic O
study O
of O
18 O
chronic O
hepatitis O
C O
patients O
concomitantly O
receiving O
methadone B-DRUG
, O
treatment O
with O
PEG B-BRAND
- I-BRAND
Intron I-BRAND
once O
weekly O
for O
4 O
weeks O
was O
associated O
with O
a O
mean O
increase O
of O
16 O
% O
in O
methadone B-DRUG
AUC O
; O
in O
2 O
out O
of O
18 O
patients O
, O
methadone B-DRUG
AUC O
doubled O
. O
The O
clinical O
significance O
of O
this O
finding O
is O
unknown O
; O
however O
, O
patients O
should O
be O
monitored O
for O
the O
signs O
and O
symptoms O
of O
increased O
narcotic O
effect O
. O

Acromegalic O
patients O
with O
diabetes O
mellitus O
being O
treated O
with O
insulin B-DRUG
and O
/ O
or O
oral O
hypoglycemic B-GROUP
agents O
may O
require O
dose O
reductions O
of O
these O
therapeutic O
agents O
after O
the O
initiation O
of O
therapy O
with O
SOMAVERT B-BRAND
. O
In O
clinical O
studies O
, O
patients O
on O
opioids B-GROUP
often O
needed O
higher O
serum O
pegvisomant B-DRUG
concentrations O
to O
achieve O
appropriate O
IGF O
- O
I O
suppression O
compared O
with O
patients O
not O
receiving O
opioids B-GROUP
. O
The O
mechanism O
of O
this O
interaction O
is O
not O
known O
. O

ALIMTA B-BRAND
is O
primarily O
eliminated O
unchanged O
renally O
as O
a O
result O
of O
glomerular O
filtration O
and O
tubular O
secretion O
. O
Concomitant O
administration O
of O
nephrotoxic O
drugs O
could O
result O
in O
delayed O
clearance O
of O
ALIMTA B-BRAND
. O
Concomitant O
administration O
of O
substances O
that O
are O
also O
tubularly O
secreted O
( O
e O
. O
g O
. O
, O
probenecid B-DRUG
) O
could O
potentially O
result O
in O
delayed O
clearance O
of O
ALIMTA B-BRAND
. O
Although O
ibuprofen B-DRUG
( O
400 O
mg O
qid O
) O
can O
be O
administered O
with O
ALIMTA B-BRAND
in O
patients O
with O
normal O
renal O
function O
( O
creatinine O
clearance O
80 O
mL O
/ O
min O
) O
, O
caution O
should O
be O
used O
when O
administering O
ibuprofen B-DRUG
concurrently O
with O
ALIMTA B-BRAND
to O
patients O
with O
mild O
to O
moderate O
renal O
insufficiency O
( O
creatinine O
clearance O
from O
45 O
to O
79 O
mL O
/ O
min O
) O
. O
Patients O
with O
mild O
to O
moderate O
renal O
insufficiency O
should O
avoid O
taking O
NSAIDs B-GROUP
with O
short O
elimination O
half O
- O
lives O
for O
a O
period O
of O
2 O
days O
before O
, O
the O
day O
of O
, O
and O
2 O
days O
following O
administration O
of O
ALIMTA B-BRAND
. O
In O
the O
absence O
of O
data O
regarding O
potential O
interaction O
between O
ALIMTA B-BRAND
and O
NSAIDs B-GROUP
with O
longer O
half O
- O
lives O
, O
all O
patients O
taking O
these O
NSAIDs B-GROUP
should O
interrupt O
dosing O
for O
at O
least O
5 O
days O
before O
, O
the O
day O
of O
, O
and O
2 O
days O
following O
ALIMTA B-BRAND
administration O
. O
If O
concomitant O
administration O
of O
an O
NSAID B-GROUP
is O
necessary O
, O
patients O
should O
be O
monitored O
closely O
for O
toxicity O
, O
especially O
myelosuppression O
, O
renal O
, O
and O
gastrointestinal O
toxicity O
. O
Drug O
/ O
Laboratory O
Test O
Interactions O
None O
known O
. O

The O
interaction O
of O
CYLERT B-BRAND
( O
pemoline B-DRUG
) O
with O
other O
drugs O
has O
not O
been O
studied O
in O
humans O
. O
Patients O
who O
are O
receiving O
CYLERT B-BRAND
concurrently O
with O
other O
drugs O
, O
especially O
drugs O
with O
CNS O
activity O
, O
should O
be O
monitored O
carefully O
. O
Decreased O
seizure O
threshold O
has O
been O
reported O
in O
patients O
receiving O
CYLERT B-BRAND
concomitantly O
with O
antiepileptic B-GROUP
medications I-GROUP
. O

Concurrent O
administration O
of O
bacteriostatic B-GROUP
antibiotics I-GROUP
( O
e O
. O
g O
. O
, O
erythromycin B-DRUG
, O
tetracycline B-DRUG
) O
may O
diminish O
the O
bactericidal O
effects O
of O
penicillins B-GROUP
by O
slowing O
the O
rate O
of O
bacterial O
growth O
. O
Bactericidal O
agents O
work O
most O
effectively O
against O
the O
immature O
cell O
wall O
of O
rapidly O
proliferating O
microorganisms O
. O
This O
has O
been O
demonstrated O
in O
vitro O
; O
however O
, O
the O
clinical O
significance O
of O
this O
interaction O
is O
not O
well O
documented O
. O
There O
are O
few O
clinical O
situations O
in O
which O
the O
concurrent O
use O
of O
' O
' O
static O
' O
' O
and O
' O
' O
cidal O
' O
' O
antibiotics B-GROUP
are O
indicated O
. O
However O
, O
in O
selected O
circumstances O
in O
which O
such O
therapy O
is O
appropriate O
, O
using O
adequate O
doses O
of O
antibacterial B-GROUP
agents O
and O
beginning O
penicillin O
therapy O
first O
, O
should O
minimize O
the O
potential O
for O
interaction O
. O
Penicillin B-GROUP
blood O
levels O
may O
be O
prolonged O
by O
concurrent O
administration O
of O
probenecid B-DRUG
which O
blocks O
the O
renal O
tubular O
secretion O
of O
penicillins B-GROUP
. O
Displacement O
of O
penicillin B-GROUP
from O
plasma O
protein O
binding O
sites O
will O
elevate O
the O
level O
of O
free O
penicillin B-GROUP
in O
the O
serum O
. O

Usage O
with O
Alcohol B-DRUG
: O
Due O
to O
the O
potential O
for O
increased O
CNS O
depressants O
effects O
, O
alcohol B-DRUG
should O
be O
used O
with O
caution O
in O
patients O
who O
are O
currently O
receiving O
pentazocine B-DRUG
. O

Interactions O
with O
cylcopholsphamide O
, O
fludarabine B-DRUG
and O
vidarabine B-DRUG

Although O
a O
causal O
relationship O
has O
not O
been O
established O
, O
there O
have O
been O
reports O
of O
bleeding O
and O
/ O
or O
prolonged O
prothrombin O
time O
in O
patients O
treated O
with O
TRENTAL B-BRAND
with O
and O
without O
anticoagulants B-GROUP
or O
platelet B-GROUP
aggregation I-GROUP
inhibitors I-GROUP
. O
Patients O
on O
Warfarin B-DRUG
should O
have O
more O
frequent O
monitoring O
of O
prothrombin O
times O
, O
while O
patients O
with O
other O
risk O
factors O
complicated O
by O
hemorrhage O
( O
e O
. O
g O
. O
, O
recent O
surgery O
, O
peptic O
ulceration O
) O
should O
have O
periodic O
examinations O
for O
bleeding O
including O
hematocrit O
and O
/ O
or O
hemoglobin O
. O
Concomitant O
administration O
of O
TRENTAL B-BRAND
and O
theophylline B-DRUG
- O
containing O
drugs O
leads O
to O
increased O
theophylline B-DRUG
levels O
and O
theophylline B-DRUG
toxicity O
in O
some O
individuals O
. O
Such O
patients O
should O
be O
closely O
monitored O
for O
signs O
of O
toxicity O
and O
have O
their O
theophylline B-DRUG
dosage O
adjusted O
as O
necessary O
. O
TRENTAL B-BRAND
has O
been O
used O
concurrently O
with O
antihypertensive B-GROUP
drugs I-GROUP
, O
beta B-GROUP
blockers I-GROUP
, O
digitalis B-GROUP
, O
diuretics B-GROUP
, O
antidiabetic B-GROUP
agents I-GROUP
, O
and O
antiarrhythmics B-GROUP
, O
without O
observed O
problems O
. O
Small O
decreases O
in O
blood O
pressure O
have O
been O
observed O
in O
some O
patients O
treated O
with O
TRENTAL B-BRAND
; O
periodic O
systemic O
blood O
pressure O
monitoring O
is O
recommended O
for O
patients O
receiving O
concomitant O
antihypertensive O
therapy O
. O
If O
indicated O
, O
dosage O
of O
the O
antihypertensive B-GROUP
agents I-GROUP
should O
be O
reduced O
. O

Dopamine B-GROUP
antagonists I-GROUP
, O
such O
as O
the O
neuroleptics B-GROUP
( O
phenothiazines B-GROUP
, O
butyrophenones B-GROUP
, O
thioxanthines B-GROUP
) O
or O
metoclopramide B-DRUG
, O
ordinarily O
should O
not O
be O
administered O
concurrently O
with O
Permax B-BRAND
( O
a O
dopamine B-GROUP
agonist I-GROUP
) O
; O
these O
agents O
may O
diminish O
the O
effectiveness O
of O
Permax B-BRAND
. O
Because O
pergolide B-DRUG
mesylate I-DRUG
is O
approximately O
90 O
% O
bound O
to O
plasma O
proteins O
, O
caution O
should O
be O
exercised O
if O
pergolide B-DRUG
mesylate I-DRUG
is O
coadministered O
with O
other O
drugs O
known O
to O
affect O
protein O
binding O
. O

Diuretics B-GROUP
: O
Patients O
on O
diuretics B-GROUP
, O
and O
especially O
those O
started O
recently O
, O
may O
occasionally O
experience O
an O
excessive O
reduction O
of O
blood O
pressure O
after O
initiation O
of O
ACEON B-BRAND
Tablets O
therapy O
. O
The O
possibility O
of O
hypotensive O
effects O
can O
be O
minimized O
by O
either O
discontinuing O
the O
diuretic B-GROUP
or O
increasing O
the O
salt O
intake O
prior O
to O
initiation O
of O
treatment O
with O
perindopril B-DRUG
. O
If O
diuretics B-GROUP
cannot O
be O
interrupted O
, O
close O
medical O
supervision O
should O
be O
provided O
with O
the O
first O
dose O
of O
ACEON B-BRAND
Tablets O
, O
for O
at O
least O
two O
hours O
and O
until O
blood O
pressure O
has O
stabilized O
for O
another O
hour O
. O
The O
rate O
and O
extent O
of O
perindopril B-DRUG
absorption O
and O
elimination O
are O
not O
affected O
by O
concomitant O
diuretics B-GROUP
. O
The O
bioavailability O
of O
perindoprilat B-DRUG_N
was O
reduced O
by O
diuretics B-GROUP
, O
however O
, O
and O
this O
was O
associated O
with O
a O
decrease O
in O
plasma O
ACE O
inhibition O
. O
Potassium B-DRUG
Supplements O
and O
Potassium B-GROUP
- I-GROUP
Sparing I-GROUP
Diuretics I-GROUP
: O
ACEON B-BRAND
Tablets O
may O
increase O
serum O
potassium O
because O
of O
its O
potential O
to O
decrease O
aldosterone O
production O
. O
Use O
of O
potassium B-GROUP
- I-GROUP
sparing I-GROUP
diuretics I-GROUP
( O
spironolactone B-DRUG
, O
amiloride B-DRUG
, O
triamterene B-DRUG
and O
others O
) O
, O
potassium B-DRUG
supplements O
or O
other O
drugs O
capable O
of O
increasing O
serum O
potassium O
( O
indomethacin B-DRUG
, O
heparin B-DRUG
, O
cyclosporine B-DRUG
and O
others O
) O
can O
increase O
the O
risk O
of O
hyperkalemia O
. O
Therefore O
, O
if O
concomitant O
use O
of O
such O
agents O
is O
indicated O
, O
they O
should O
be O
given O
with O
caution O
and O
the O
patient O
' O
s O
serum O
potassium O
should O
be O
monitored O
frequently O
. O
Lithium B-DRUG
: O
Increased O
serum O
lithium B-DRUG
and O
symptoms O
of O
lithium B-DRUG
toxicity O
have O
been O
reported O
in O
patients O
receiving O
concomitant O
lithium B-DRUG
and O
ACE O
inhibitor O
therapy O
. O
These O
drugs O
should O
be O
coadministered O
with O
caution O
and O
frequent O
monitoring O
of O
serum O
lithium B-DRUG
concentration O
is O
recommended O
. O
Use O
of O
a O
diuretic B-GROUP
may O
further O
increase O
the O
risk O
of O
lithium B-DRUG
toxicity O
. O
Digoxin B-DRUG
: O
A O
controlled O
pharmacokinetic O
study O
has O
shown O
no O
effect O
on O
plasma O
digoxin B-DRUG
concentrations O
when O
coadministered O
with O
ACEON B-BRAND
Tablets O
, O
but O
an O
effect O
of O
digoxin B-DRUG
on O
the O
plasma O
concentration O
of O
perindopril B-DRUG
/ O
perindoprilat B-DRUG_N
has O
not O
been O
excluded O
. O
Gentamicin B-DRUG
: O
Animal O
data O
have O
suggested O
the O
possibility O
of O
interaction O
between O
perindopril B-DRUG
and O
gentamicin B-DRUG
. O
However O
, O
this O
has O
not O
been O
investigated O
in O
human O
studies O
. O
Coadministration O
of O
both O
drugs O
should O
proceed O
with O
caution O
. O
Food O
Interaction O
: O
Oral O
administration O
of O
ACEON B-BRAND
Tablets O
with O
food O
does O

not O
significantly O
lower O
the O
rate O
or O
extent O
of O
perindopril B-DRUG
absorption O
relative O
to O
the O
fasted O
state O
. O
However O
, O
the O
extent O
of O
biotransformation O
of O
perindopril B-DRUG
to O
the O
active O
metabolite O
, O
perindoprilat B-DRUG_N
, O
is O
reduced O
approximately O
43 O
% O
, O
resulting O
in O
a O
reduction O
in O
the O
plasma O
ACE O
inhibition O
curve O
of O
approximately O
20 O
% O
, O
probably O
clinically O
insignificant O
. O
In O
clinical O
trials O
, O
perindopril B-DRUG
was O
generally O
administered O
in O
a O
non O
- O
fasting O
state O
. O

Concomitant O
use O
of O
alcohol B-DRUG
with O
phentermine B-DRUG
hydrochloride I-DRUG
may O
result O
in O
an O
adverse O
drug O
interaction O
. O

Diagnosis O
of O
pheochromocytoma O
- O
phentolamine O
blocking O
test O
. O
The O
test O
is O
most O
reliable O
in O
detecting O
pheochromocytoma O
in O
patients O
with O
sustained O
hypertension O
and O
least O
reliable O
in O
those O
with O
paroxysmal O
hypertension O
. O
False O
- O
positive O
tests O
may O
occur O
in O
patients O
with O
hypertension O
without O
pheochromocytoma O
. O

Vasopressors B-GROUP
, O
particularly O
metaraminol B-DRUG
, O
may O
cause O
serious O
cardiac O
arrhythmias O
during O
halothane B-DRUG
anesthesia O
and O
therefore O
should O
be O
used O
only O
with O
great O
caution O
or O
not O
at O
all O
. O
MAO B-GROUP
Inhibitors I-GROUP
: O
The O
pressor O
effect O
of O
sympathomimetic B-GROUP
pressor I-GROUP
amines I-GROUP
is O
markedly O
potentiated O
in O
patients O
receiving O
monoamine B-GROUP
oxidase I-GROUP
inhibitors I-GROUP
( O
MAOI B-GROUP
) O
. O
Therefore O
, O
when O
initiating O
pressor O
therapy O
in O
these O
patients O
, O
the O
initial O
dose O
should O
be O
small O
and O
used O
with O
due O
caution O
. O
The O
pressor O
response O
of O
adrenergic B-GROUP
agents I-GROUP
may O
also O
be O
potentiated O
by O
tricyclic B-GROUP
antidepressants I-GROUP
. O

Vasopressors B-GROUP
, O
particularly O
metaraminol B-DRUG
, O
may O
cause O
serious O
cardiac O
arrhythmias O
during O
halothane B-DRUG
anesthesia O
and O
therefore O
should O
be O
used O
only O
with O
great O
caution O
or O
not O
at O
all O
. O
MAO B-GROUP
Inhibitors I-GROUP
- O
The O
pressor O
effect O
of O
sympathomimetic B-GROUP
pressor I-GROUP
amines I-GROUP
is O
markedly O
potentiated O
in O
patients O
receiving O
monoamine B-GROUP
oxidase I-GROUP
inhibitors I-GROUP
( O
MAOI B-GROUP
) O
. O
Therefore O
, O
when O
initiating O
pressor O
therapy O
in O
these O
patients O
, O
the O
initial O
dose O
should O
be O
small O
and O
used O
with O
due O
caution O
. O
The O
pressor O
response O
of O
adrenergic B-GROUP
agents I-GROUP
may O
also O
be O
potentiated O
by O
tricyclic B-GROUP
antidepressants I-GROUP
. O

Pilocarpine B-DRUG
should O
be O
administered O
with O
caution O
to O
patients O
taking O
beta B-GROUP
adrenergic I-GROUP
antagonists I-GROUP
because O
of O
the O
possibility O
of O
conduction O
disturbances O
. O
Drugs O
with O
parasympathomimetic O
effects O
administered O
concurrently O
with O
pilocarpine B-DRUG
would O
be O
expected O
to O
result O
in O
additive O
pharmacologic O
effects O
. O
Pilocarpine B-DRUG
might O
antagonize O
the O
anticholinergic O
effects O
of O
drugs O
used O
concomitantly O
. O
These O
effects O
should O
be O
considered O
when O
anticholinergic O
properties O
may O
be O
contributing O
to O
the O
therapeutic O
effect O
of O
concomitant O
medication O
( O
e O
. O
g O
. O
, O
atropine B-DRUG
, O
inhaled O
ipratropium B-DRUG
) O
. O
While O
no O
formal O
drug O
interaction O
studies O
have O
been O
performed O
, O
the O
following O
concomitant O
drugs O
were O
used O
in O
at O
least O
10 O
% O
of O
patients O
in O
either O
or O
both O
Sj O
grens O
efficacy O
studies O
: O
acetylsalicylic B-DRUG
acid I-DRUG
, O
artificial O
tears O
, O
calcium B-DRUG
, O
conjugated B-DRUG
estrogens I-DRUG
, O
hydroxychloroquine B-DRUG
sulfate I-DRUG
, O
ibuprofen B-DRUG
, O
levothyroxine B-DRUG
sodium I-DRUG
, O
medroxyprogesterone B-DRUG
acetate I-DRUG
, O
methotrexate B-DRUG
, O
multivitamins B-GROUP
, O
naproxen B-DRUG
, O
omeprazole B-DRUG
, O
paracetamol B-DRUG
, O
and O
prednisone B-DRUG
. O

Potential O
interactions O
between O
Elidel B-BRAND
and O
other O
drugs O
, O
including O
immunizations O
, O
have O
not O
been O
systematically O
evaluated O
. O
Due O
to O
the O
very O
low O
blood O
levels O
of O
pimecrolimus B-DRUG
detected O
in O
some O
patients O
after O
topical O
application O
, O
systemic O
drug O
interactions O
are O
not O
expected O
, O
but O
cannot O
be O
ruled O
out O
. O
The O
concomitant O
administration O
of O
known O
CYP3A O
family O
of O
inhibitors O
in O
patients O
with O
widespread O
and O
/ O
or O
erythrodermic O
disease O
should O
be O
done O
with O
caution O
. O
Some O
examples O
of O
such O
drugs O
are O
erythromycin B-DRUG
, O
itraconazole B-DRUG
, O
ketoconazole B-DRUG
, O
fluconazole B-DRUG
, O
calcium B-GROUP
channel I-GROUP
blockers I-GROUP
and O
cimetidine B-DRUG
. O

Catecholamine O
- O
depleting O
drugs O
( O
e O
. O
g O
. O
, O
reserpine B-DRUG
) O
may O
have O
an O
additive O
effect O
when O
given O
with O
beta B-GROUP
- I-GROUP
blocking I-GROUP
agents I-GROUP
. O
Patients O
receiving O
pindolol B-DRUG
plus O
a O
catecholamine O
- O
depleting O
agent O
should O
, O
therefore O
, O
be O
closely O
observed O
for O
evidence O
of O
hypotension O
and O
/ O
or O
marked O
bradycardia O
which O
may O
produce O
vertigo O
, O
syncope O
, O
or O
postural O
hypotension O
. O
Pindolol B-DRUG
has O
been O
used O
with O
a O
variety O
of O
antihypertensive B-GROUP
agents I-GROUP
, O
including O
hydrochlorothiazide B-DRUG
, O
hydralazine B-DRUG
, O
and O
guanethidine B-DRUG
without O
unexpected O
adverse O
interactions O
. O
Pindolol B-DRUG
has O
been O
shown O
to O
increase O
serum O
thioridazine B-DRUG
levels O
when O
both O
drugs O
are O
co O
- O
administered O
. O
Pindolol B-DRUG
levels O
may O
also O
be O
increased O
with O
this O
combination O
. O
Risk O
of O
anaphylactic O
reaction O
: O
While O
taking O
beta B-GROUP
blockers I-GROUP
, O
patients O
with O
a O
history O
of O
severe O
anaphylactic O
reaction O
to O
a O
variety O
of O
allergens O
may O
be O
more O
reactive O
to O
repeated O
challenge O
, O
either O
accidental O
, O
diagnostic O
, O
or O
therapeutic O
. O
Such O
patients O
may O
be O
unresponsive O
to O
the O
usual O
doses O
of O
epinephrine B-DRUG
used O
to O
treat O
allergic O
reactions O
. O

In O
vivo O
drug O
- O
drug O
interaction O
studies O
have O
suggested O
that O
pioglitazone B-DRUG
may O
be O
a O
weak O
inducer O
of O
CYP O
450 O
isoform O
3A4 O
substrate O
. O

Other O
short B-GROUP
- I-GROUP
acting I-GROUP
beta I-GROUP
adrenergic I-GROUP
aerosol I-GROUP
bronchodilators I-GROUP
should O
not O
be O
used O
concomitantly O
with O
MAXAIR B-BRAND
AUTOHALER I-BRAND
because O
they O
may O
have O
additive O
effects O
. O

Drug O
Interactions O
: O
Pirenzepine B-DRUG
may O
interact O
with O
the O
following O
drugs O
, O
which O
may O
affect O
the O
effect O
of O
Pirenzepine B-DRUG
or O
whose O
effects O
may O
be O
affected O
. O
- O
Antacids B-GROUP
- O
Diarrhea O
medicine O
containing O
kaolin B-DRUG
or O
attapulgite B-DRUG
- O
Ketoconazole B-DRUG
- O
Central B-GROUP
nervous I-GROUP
system I-GROUP
( I-GROUP
CNS I-GROUP
) I-GROUP
depressants I-GROUP
- O
Other O
anticholinergics B-GROUP
- O
Tricyclic B-GROUP
antidepressants I-GROUP
( O
e O
. O
g O
. O
, O
Elavil B-BRAND
, O
Asendin B-BRAND
, O
Anafranil B-BRAND
, O
Pertofrane B-BRAND
, O
Sinequan B-BRAND
, O
Tofranil B-BRAND
, O
Aventyl B-BRAND
, O
Surmontil B-BRAND
) O
- O
Potassium B-DRUG
chloride I-DRUG
( O
e O
. O
g O
. O
, O
Kay B-BRAND
Ciel I-BRAND
) O

FELDENE B-BRAND
is O
highly O
protein O
bound O
, O
and O
therefore O
, O
might O
be O
expected O
to O
displace O
other O
protein O
- O
bound O
drugs O
. O
Although O
this O
has O
not O
occurred O
in O
in O
vitro O
studies O
with O
coumarin B-GROUP
- I-GROUP
type I-GROUP
anticoagulants I-GROUP
, O
interactions O
with O
coumarin B-GROUP
- I-GROUP
type I-GROUP
anticoagulants I-GROUP
have O
been O
reported O
with O
FELDENE B-BRAND
since O
marketing O
, O
therefore O
, O
physicians O
should O
closely O
monitor O
patients O
for O
a O
change O
in O
dosage O
requirements O
when O
administering O
FELDENE B-BRAND
to O
patients O
on O
coumarin B-GROUP
- I-GROUP
type I-GROUP
anticoagulants I-GROUP
and O
other O
highly O
protein O
- O
bound O
drugs O
. O
Plasma O
levels O
of O
piroxicam B-DRUG
are O
depressed O
to O
approximately O
80 O
% O
of O
their O
normal O
values O
when O
FELDENE B-BRAND
is O
administered O
in O
conjunction O
with O
aspirin B-BRAND
( O
3900 O
mg O
/ O
day O
) O
, O
but O
concomitant O
administration O
of O
antacids B-GROUP
has O
no O
effect O
on O
piroxicam B-DRUG
plasma O
levels O
. O
Nonsteroidal B-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
agents I-GROUP
, O
including O
FELDENE B-BRAND
, O
have O
been O
reported O
to O
increase O
steady O
state O
plasma O
lithium B-DRUG
levels O
. O
It O
is O
recommended O
that O
plasma O
lithium B-DRUG
levels O
be O
monitored O
when O
initiating O
, O
adjusting O
and O
discontinuing O
FELDENE B-BRAND
. O

There O
have O
been O
no O
formal O
interaction O
studies O
of O
PHOTOFRIN B-BRAND
and O
any O
other O
drugs O
. O
However O
, O
it O
is O
possible O
that O
concomitant O
use O
of O
other O
photosensitizing B-GROUP
agents I-GROUP
( O
e O
. O
g O
. O
, O
tetracyclines B-GROUP
, O
sulfonamides B-GROUP
, O
phenothiazines B-GROUP
, O
sulfonylurea B-GROUP
hypoglycemia O
agents O
, O
thiazide B-GROUP
diuretics I-GROUP
, O
and O
griseofulvin B-DRUG
) O
could O
increase O
the O
photosensitivity O
reaction O
. O
PHOTOFRIN B-BRAND
PDT O
causes O
direct O
intracellular O
damage O
by O
initiating O
radical O
chain O
reactions O
that O
damage O
intracellular O
membranes O
and O
mitochondria O
. O
Tissue O
damage O
also O
results O
from O
ischemia O
secondary O
to O
vasoconstriction O
, O
platelet O
activation O
and O
aggregation O
and O
clotting O
. O
Research O
in O
animals O
and O
in O
cell O
culture O
has O
suggested O
that O
many O
drugs O
could O
influence O
the O
effects O
of O
PDT O
, O
possible O
examples O
of O
which O
are O
described O
below O
. O
There O
are O
no O
human O
data O
that O
support O
or O
rebut O
these O
possibilities O
. O
Compounds O
that O
quench O
active O
oxygen O
species O
or O
scavenge O
radicals O
, O
such O
as O
dimethyl B-DRUG_N
sufloxide I-DRUG_N
, O
b B-DRUG
- I-DRUG
carotene I-DRUG
, O
ethanol B-DRUG
, O
formate B-DRUG_N
and O
mannitol B-DRUG
would O
be O
expected O
to O
decrease O
PDT O
activity O
. O
Preclinical O
data O
also O
suggest O
that O
tissue O
ischemia O
, O
allopurinol B-DRUG
, O
calcium B-GROUP
channel I-GROUP
blockers I-GROUP
and O
some O
prostaglandin O
synthesis O
inhibitors O
could O
interfere O
with O
PHOTOFRIN O
PDT O
. O
Drugs O
that O
decrease O
clotting O
, O
vasoconstriction O
or O
platelet O
aggregation O
, O
e O
. O
g O
. O
, O
thromboxane O
A2 O
inhibitors O
, O
could O
decrease O
the O
efficacy O
of O
PDT O
. O
Glucocorticoid B-GROUP
hormones O
given O
before O
or O
concomitant O
with O
PDT O
may O
decrease O
the O
efficacy O
of O
the O
treatment O
. O

When O
atropine B-DRUG
and O
pralidoxime B-DRUG
are O
used O
together O
, O
the O
signs O
of O
atropinization O
( O
flushing O
, O
mydriasis O
, O
tachycardia O
, O
dryness O
of O
the O
mouth O
and O
nose O
) O
may O
occur O
earlier O
than O
might O
be O
expected O
when O
atropine B-DRUG
is O
used O
alone O
. O
This O
is O
especially O
true O
if O
the O
total O
dose O
of O
atropine B-DRUG
has O
been O
large O
and O
the O
administration O
of O
pralidoxime B-DRUG
has O
been O
delayed O
. O
2 O
- O
4 O
The O
following O
precautions O
should O
be O
kept O
in O
mind O
in O
the O
treatment O
of O
anticholinesterase O
poisoning O
, O
although O
they O
do O
not O
bear O
directly O
on O
the O
use O
of O
pralidoxime B-DRUG
: O
since O
barbiturates B-GROUP
are O
potentiated O
by O
the O
anticholinesterases B-GROUP
, O
they O
should O
be O
used O
cautiously O
in O
the O
treatment O
of O
convulsions O
; O
morphine B-DRUG
, O
theophylline B-DRUG
, O
aminophylline B-DRUG
, O
succinylcholine B-DRUG
, O
reserpine B-DRUG
, O
and O
phenothiazine B-GROUP
- I-GROUP
type I-GROUP
tranquilizers I-GROUP
should O
be O
avoided O
in O
patients O
with O
organophosphate O
poisoning O
. O

Carbidopa B-DRUG
/ O
Levodopa B-DRUG
: O
Carbidopa B-DRUG
/ O
Levodopa B-DRUG
does O
not O
influence O
the O
pharmacokinetics O
of O
pramipexole B-DRUG
in O
healthy O
volunteers O
( O
N O
= O
10 O
) O
. O
5 O
hours O
. O
Selegiline B-DRUG
: O
In O
healthy O
volunteers O
( O
N O
= O
11 O
) O
, O
selegiline B-DRUG
did O
not O
influence O
the O
pharmacokinetics O
of O
pramipexole B-DRUG
. O
Amantadine B-DRUG
: O
Population O
pharmacokinetic O
analysis O
suggests O
that O
amantadine B-DRUG
is O
unlikely O
to O
alter O
the O
oral O
clearance O
of O
pramipexole B-DRUG
( O
N O
= O
54 O
) O
. O
Cimetidine B-DRUG
: O
Cimetidine B-DRUG
, O
a O
known O
inhibitor O
of O
renal O
tubular O
secretion O
of O
organic O
bases O
via O
the O
cationic O
transport O
system O
, O
caused O
a O
50 O
% O
increase O
in O
pramipexole B-DRUG
AUC O
and O
a O
40 O
% O
increase O
in O
half O
- O
life O
( O
N O
= O
12 O
) O
. O
Probenecid B-DRUG
: O
Probenecid B-DRUG
, O
a O
known O
inhibitor O
of O
renal O
tubular O
secretion O
of O
organic O
acids O
via O
the O
aruonic O
transporter O
, O
did O
not O
noticeably O
influence O
pramipexole B-DRUG
pharmacokinetics O
( O
N O
= O
12 O
) O
. O
Other O
drugs O
eliminated O
via O
renal O
secretion O
: O
Population O
pharmacokinetic O
analysis O
suggests O
that O
coadministration O
of O
drugs O
that O
are O
secreted O
by O
the O
cationic O
transport O
system O
( O
e O
. O
g O
. O
, O
cimetidine B-DRUG
, O
ranitidine B-DRUG
, O
diltiazem B-DRUG
, O
triamterene B-DRUG
, O
verapamil B-DRUG
, O
quinidine B-DRUG
, O
and O
quinine B-DRUG
) O
decreases O
the O
oral O
clearance O
of O
pramipexole B-DRUG
by O
about O
20 O
% O
, O
while O
those O
secreted O
by O
the O
anionic O
transport O
system O
( O
e O
. O
g O
. O
, O
cephalosporins B-GROUP
, O
penicillins B-GROUP
, O
indomethacin B-DRUG
, O
hydrochlorothiazide B-DRUG
, O
and O
chlorpropamide B-DRUG
) O
are O
likely O
to O
have O
little O
effect O
on O
the O
oral O
clearance O
of O
pramipexole B-DRUG
. O
CYP O
interactions O
: O
Inhibitors O
of O
cytochrome O
P450 O
enzymes O
would O
not O
be O
expected O
to O
affect O
pramipexole B-DRUG
elimination O
because O
pramipexole B-DRUG
is O
not O
appreciably O
metabolized O
by O
these O
enzymes O
in O
vivo O
or O
in O
vitro O
. O
Pramipexole B-DRUG
does O
not O
inhibit O
CYP O
enzymes O
CYPIA2 O
, O
CYP2C9 O
, O
CYP2CI9 O
, O
CYP2EI O
, O
and O
CYP3A4 O
. O
Inhibition O
of O
CYP2D6 O
was O
observed O
with O
an O
apparent O
Ki O
of O
30 O
uM O
, O

indicating O
that O
pramipexole B-DRUG
will O
not O
inhibit O
CYP O
enzymes O
at O
plasma O
concentrations O
observed O
following O
the O
highest O
recommended O
clinical O
dose O
( O
1 O
. O
5 O
mg O
tid O
) O
. O
Dopamine B-GROUP
antagonists I-GROUP
: O
Since O
pramipexole B-DRUG
is O
a O
dopamine B-GROUP
agonist I-GROUP
, O
it O
is O
possible O
that O
dopamine B-GROUP
antagonists I-GROUP
, O
such O
as O
the O
neuroleptics B-GROUP
( O
phenothiazines B-GROUP
, O
butyrophenones B-GROUP
, O
thioxanthenes B-GROUP
) O
or O
metoclopramide B-GROUP
, O
may O
diminish O
the O
effectiveness O
of O
MIRAPEX B-BRAND
. O
Drug O
/ O
Laboratory O
Test O
Interactions O
There O
are O
no O
known O
interactions O
between O
MIRAPEX B-BRAND
and O
laboratory O
tests O
. O

Due O
to O
its O
effects O
on O
gastric O
emptying O
, O
SYMLIN B-BRAND
therapy O
should O
not O
be O
considered O
for O
patients O
taking O
drugs O
that O
alter O
gastrointestinal O
motility O
( O
e O
. O
g O
. O
, O
anticholinergic B-GROUP
agents I-GROUP
such O
as O
atropine B-DRUG
) O
and O
agents O
that O
slow O
the O
intestinal O
absorption O
of O
nutrients O
( O
e O
. O
g O
. O
, O
alpha B-GROUP
glucosidase I-GROUP
inhibitors I-GROUP
) O
. O
Patients O
using O
these O
drugs O
have O
not O
been O
studied O
in O
clinical O
trials O
. O
SYMLIN B-BRAND
has O
the O
potential O
to O
delay O
the O
absorption O
of O
concomitantly O
administered O
oral O
medications O
. O
When O
the O
rapid O
onset O
of O
a O
concomitant O
orally O
administered O
agent O
is O
a O
critical O
determinant O
of O
effectiveness O
( O
such O
as O
analgesics B-GROUP
) O
, O
the O
agent O
should O
be O
administered O
at O
least O
1 O
hour O
prior O
to O
or O
2 O
hours O
after O
SYMLIN B-BRAND
injection O
. O
In O
clinical O
trials O
, O
the O
concomitant O
use O
of O
sulfonylureas B-GROUP
or O
biguanides B-GROUP
did O
not O
alter O
the O
adverse O
event O
profile O
of O
SYMLIN B-BRAND
. O
No O
formal O
interaction O
studies O
have O
been O
performed O
to O
assess O
the O
effect O
of O
SYMLIN B-BRAND
on O
the O
kinetics O
of O
oral O
antidiabetic B-GROUP
agents I-GROUP
. O
Mixing O
SYMLIN B-BRAND
and O
Insulin B-DRUG
The O
pharmacokinetic O
parameters O
of O
SYMLIN B-BRAND
were O
altered O
when O
mixed O
with O
regular O
, O
NPH O
, O
and O
70 O
/ O
30 O
premixed O
formulations O
of O
recombinant O
human B-DRUG
insulin I-DRUG
immediately O
prior O
to O
injection O
. O
Thus O
, O
SYMLIN B-BRAND
and O
insulin B-DRUG
should O
not O
be O
mixed O
and O
must O
be O
administered O
separately O
. O

No O
data O
are O
available O
regarding O
interaction O
of O
BILTRICIDE B-BRAND
with O
other O
drugs O
. O

The O
pharmacokinetic O
interactions O
listed O
below O
are O
potentially O
clinically O
important O
. O
Drugs O
that O
induce O
hepatic O
enzymes O
such O
as O
phenobarbital B-DRUG
, O
phenytoin B-DRUG
and O
rifampin B-DRUG
may O
increase O
the O
clearance O
of O
corticosteroids B-GROUP
and O
may O
require O
increases O
in O
corticosteroid B-GROUP
dose O
to O
achieve O
the O
desired O
response O
. O
Drugs O
such O
as O
troleandomycin B-DRUG
and O
ketoconazole B-DRUG
may O
inhibit O
the O
metabolism O
of O
corticosteroids B-GROUP
and O
thus O
decrease O
their O
clearance O
. O
Therefore O
, O
the O
dose O
of O
corticosteroid B-GROUP
should O
be O
titrated O
to O
avoid O
steroid O
toxicity O
. O
Corticosteroids B-GROUP
may O
increase O
the O
clearance O
of O
chronic O
high O
dose O
aspirin B-BRAND
. O
This O
could O
lead O
to O
decreased O
salicylate B-GROUP
serum O
levels O
or O
increase O
the O
risk O
of O
salicylate B-GROUP
toxicity O
when O
corticosteroid B-GROUP
is O
withdrawn O
. O
Aspirin B-BRAND
should O
be O
used O
cautiously O
in O
conjunction O
with O
corticosteroids B-GROUP
in O
patients O
suffering O
from O
hypoprothrombinemia O
. O
The O
effect O
of O
corticosteroids B-GROUP
on O
oral O
anticoagulants B-GROUP
is O
variable O
. O
There O
are O
reports O
of O
enhanced O
as O
well O
as O
diminished O
effects O
of O
anticoagulants B-GROUP
when O
given O
concurrently O
with O
corticosteroids B-GROUP
. O
Therefore O
, O
coagulation O
indices O
should O
be O
monitored O
to O
maintain O
the O
desired O
anticoagulant O
effect O
. O

Anticholinesterases B-GROUP
: O
Concurrent O
use O
of O
procaine B-DRUG
hydrochloride I-DRUG
and O
anticholinesterase B-GROUP
agents I-GROUP
may O
result O
in O
increased O
systemic O
toxicity O
since O
anticholinesterases B-GROUP
inhibit O
the O
breakdown O
of O
procaine B-DRUG
hydrochloride I-DRUG
. O
Antimyasthenics O
Concurrent O
use O
of O
procaine B-DRUG
hydrochloride I-DRUG
and O
antimyasthenics O
may O
result O
in O
loss O
of O
control O
of O
symptoms O
of O
myasthenia O
gravis O
due O
to O
antagonism O
of O
the O
effects O
of O
antimyasthenics O
on O
skeletal O
muscle O
. O
Temporary O
dosage O
adjustment O
of O
antimyasthenics O
may O
be O
required O
. O
Also O
antimyasthenics O
may O
have O
anticholinesterase O
activity O
. O
CNS B-GROUP
depressant I-GROUP
medications O
: O
Concurrent O
use O
of O
procaine B-DRUG
hydrochloride I-DRUG
and O
CNS B-GROUP
depressant I-GROUP
medications I-GROUP
may O
result O
in O
additive O
depressant O
effects O
. O
Hyaluronidase B-DRUG
: O
Hyaluronidase B-DRUG
may O
increase O
the O
diffusion O
rate O
of O
procaine B-DRUG
hydrochloride I-DRUG
, O
resulting O
in O
a O
decreased O
time O
of O
onset O
, O
but O
an O
increase O
in O
systemic O
toxicity O
. O
Neuromuscular B-GROUP
blocking I-GROUP
agents I-GROUP
( O
such O
as O
suxamethonium B-DRUG
chloride I-DRUG
) O
: O
Concurrent O
use O
of O
procaine B-DRUG
hydrochloride I-DRUG
and O
neuromuscular B-GROUP
blocking I-GROUP
agents I-GROUP
may O
result O
in O
prolongation O
or O
enhancement O
of O
the O
neuromuscular O
blockade O
. O
Sulfonamides B-GROUP
: O
Concurrent O
use O
of O
procaine B-DRUG
hydrochloride I-DRUG
and O
sulfonamides B-GROUP
may O
result O
in O
a O
reduction O
of O
the O
antibacterial O
action O
of O
the O
sulfonamide B-GROUP
. O
Acetazolamide B-DRUG
: O
Concurrent O
use O
of O
acetazolamide B-DRUG
and O
procaine B-DRUG
hydrochloride I-DRUG
may O
extend O
the O
plasma O
half O
- O
life O
of O
procaine B-DRUG
. O

To O
minimize O
CNS O
depression O
and O
possible O
potentiation O
, O
barbiturates B-GROUP
, O
antihistamines B-GROUP
, O
narcotics B-GROUP
, O
hypotensive B-GROUP
agents I-GROUP
or O
phenothiazines B-GROUP
should O
be O
used O
with O
caution O
. O
Ethyl B-DRUG
alcohol I-DRUG
should O
not O
be O
used O
since O
there O
may O
be O
an O
Antabuse O
( O
disulfiram O
) O
- O
like O
reaction O
. O
Because O
Matulane B-BRAND
exhibits O
some O
monoamine O
oxidase O
inhibitory O
activity O
, O
sympathomimetic B-GROUP
drugs I-GROUP
, O
tricyclic B-GROUP
antidepressant I-GROUP
drugs O
( O
e O
. O
g O
. O
, O
amitriptyline B-DRUG
HCl I-DRUG
, O
imipramine B-DRUG
HCl I-DRUG
) O
and O
other O
drugs O
and O
foods O
with O
known O
high O
tyramine B-DRUG_N
content O
, O
such O
as O
wine O
, O
yogurt O
, O
ripe O
cheese O
and O
bananas O
, O
should O
be O
avoided O
. O
A O
further O
phenomenon O
of O
toxicity O
common O
to O
many O
hydrazine B-GROUP
derivatives I-GROUP
is O
hemolysis O
and O
the O
appearance O
of O
Heinz O
- O
Ehrlich O
inclusion O
bodies O
in O
erythrocytes O
. O
No O
cross O
- O
resistance O
with O
other O
chemotherapeutic B-GROUP
agents I-GROUP
, O
radiotherapy O
or O
steroids B-GROUP
has O
been O
demonstrated O
. O

Thiazide B-GROUP
diuretics I-GROUP
may O
accentuate O
the O
orthostatic O
hypotension O
that O
may O
occur O
with O
phenothiazines B-GROUP
. O
Antihypertensive O
effects O
of O
guanethidine B-DRUG
and O
related O
compounds O
may O
be O
counteracted O
when O
phenothiazines B-GROUP
are O
used O
concomitantly O
. O
Concomitant O
administration O
of O
propranolol B-DRUG
with O
phenothiazines B-GROUP
results O
in O
increased O
plasma O
levels O
of O
both O
drugs O
. O

The O
induction O
dose O
requirements O
of O
DIPRIVAN B-BRAND
Injectable O
Emulsion O
may O
be O
reduced O
in O
patients O
with O
intramuscular O
or O
intravenous O
premedication O
, O
particularly O
with O
narcotics B-GROUP
( O
eg O
, O
morphine B-DRUG
, O
meperidine B-DRUG
, O
and O
fentanyl B-DRUG
, O
etc O
. O
) O
and O
combinations O
of O
opioids B-GROUP
and O
sedatives B-GROUP
( O
eg O
, O
benzodiazepines B-GROUP
, O
barbiturates B-GROUP
, O
chloral B-DRUG
hydrate I-DRUG
, O
droperidol B-DRUG
, O
etc O
. O
) O
. O
These O
agents O
may O
increase O
the O
anesthetic O
or O
sedative O
effects O
of O
DIPRIVAN B-BRAND
Injectable O
Emulsion O
and O
may O
also O
result O
in O
more O
pronounced O
decreases O
in O
systolic O
, O
diastolic O
, O
and O
mean O
arterial O
pressures O
and O
cardiac O
output O
. O
During O
maintenance O
of O
anesthesia O
or O
sedation O
, O
the O
rate O
of O
DIPRIVAN B-BRAND
Injectable O
Emulsion O
administration O
should O
be O
adjusted O
according O
to O
the O
desired O
level O
of O
anesthesia O
or O
sedation O
and O
may O
be O
reduced O
in O
the O
presence O
of O
supplemental O
analgesic B-GROUP
agents I-GROUP
( O
eg O
, O
nitrous B-DRUG
oxide I-DRUG
or O
opioids B-GROUP
) O
. O
The O
concurrent O
administration O
of O
potent O
inhalational O
agents O
( O
eg O
, O
isoflurane B-DRUG
, O
enflurane B-DRUG
, O
and O
halothane B-DRUG
) O
during O
maintenance O
with O
DIPRIVAN B-BRAND
Injectable O
Emulsion O
has O
not O
been O
extensively O
evaluated O
. O
These O
inhalational O
agents O
can O
also O
be O
expected O
to O
increase O
the O
anesthetic O
or O
sedative O
and O
cardiorespiratory O
effects O
of O
DIPRIVAN B-BRAND
Injectable O
Emulsion O
. O
DIPRIVAN B-BRAND
Injectable O
Emulsion O
does O
not O
cause O
a O
clinically O
significant O
change O
in O
onset O
, O
intensity O
, O
or O
duration O
of O
action O
of O
the O
commonly O
used O
neuromuscular B-GROUP
blocking I-GROUP
agents I-GROUP
( O
eg O
, O
succinylcholine B-DRUG
and O
nondepolarizing B-GROUP
muscle I-GROUP
relaxants I-GROUP
) O
. O
No O
significant O
adverse O
interactions O
with O
commonly O
used O
premedications O
or O
drugs O
used O
during O
anesthesia O
or O
sedation O
( O
including O
a O
range O
of O
muscle B-GROUP
relaxants I-GROUP
, O
inhalational O
agents O
, O
analgesic B-GROUP
agents I-GROUP
, O
and O
local O
anesthetic B-GROUP
agents I-GROUP
) O
have O
been O
observed O
. O

The O
CNS O
- O
depressant O
effect O
of O
propoxyphene B-DRUG
is O
additive O
with O
that O
of O
other O
CNS B-GROUP
depressants I-GROUP
, O
including O
alcohol B-DRUG
. O
As O
is O
the O
case O
with O
many O
medicinal O
agents O
, O
propoxyphene B-DRUG
may O
slow O
the O
metabolism O
of O
a O
concomitantly O
administered O
drug O
. O
Should O
this O
occur O
, O
the O
higher O
serum O
concentrations O
of O
that O
drug O
may O
result O
in O
increased O
pharmacologic O
or O
adverse O
effects O
of O
that O
drug O
. O
Such O
occurrences O
have O
been O
reported O
when O
propoxyphene B-DRUG
was O
administered O
to O
patients O
on O
antidepressants B-GROUP
, O
anticonvulsants B-GROUP
, O
or O
warfarin B-DRUG
- O
like O
drugs O
. O
Sever O
neurologic O
signs O
, O
including O
coma O
, O
have O
occurred O
with O
concurrent O
use O
of O
carbamazepine B-DRUG
. O

May O
increase O
the O
effect O
of O
oral O
blood B-GROUP
thinners I-GROUP
, O
for O
example O
warfarin B-DRUG
( O
Coumadin B-BRAND
) O
. O
Therefore O
, O
warfarin B-DRUG
dose O
changes O
and O
monitoring O
for O
the O
effects O
of O
warfarin B-DRUG
on O
blood O
clotting O
are O
necessary O
. O

MAO B-GROUP
inhibitors I-GROUP
and O
beta B-GROUP
adrenergic I-GROUP
blockers I-GROUP
increase O
the O
effects O
of O
pseudoephedrine B-DRUG
. O
Sympathomimetics B-GROUP
may O
reduce O
the O
antihypertensive O
effects O
of O
methyldopa B-DRUG
, O
mecamylamine B-DRUG
, O
reserpine B-DRUG
and O
veratrum B-GROUP
alkaloids I-GROUP
. O

Pyrazinamide B-DRUG
has O
been O
reported O
to O
interfere O
with O
ACETEST O
and O
KETOSTIX O
urine O
tests O
to O
produce O
a O
pink O
- O
brown O
color O
. O
5 O

Pyrimethamine B-DRUG
may O
be O
used O
with O
sulfonamides B-GROUP
, O
quinine B-DRUG
and O
other O
antimalarials B-GROUP
, O
and O
with O
other O
antibiotics B-GROUP
. O
If O
signs O
of O
folate O
deficiency O
develop O
, O
pyrimethamine B-DRUG
should O
be O
discontinued O
. O
Folinic B-DRUG
acid I-DRUG
( O
leucovorin B-DRUG
) O
should O
be O
administered O
until O
normal O
hematopoiesis O
is O
restored O
. O
Mild O
hepatotoxicity O
has O
been O
reported O
in O
some O
patients O
when O
lorazepam B-DRUG
and O
pyrimethamine B-DRUG
were O
administered O
concomitantly O
. O

Alcohol B-DRUG
( O
this O
combination O
may O
make O
you O
very O
sick O
) O
and O
primaquine B-DRUG

Cholestyramine B-DRUG
: O
Cholestyramine B-DRUG
causes O
a O
60 O
% O
reduction O
in O
the O
absorption O
and O
enterohepatic O
cycling O
of O
raloxifene B-DRUG
and O
should O
not O
be O
coadministered O
with O
EVISTA B-BRAND
. O
Warfarin B-DRUG
: O
The O
coadministration O
of O
EVISTA B-BRAND
and O
warfarin B-DRUG
has O
not O
been O
assessed O
under O
chronic O
conditions O
. O
However O
, O
10 O
% O
decreases O
in O
prothrombin O
time O
have O
been O
observed O
in O
single O
- O
dose O
studies O
. O
If O
EVISTA B-BRAND
is O
given O
concurrently O
with O
warfarin B-DRUG
, O
prothrombin O
time O
should O
be O
monitored O
. O
Other O
Highly O
Protein O
- O
Bound O
Drugs O
: O
Raloxifene B-DRUG
is O
more O
than O
95 O
% O
bound O
to O
plasma O
proteins O
. O
In O
vitro O
, O
raloxifene B-DRUG
did O
not O
affect O
the O
binding O
of O
warfarin B-DRUG
, O
phenytoin B-DRUG
, O
or O
tamoxifen B-DRUG
. O
Caution O
should O
be O
used O
when O
EVISTA B-BRAND
is O
coadministered O
with O
other O
highly O
protein O
- O
bound O
drugs O
, O
such O
as O
clofibrate B-DRUG
, O
indomethacin B-DRUG
, O
naproxen B-DRUG
, O
ibuprofen B-DRUG
, O
diazepam B-DRUG
, O
and O
diazoxide B-DRUG
. O
See O
also O
CLINICAL O
PHARMACOLOGY O
, O
Drug O
- O
Drug O
Interactions O

Drug O
interaction O
studies O
have O
not O
been O
conducted O
with O
LUCENTIS B-BRAND
. O
LUCENTIS B-BRAND
intravitreal O
injection O
has O
been O
used O
adjunctively O
with O
verteporfin B-DRUG
photodynamic O
therapy O
( O
PDT O
) O
. O
Twelve O
of O
105 O
( O
11 O
% O
) O
patients O
developed O
serious O
intraocular O
inflammation O
; O
in O
10 O
of O
the O
12 O
patients O
, O
this O
occurred O
when O
LUCENTIS B-BRAND
was O
administered O
7 O
days O
( O
2 O
days O
) O
after O
verteporfin B-DRUG
PDT O
. O

Coadministration O
of O
TRITEC B-BRAND
with O
clarithromycin B-DRUG
resulted O
in O
increased O
plasma O
ranitidine B-DRUG
concentrations O
( O
57 O
% O
) O
, O
increased O
plasma O
bismuth O
trough O
concentrations O
( O
48 O
% O
) O
, O
and O
increased O
14 B-DRUG_N
- I-DRUG_N
hydroxy I-DRUG_N
- I-DRUG_N
clarithromycin I-DRUG_N
plasma O
concentrations O
( O
31 O
% O
) O
. O
Coadministration O
with O
aspirin B-BRAND
results O
in O
a O
slight O
decrease O
in O
the O
rate O
of O
salicylate B-GROUP
absorption O
that O
is O
clinically O
unimportant O
. O
Coadministration O
with O
a O
high O
dose O
of O
antacid B-GROUP
( O
170 O
mEq O
) O
results O
in O
a O
28 O
% O
decrease O
in O
plasma O
concentrations O
of O
ranitidine B-DRUG
and O
may O
decrease O
plasma O
concentrations O
of O
bismuth O
from O
TRITEC B-BRAND
. O
These O
effects O
are O
clinically O
insignificant O
. O
For O
information O
on O
drug O
interactions O
associated O
with O
ranitidine B-DRUG
, O
refer O
to O
the O
ZANTAC B-BRAND
package O
insert O
. O

Combined O
usage O
of O
MAO B-GROUP
inhibitors I-GROUP
should O
be O
avoided O

In O
animals O
the O
duration O
of O
muscle O
paralysis O
from O
succinylcholine B-DRUG
is O
not O
prolonged O
by O
remifentanil B-DRUG
. O
Remifentanil B-DRUG
clearance O
is O
not O
altered O
by O
concomitant O
administration O
of O
thiopental B-DRUG
, O
isoflurane B-DRUG
, O
propofol B-DRUG
, O
or O
temazepam B-DRUG
during O
anesthesia O
. O
In O
vitro O
studies O
with O
atracurium B-DRUG
, O
mivacurium B-DRUG
, O
esmolol B-DRUG
, O
echothiophate B-DRUG
, O
neostigmine B-DRUG
, O
physostigmine B-DRUG
, O
and O
midazolam B-DRUG
revealed O
no O
inhibition O
of O
remifentanil B-DRUG
hydrolysis O
in O
whole O
human O
blood O
by O
these O
drugs O
. O

There O
are O
, O
as O
yet O
, O
no O
known O
drug O
interactions O
, O
but O
further O
study O
is O
required O
. O

Co O
- O
administration O
of O
oral O
ketoconazole B-DRUG
200 O
mg O
twice O
daily O
increased O
retapamulin B-DRUG
geometric O
mean O
AUC O
( O
0 O
- O
24 O
) O
and O
Cmax O
by O
81 O
% O
after O
topical O
application O
of O
retapamulin B-DRUG
ointment O
, O
1 O
% O
on O
the O
abraded O
skin O
of O
healthy O
adult O
males O
. O
Due O
to O
low O
systemic O
exposure O
to O
retapamulin B-DRUG
following O
topical O
application O
in O
patients O
, O
dosage O
adjustments O
for O
retapamulin B-DRUG
are O
unnecessary O
when O
co O
- O
administered O
with O
CYP3A4 O
inhibitors O
, O
such O
as O
ketoconazole B-DRUG
. O
Based O
on O
in O
vitro O
P450 O
inhibition O
studies O
and O
the O
low O
systemic O
exposure O
observed O
following O
topical O
application O
of O
ALTABAX B-BRAND
, O
retapamulin B-DRUG
is O
unlikely O
to O
affect O
the O
metabolism O
of O
other O
P450 O
substrates O
. O
The O
effect O
of O
concurrent O
application O
of O
ALTABAX B-BRAND
and O
other O
topical O
products O
to O
the O
same O
area O
of O
skin O
has O
not O
been O
studied O
. O

The O
interaction O
of O
Retavase B-BRAND
with O
other O
cardioactive O
drugs O
has O
not O
been O
studied O
. O
In O
addition O
to O
bleeding O
associated O
with O
heparin B-DRUG
and O
vitamin B-GROUP
K I-GROUP
antagonists I-GROUP
, O
drugs O
that O
alter O
platelet O
function O
( O
such O
as O
aspirin B-BRAND
, O
dipyridamole B-DRUG
, O
and O
abciximab B-DRUG
) O
may O
increase O
the O
risk O
of O
bleeding O
if O
administered O
prior O
to O
or O
after O
Retavase B-BRAND
therapy O
. O

Clinical O
studies O
of O
interactions O
of O
VIRAZOLE B-BRAND
with O
other O
drugs O
commonly O
used O
to O
treat O
infants O
with O
RSV O
infections O
, O
such O
as O
digoxin B-DRUG
, O
bronchodilators B-GROUP
, O
other O
antiviral B-GROUP
agents I-GROUP
, O
antibiotics B-GROUP
, O
or O
anti B-GROUP
- I-GROUP
metabolites I-GROUP
have O
not O
been O
conducted O
. O
Interference O
by O
VIRAZOLE B-BRAND
with O
laboratory O
tests O
has O
not O
been O
evaluated O
. O

Interactions O
for O
Vitamin B-DRUG
B2 I-DRUG
( O
Riboflavin B-DRUG
) O
: O
Alcohol B-DRUG
- O
impairs O
the O
intestinal O
absorption O
of O
riboflavin B-DRUG
Probenecid B-DRUG
- O
concurrent O
use O
decreases O
gastrointestinal O
absorption O
of O
riboflavin B-DRUG
; O
requirements O
for O
riboflavin B-DRUG
may O
be O
increased O
in O
patients O
receiving O
probenecid B-DRUG
. O

Drug O
- O
Drug O
Interactions O
Although O
in O
vitro O
studies O
demonstrated O
the O
potential O
of O
rifaximin B-DRUG
to O
interact O
with O
cytochrome O
P450 O
3A4 O
( O
CYP3A4 O
) O
, O
a O
clinical O
drug O
- O
drug O
interaction O
study O
demonstrated O
that O
rifaximin B-DRUG
did O
not O
significantly O
affect O
the O
pharmacokinetics O
of O
midazolam B-DRUG
either O
presystemically O
or O
systemically O
. O
An O
additional O
clinical O
drug O
- O
drug O
interaction O
study O
showed O
no O
effect O
of O
rifaximin B-DRUG
on O
the O
presystemic O
metabolism O
of O
an O
oral O
contraceptive B-GROUP
containing O
ethinyl B-DRUG
estradiol I-DRUG
and O
norgestimate B-DRUG
. O
Therefore O
, O
clinical O
interactions O
with O
drugs O
metabolized O
by O
human O
cytochrome O
P450 O
isoenzymes O
are O
not O
expected O
. O

Cimetidine B-DRUG
: O
The O
effects O
of O
chronic O
cimetidine B-DRUG
use O
on O
the O
metabolism O
of O
rimantadine B-DRUG
are O
not O
known O
. O
When O
a O
single O
100 O
mg O
dose O
of O
rimantadine B-DRUG
HCl I-DRUG
was O
administered O
one O
hour O
after O
the O
initiation O
of O
Cimetidine B-DRUG
( O
300 O
mg O
four O
times O
a O
day O
) O
, O
the O
apparent O
total O
rimantadine B-DRUG
clearance O
of O
this O
single O
dose O
in O
normal O
healthy O
adults O
was O
reduced O
by O
18 O
% O
( O
compared O
to O
the O
apparent O
total O
rimantadine B-DRUG
clearance O
in O
the O
same O
subjects O
in O
the O
absence O
of O
cimetidine B-DRUG
) O
. O
Acetaminophen B-DRUG
: O
Rimantadine B-DRUG
HCl I-DRUG
, O
100 O
mg O
, O
was O
given O
twice O
daily O
for O
13 O
days O
to O
12 O
healthy O
volunteers O
. O
On O
day O
11 O
, O
acetaminophen B-DRUG
( O
650 O
mg O
four O
times O
daily O
) O
was O
started O
and O
continued O
for O
8 O
days O
. O
The O
pharmacokinetics O
of O
rimantadine B-DRUG
were O
assessed O
on O
days O
11 O
and O
13 O
. O
Coadministration O
with O
acetaminophen B-DRUG
reduced O
the O
peak O
concentration O
and O
AUC O
values O
for O
rimantadine B-DRUG
by O
approximately O
11 O
% O
. O
Aspirin B-BRAND
: O
Rimantadine B-DRUG
HCl I-DRUG
, O
100 O
mg O
, O
was O
given O
twice O
daily O
fro O
13 O
days O
to O
12 O
healthy O
volunteers O
. O
On O
day O
11 O
, O
aspirin B-BRAND
( O
650 O
mg O
, O
four O
times O
daily O
) O
was O
started O
and O
continued O
for O
8 O
days O
. O
The O
pharmacokinetics O
of O
rimantadine B-DRUG
were O
assessed O
on O
days O
11 O
and O
13 O
. O
Peak O
plasma O
concentrations O
and O
AUC O
of O
rimantadine B-DRUG
were O
reduced O
approximately O
10 O
% O
in O
the O
presence O
of O
aspirin B-BRAND
. O

Drug O
/ O
Laboratory O
Interactions O
: O
There O
have O
been O
no O
formal O
drug O
interaction O
studies O
performed O
with O
RITUXAN B-BRAND
. O
However O
, O
renal O
toxicity O
was O
seen O
with O
this O
drug O
in O
combination O
with O
cisplatin B-DRUG
in O
clinical O
trials O
. O

Drug O
- O
Drug O
Interactions O
Effect O
of O
Exelon B-BRAND
( O
rivastigmine B-DRUG
tartrate I-DRUG
) O
on O
the O
Metabolism O
of O
Other O
Drugs O
: O
Rivastigmine B-DRUG
is O
primarily O
metabolized O
through O
hydrolysis O
by O
esterases O
. O
Minimal O
metabolism O
occurs O
via O
the O
major O
cytochrome O
P450 O
isoenzymes O
. O
Based O
on O
in O
vitro O
studies O
, O
no O
pharmacokinetic O
drug O
interactions O
with O
drugs O
metabolized O
by O
the O
following O
isoenzyme O
systems O
are O
expected O
: O
CYP1A2 O
, O
CYP2D6 O
, O
CYP3A4 O
/ O
5 O
, O
CYP2E1 O
, O
CYP2C9 O
, O
CYP2C8 O
, O
or O
CYP2C19 O
. O
No O
pharmacokinetic O
interaction O
was O
observed O
between O
rivastigmine B-DRUG
and O
digoxin B-DRUG
, O
warfarin B-DRUG
, O
diazepam B-DRUG
, O
or O
fluoxetine B-DRUG
in O
studies O
in O
healthy O
volunteers O
. O
The O
elevation O
of O
prothrombin O
time O
induced O
by O
warfarin B-DRUG
is O
not O
affected O
by O
administration O
of O
Exelon B-BRAND
. O
Effect O
of O
Other O
Drugs O
on O
the O
Metabolism O
of O
Exelon B-BRAND
: O
Drugs O
that O
induce O
or O
inhibit O
CYP450 O
metabolism O
are O
not O
expected O
to O
alter O
the O
metabolism O
of O
rivastigmine B-DRUG
. O
Single O
dose O
pharmacokinetic O
studies O
demonstrated O
that O
the O
metabolism O
of O
rivastigmine B-DRUG
is O
not O
significantly O
affected O
by O
concurrent O
administration O
of O
digoxin B-DRUG
, O
warfarin B-DRUG
, O
diazepam B-DRUG
, O
or O
fluoxetine B-DRUG
. O
Population O
PK O
analysis O
with O
a O
database O
of O
625 O
patients O
showed O
that O
the O
pharmacokinetics O
of O
rivastigmine B-DRUG
were O
not O
influenced O
by O
commonly O
prescribed O
medications O
such O
as O
antacids B-GROUP
( O
n O
= O
77 O
) O
, O
antihypertensives B-GROUP
( O
n O
= O
72 O
) O
, O
calcium B-GROUP
channel I-GROUP
blockers I-GROUP
( O
n O
= O
75 O
) O
, O
antidiabetics B-GROUP
( O
n O
= O
21 O
) O
, O
nonsteroidal B-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
drugs I-GROUP
( O
n O
= O
79 O
) O
, O
estrogens B-GROUP
( O
n O
= O
70 O
) O
, O
salicylate B-GROUP
analgesics I-GROUP
( O
n O
= O
177 O
) O
, O
antianginals B-GROUP
( O
n O
= O
35 O
) O
, O
and O
antihistamines B-GROUP
( O
n O
= O
15 O
) O
. O
Use O
with O
Anticholinergics B-GROUP
: O
Because O
of O
their O
mechanism O
of O
action O
, O
cholinesterase B-GROUP
inhibitors I-GROUP
have O
the O
potential O
to O
interfere O
with O
the O
activity O
of O
anticholinergic B-GROUP
medications I-GROUP
. O
Use O
with O
Cholinomimetics B-GROUP
and O
Other O
Cholinesterase B-GROUP
Inhibitors I-GROUP
: O
A O
synergistic O
effect O
may O
be O
expected O
when O
cholinesterase B-GROUP
inhibitors I-GROUP
are O
given O
concurrently O
with O
succinylcholine B-DRUG
, O
similar O

neuromuscular B-GROUP
blocking I-GROUP
agents I-GROUP
or O
cholinergic B-GROUP
agonists I-GROUP
such O
as O
bethanechol B-DRUG
. O

Drug O
Interactions O
: O
The O
use O
of O
ZEMURON B-BRAND
( O
rocuronium B-DRUG
bromide I-DRUG
) O
Injection O
before O
succinylcholine B-DRUG
, O
for O
the O
purpose O
of O
attenuating O
some O
of O
the O
side O
effects O
of O
succinylcholine B-DRUG
, O
has O
not O
been O
studied O
. O
If O
ZEMURON B-BRAND
is O
administered O
following O
administration O
of O
succinylcholine B-DRUG
, O
it O
should O
not O
be O
given O
until O
recovery O
from O
succinylcholine B-DRUG
has O
been O
observed O
. O
The O
median O
duration O
of O
action O
of O
ZEMURON B-BRAND
0 O
. O
6 O
mg O
/ O
kg O
administered O
after O
a O
1 O
mg O
/ O
kg O
dose O
of O
succinylcholine B-DRUG
when O
T O
1 O
returned O
to O
75 O
% O
of O
control O
was O
36 O
minutes O
( O
range O
14 O
- O
57 O
, O
n O
= O
12 O
) O
vs O
. O
28 O
minutes O
( O
17 O
- O
51 O
, O
n O
= O
12 O
) O
without O
succinylcholine B-DRUG
. O
There O
are O
no O
controlled O
studies O
documenting O
the O
use O
of O
ZEMURON B-BRAND
before O
or O
after O
other O
nondepolarizing B-GROUP
muscle I-GROUP
relaxants I-GROUP
. O
Interactions O
have O
been O
observed O
when O
other O
nondepolarizing B-GROUP
muscle I-GROUP
relaxants I-GROUP
have O
been O
administered O
in O
succession O
. O
Drug O
/ O
Laboratory O
Test O
Interactions O
: O
None O
known O
. O

Ropivacaine B-DRUG
should O
be O
used O
with O
caution O
in O
patients O
receiving O
other O
local O
anesthetics B-GROUP
or O
agents O
structurally O
related O
to O
amide B-GROUP
- I-GROUP
type I-GROUP
local I-GROUP
anesthetics I-GROUP
, O
since O
the O
toxic O
effects O
of O
these O
drugs O
are O
additive O
. O
Cytochrome O
P4501A2 O
is O
involved O
in O
the O
formation O
of O
3 B-DRUG_N
- I-DRUG_N
hydroxy I-DRUG_N
ropivacaine I-DRUG_N
, O
the O
major O
metabolite O
. O
In O
vivo O
, O
the O
plasma O
clearance O
of O
ropivacaine B-DRUG
was O
reduced O
by O
70 O
% O
during O
coadministration O
of O
fluvoxamine B-DRUG
( O
25 O
mg O
bid O
for O
2 O
days O
) O
, O
a O
selective O
and O
potent O
CYP1A2 O
inhibitor O
. O
Thus O
strong O
inhibitors O
of O
cytochrome O
P4501A2 O
, O
such O
as O
fluvoxamine B-DRUG
, O
given O
concomitantly O
during O
administration O
of O
Ropivacaine B-DRUG
, O
can O
interact O
with O
Ropivacaine B-DRUG
leading O
to O
increased O
ropivacaine B-DRUG
plasma O
levels O
. O
Caution O
should O
be O
exercised O
when O
CYP1A2 O
inhibitors O
are O
coadministered O
. O
Possible O
interactions O
with O
drugs O
known O
to O
be O
metabolized O
by O
CYP1A2 O
via O
competitive O
inhibition O
such O
as O
theophylline B-DRUG
and O
imipramine B-DRUG
may O
also O
occur O
. O
Coadministration O
of O
a O
selective O
and O
potent O
inhibitor O
of O
CYP3A4 O
, O
ketoconazole B-DRUG
( O
100 O
mg O
bid O
for O
2 O
days O
with O
ropivacaine B-DRUG
infusion O
administered O
1 O
hour O
after O
ketoconazole B-DRUG
) O
caused O
a O
15 O
% O
reduction O
in O
in O
- O
vivo O
plasma O
clearance O
of O
ropivacaine B-DRUG
. O

An O
inhibitor O
of O
CYP2C8 O
( O
such O
as O
gemfibrozil B-DRUG
) O
may O
increase O
the O
AUC O
of O
rosiglitazone B-DRUG
and O
an O
inducer O
of O
CYP2C8 O
( O
such O
as O
rifampin B-DRUG
) O
may O
decrease O
the O
AUC O
of O
rosiglitazone B-DRUG
. O
Therefore O
, O
if O
an O
inhibitor O
or O
an O
inducer O
of O
CYP2C8 O
is O
started O
or O
stopped O
during O
treatment O
with O
rosiglitazone B-DRUG
, O
changes O
in O
diabetes O
treatment O
may O
be O
needed O
based O
upon O
clinical O
response O
. O

Concomitant O
administration O
contra O
- O
indicated O
: O
- O
Vasoconstrictive O
ergot B-GROUP
alkaloids I-GROUP
. O
Concomitant O
administrations O
not O
recommended O
: O
- O
Terfenadine B-DRUG
and O
astemizole B-DRUG
: O
Certain O
macrolides B-GROUP
interact O
with O
terfenadine B-DRUG
and O
astemizole B-DRUG
leading O
to O
increased O
serum O
concentrations O
of O
the O
latter O
. O
This O
may O
result O
in O
severe O
ventricular O
arrhythmia O
, O
typically O
torsades O
de O
pointe O
. O
Although O
such O
a O
reaction O
has O
not O
been O
demonstrated O
with O
roxithromycin B-DRUG
, O
concomitant O
administration O
of O
roxithromycin B-DRUG
with O
terfenadine B-DRUG
or O
astemizole B-DRUG
is O
not O
recommended O
. O
- O
Cisapride B-DRUG
, O
pimozide B-DRUG
: O
Other O
drugs O
such O
as O
cisapride B-DRUG
or O
pimozide B-DRUG
, O
which O
are O
metabolised O
by O
hepatic O
CYP3A O
isozymes O
have O
been O
associated O
with O
QT O
interval O
prolongation O
and O
/ O
or O
cardiac O
arrythmias O
( O
typically O
torsades O
de O
pointe O
) O
as O
a O
result O
of O
increase O
in O
their O
serum O
level O
subsequent O
to O
interaction O
with O
significant O
inhibitors O
of O
the O
isozyme O
, O
including O
some O
macrolide B-GROUP
antibacterials I-GROUP
. O
Although O
such O
a O
risk O
is O
not O
verified O
for O
roxithromycin B-DRUG
, O
combination O
of O
roxithromycin B-DRUG
with O
such O
drugs O
is O
not O
recommended O
. O

There O
are O
so O
far O
no O
reported O
adverse O
interactions O
with O
SAMe B-DRUG
and O
other O
drugs O
, O
dietary O
supplements O
or O
foods O
. O

Nasal O
Spray O
: O
Formal O
studies O
designed O
to O
evaluate O
drug O
interactions O
with O
Calcitonin B-DRUG
( I-DRUG
salmon I-DRUG
) I-DRUG
have O
not O
been O
done O
. O
No O
drug O
interaction O
studies O
have O
been O
performed O
with O
Calcitonin B-DRUG
( I-DRUG
salmon I-DRUG
) I-DRUG
nasal O
spray O
ingredients O
. O
Currently O
, O
no O
drug O
interactions O
with O
Calcitonin B-DRUG
( I-DRUG
salmon I-DRUG
) I-DRUG
have O
been O
observed O
. O
The O
effects O
of O
prior O
use O
of O
diphosphonates B-GROUP
in O
postmenopausal O
osteoporosis O
patients O
have O
not O
been O
assessed O
; O
however O
, O
in O
patients O
with O
Paget O
' O
s O
Disease O
prior O
diphosphonate B-GROUP
use O
appears O
to O
reduce O
the O
anti O
- O
resorptive O
response O
to O
Calcitonin B-DRUG
( I-DRUG
salmon I-DRUG
) I-DRUG
nasal O
spray O
. O

Salicylates B-GROUP
antagonize O
the O
uricosuric O
action O
of O
. O
drugs O
used O
to O
treat O
gout O
. O
ASPIRIN B-BRAND
AND O
OTHER O
SALICYLATE B-GROUP
DRUGS I-GROUP
WILL O
BE O
ADDITIVE O
TO O
DISALCID B-BRAND
AND O
MAY O
INCREASE O
PLASMA O
CONCENTRATIONS O
OF O
SALICYLIC B-DRUG
ACID I-DRUG
TO O
TOXIC O
LEVELS O
. O
Drugs O
and O
foods O
that O
raise O
urine O
pH O
will O
increase O
renal O
clearance O
and O
urinary O
excretion O
of O
salicylic B-DRUG
acid I-DRUG
, O
thus O
lowering O
plasma O
levels O
; O
acidifying O
drugs O
or O
foods O
will O
decrease O
urinary O
excretion O
and O
increase O
plasma O
levels O
. O
Salicylates B-GROUP
given O
concomitantly O
with O
anticoagulant B-GROUP
drugs I-GROUP
may O
predispose O
to O
systemic O
bleeding O
. O
Salicylates B-GROUP
may O
enhance O
the O
hypoglycemic O
effect O
of O
oral O
antidiabetic B-GROUP
drugs I-GROUP
of O
the O
sulfonylurea O
class O
. O
Salicylate B-GROUP
competes O
with O
a O
number O
of O
drugs O
for O
protein O
binding O
sites O
, O
notably O
penicillin B-DRUG
, O
thiopental B-DRUG
, O
thyroxine B-DRUG
, O
triiodothyronine B-DRUG
, O
phenytoin B-DRUG
, O
sulfinpyrazone B-DRUG
, O
naproxen B-DRUG
, O
warfarin B-DRUG
, O
methotrexate B-DRUG
, O
and O
possibly O
corticosteroids B-GROUP
. O
Drug O
/ O
Laboratory O
Test O
Interactions O
Salicylate B-GROUP
competes O
with O
thyroid O
hormone O
for O
binding O
to O
plasma O
proteins O
, O
which O
may O
be O
reflected O
in O
a O
depressed O
plasma O
T4 O
value O
in O
some O
patients O
; O
thyroid O
function O
and O
basal O
metabolism O
are O
unaffected O
. O

Interactions O
between O
Leukine B-BRAND
and O
other O
drugs O
have O
not O
been O
fully O
evaluated O
. O
Drugs O
which O
may O
potentiate O
the O
myeloproliferative O
effects O
of O
Leukine B-BRAND
, O
such O
as O
lithium B-DRUG
and O
corticosteroids B-GROUP
, O
should O
be O
used O
with O
caution O
. O

The O
absorption O
of O
oral O
medications O
may O
be O
decreased O
during O
the O
concurrent O
use O
of O
scopolamine B-DRUG
because O
of O
decreased O
gastric O
motility O
and O
delayed O
gastric O
emptying O
. O
Scopolamine B-DRUG
should O
be O
used O
with O
care O
in O
patients O
taking O
other O
drugs O
that O
are O
capable O
of O
causing O
CNS O
effects O
such O
as O
sedatives B-GROUP
, O
tranquilizers B-GROUP
, O
or O
alcohol B-DRUG
. O
Special O
attention O
should O
be O
paid O
to O
potential O
interactions O
with O
drugs O
having O
anticholinergic O
properties O
; O
e O
. O
g O
. O
, O
other O
belladonna B-GROUP
alkaloids I-GROUP
, O
antihistamines B-GROUP
( O
including O
meclizine B-DRUG
) O
, O
tricyclic B-GROUP
antidepressants I-GROUP
, O
and O
muscle B-GROUP
relaxants I-GROUP
. O
Laboratory O
Test O
Interactions O
Scopolamine B-DRUG
will O
interfere O
with O
the O
gastric O
secretion O
test O
. O

Barbiturates B-GROUP
may O
decrease O
the O
effectiveness O
of O
oral O
contraceptives B-GROUP
, O
certain O
antibiotics B-GROUP
, O
quinidine B-GROUP
, O
theophylline B-DRUG
, O
corticosteroids B-GROUP
, O
anticoagulants B-GROUP
, O
and O
beta B-GROUP
blockers I-GROUP
. O

Drug O
/ O
Laboratory O
Test O
Interaction O
: O
The O
concomitant O
use O
of O
anticholinergic B-GROUP
agents I-GROUP
may O
make O
patients O
hyporesponsive O
, O
i O
. O
e O
. O
may O
produce O
a O
false O
positive O
result O
. O

The O
occurrence O
of O
stupor O
, O
muscular O
rigidity O
, O
severe O
agitation O
, O
and O
elevated O
temperature O
has O
been O
reported O
in O
some O
patients O
receiving O
the O
combination O
of O
selegiline B-DRUG
and O
meperidine B-DRUG
. O
Symptoms O
usually O
resolve O
over O
days O
when O
the O
combination O
is O
discontinued O
. O
This O
is O
typical O
of O
the O
interaction O
of O
meperidine B-DRUG
and O
MAOIs B-GROUP
. O
Other O
serious O
reactions O
( O
including O
severe O
agitation O
, O
hallucinations O
, O
and O
death O
) O
have O
been O
reported O
in O
patients O
receiving O
this O
combination O
. O
Severe O
toxicity O
has O
also O
been O
reported O
in O
patients O
receiving O
the O
combination O
of O
tricyclic B-GROUP
antidepressants I-GROUP
and O
ELDEPRYL B-BRAND
and O
selective B-GROUP
serotonin I-GROUP
reuptake I-GROUP
inhibitors I-GROUP
and O
ELDEPRYL B-BRAND
. O
One O
case O
of O
hypertensive O
crisis O
has O
been O
reported O
in O
a O
patient O
taking O
the O
recommended O
doses O
of O
selegiline B-DRUG
and O
a O
sympathomimetic B-GROUP
medication I-GROUP
( O
ephedrine B-DRUG
) O
. O

Concomitant O
glucocorticoid O
therapy O
may O
inhibit O
the O
response O
to O
Geref B-BRAND
. O
There O
was O
no O
evidence O
in O
the O
controlled O
studies O
of O
Geref B-BRAND
' O
s O
interaction O
with O
drugs O
commonly O
used O
in O
the O
treatment O
of O
routine O
pediatric O
problems O
/ O
illnesses O
. O
However O
, O
formal O
drug O
interactions O
studies O
have O
not O
been O
conducted O
. O

Drug O
/ O
Laboratory O
Test O
Interactions O
: O
Potential O
interactions O
between O
ERTACZOTM B-BRAND
Cream O
, O
2 O
% O
, O
and O
other O
drugs O
or O
laboratory O
tests O
have O
not O
been O
systematically O
evaluated O
. O

Digoxin B-DRUG
: O
There O
was O
a O
slight O
increase O
in O
the O
area O
under O
the O
curve O
( O
AUC O
, O
11 O
% O
) O
and O
mean O
peak O
drug O
concentration O
( O
Cmax O
, O
18 O
% O
) O
of O
digoxin B-DRUG
with O
the O
co O
- O
administration O
of O
100 O
mg O
sitagliptin B-DRUG
for O
10 O
days O
. O
Patients O
receiving O
digoxin B-DRUG
should O
be O
monitored O
appropriately O
. O
No O
dosage O
adjustment O
of O
digoxin B-DRUG
or O
JANUVIA B-BRAND
is O
recommended O
. O

Interactions O
for O
Sodium B-DRUG
Tetradecyl I-DRUG
Sulfate I-DRUG
: O
No O
well O
- O
controlled O
studies O
have O
been O
performed O
on O
patients O
taking O
antiovulatory O
agents O
. O
The O
physician O
must O
use O
judgment O
and O
evaluate O
any O
patient O
taking O
antiovulatory O
drugs O
prior O
to O
initiating O
treatment O
with O
Sotradecol B-BRAND
. O
Heparin B-DRUG
should O
not O
be O
included O
in O
the O
same O
syringe O
as O
Sodium B-DRUG
Tetradecyl I-DRUG
Sulfate I-DRUG
, O
since O
the O
two O
are O
incompatible O
. O

Additives O
may O
be O
incompatible O
; O
norepinephrine B-DRUG
and O
dobutamine B-DRUG
are O
incompatible O
with O
sodium B-DRUG
bicarbonate I-DRUG
solution O
. O
The O
addition O
of O
sodium B-DRUG
bicarbonate I-DRUG
to O
parenteral O
solutions O
containing O
calcium B-DRUG
should O
be O
avoided O
, O
except O
where O
compatibility O
has O
been O
previously O
established O
. O
Precipitation O
or O
haze O
may O
result O
from O
sodium O
bicarbonate O
- O
calcium O
admixtures O
. O
NOTE O
: O
Do O
not O
use O
the O
injection O
if O
it O
contains O
precipitate O
. O
Additives O
may O
be O
incompatible O
. O
Consult O
with O
pharmacist O
, O
if O
available O
. O
When O
introducing O
additives O
, O
use O
aseptic O
technique O
, O
mix O
thoroughly O
and O
do O
not O
store O
. O

Do O
not O
exceed O
a O
5 O
mg O
daily O
dose O
of O
VESIcare B-BRAND
when O
administered O
with O
therapeutic O
doses O
of O
ketoconazole B-DRUG
or O
other O
potent O
CYP3A4 O
inhibitors O
. O
Patients O
with O
Congenital O
or O
Acquired O
QT O
Prolongation O
In O
a O
study O
of O
the O
effect O
of O
solifenacin B-DRUG
on O
the O
QT O
interval O
in O
76 O
healthy O
women O
, O
the O
QT O
prolonging O
effect O
appeared O
less O
with O
solifenacin B-DRUG
10 O
mg O
than O
with O
30 O
mg O
( O
three O
times O
the O
maximum O
recommended O
dose O
) O
, O
and O
the O
effect O
of O
solifenacin B-DRUG
30 O
mg O
did O
not O
appear O
as O
large O
as O
that O
of O
the O
positive O
control O
moxifloxacin B-DRUG
at O
its O
therapeutic O
dose O
. O
This O
observation O
should O
be O
considered O
in O
clinical O
decisions O
to O
prescribe O
VESIcare B-BRAND
for O
patients O
with O
a O
known O
history O
of O
QT O
prolongation O
or O
patients O
who O
are O
taking O
medications O
known O
to O
prolong O
the O
QT O
interval O
. O

Excessive O
glucocorticoid O
therapy O
will O
inhibit O
the O
growth O
- O
promoting O
effect O
of O
human B-DRUG
GH I-DRUG
. O
Patients O
with O
ACTH O
deficiency O
should O
have O
their O
glucocorticoid B-GROUP
- O
replacement O
dose O
carefully O
adjusted O
to O
avoid O
an O
inhibitory O
effect O
on O
growth O
. O
The O
use O
of O
Nutropin B-BRAND
in O
patients O
with O
chronic O
renal O
insufficiency O
receiving O
glucocorticoid O
therapy O
has O
not O
been O
evaluated O
. O
Concomitant O
glucocorticoid O
therapy O
may O
inhibit O
the O
growth O
- O
promoting O
effect O
of O
Nutropin B-BRAND
. O
If O
glucocorticoid B-GROUP
replacement O
is O
required O
, O
the O
glucocorticoid B-GROUP
dose O
should O
be O
carefully O
adjusted O
. O
There O
was O
no O
evidence O
in O
the O
controlled O
studies O
of O
Nutropin B-BRAND
s O
interaction O
with O
drugs O
commonly O
used O
in O
chronic O
renal O
insufficiency O
patients O
. O
Limited O
published O
data O
indicate O
that O
GH B-DRUG
treatment O
increases O
cytochrome O
P450 O
( O
CP450 O
) O
mediated O
antipyrine B-DRUG
clearance O
in O
man O
. O
These O
data O
suggest O
that O
GH B-DRUG
administration O
may O
alter O
the O
clearance O
of O
compounds O
known O
to O
be O
metabolized O
by O
CP450 O
liver O
enzymes O
( O
e O
. O
g O
. O
, O
corticosteroids B-GROUP
, O
sex B-GROUP
steroids I-GROUP
, O
anticonvulsants B-GROUP
, O
cyclosporin B-DRUG
) O
. O
Careful O
monitoring O
is O
advisable O
when O
GH B-DRUG
is O
administered O
in O
combination O
with O
other O
drugs O
known O
to O
be O
metabolized O
by O
CP450 O
liver O
enzymes O
. O

Caution O
is O
recommended O
when O
administering O
NEXAVAR B-BRAND
with O
compounds O
that O
are O
metabolized O
/ O
eliminated O
predominantly O
by O
the O
UGT1A1 O
pathway O
( O
e O
. O
g O
. O
irinotecan B-DRUG
) O
. O
Concomitant O
treatment O
with O
NEXAVAR B-BRAND
resulted O
in O
a O
21 O
% O
increase O
in O
the O
AUC O
of O
doxorubicin B-DRUG
. O
Caution O
is O
recommended O
when O
administering O
doxorubicin B-DRUG
with O
NEXAVAR B-BRAND
. O
Sorafenib B-DRUG
inhibits O
CYP2B6 O
and O
CYP2C8 O
in O
vitro O
with O
Ki O
values O
of O
6 O
and O
1 O
- O
2 O
? O
M O
, O
respectively O
. O
Systemic O
exposure O
to O
substrates O
of O
CYP2B6 O
and O
CYP2C8 O
is O
expected O
to O
increase O
when O
co O
- O
administered O
with O
NEXAVAR B-BRAND
. O
Caution O
is O
recommended O
when O
administering O
substrates O
of O
CYP2B6 O
and O
CYP2C8 O
with O
NEXAVAR B-BRAND
. O

Digoxin B-DRUG
: O
Sparfloxacin B-DRUG
has O
no O
effect O
on O
the O
pharmacokinetics O
of O
digoxin B-DRUG
. O
Methylxanthines B-GROUP
: O
Sparfloxacin B-DRUG
does O
not O
increase O
plasma O
theophylline B-DRUG
concentrations O
. O
Since O
there O
is O
no O
interaction O
with O
theophylline B-DRUG
, O
interaction O
with O
other O
methylxanthines B-GROUP
such O
as O
caffeine B-DRUG
is O
unlikely O
. O
Warfarin B-DRUG
: O
Sparfloxacin B-DRUG
does O
not O
increase O
the O
anti O
- O
coagulant O
effect O
of O
warfarin B-DRUG
. O
Cimetidine B-DRUG
: O
Cimetidine B-DRUG
does O
not O
affect O
the O
pharmacokinetics O
of O
sparfloxacin B-DRUG
. O
The O
oral O
bioavailability O
of O
sparfloxacin B-DRUG
is O
not O
reduced O
when O
the O
aluminum B-DRUG
- O
magnesium B-DRUG
suspension O
is O
administered O
4 O
hours O
following O
sparfloxacin O
administration O
. O
Zinc B-DRUG
/ O
iron B-DRUG
salts O
: O
Absorption O
of O
quinolones B-GROUP
is O
reduced O
significantly O
by O
these O
preparations O
. O
These O
products O
may O
be O
taken O
4 O
hours O
after O
sparfloxacin B-DRUG
administration O
. O
Probenecid B-DRUG
: O
Probenecid B-DRUG
does O
not O
alter O
the O
pharmacokinetics O
of O
sparfloxacin B-DRUG
. O

Zidovudine B-DRUG
competitively O
inhibits O
the O
intracellular O
phosphorylation O
of O
stavudine B-DRUG
. O
Therefore O
, O
use O
of O
zidovudine B-DRUG
in O
combination O
with O
ZERIT B-BRAND
should O
be O
avoided O
. O
In O
vitro O
data O
indicate O
that O
the O
phosphorylation O
of O
stavudine B-DRUG
is O
also O
inhibited O
at O
relevant O
concentrations O
by O
doxorubicin B-DRUG
and O
ribavirin B-DRUG
. O
The O
clinical O
significance O
of O
these O
in O
vitro O
interactions O
is O
unknown O
; O
therefore O
, O
concomitant O
use O
of O
stavudine B-DRUG
with O
either O
of O
these O
drugs O
should O
be O
undertaken O
with O
caution O
. O

The O
interaction O
of O
Streptase B-BRAND
, O
Streptokinase B-DRUG
, O
with O
other O
drugs O
has O
not O
been O
well O
studied O
. O
Use O
of O
Anticoagulants B-GROUP
and O
Antiplatelet B-GROUP
Agents I-GROUP
- O
- O
Streptase B-BRAND
, O
Streptokinase B-DRUG
, O
alone O
or O
in O
combination O
with O
antiplatelet B-GROUP
agents I-GROUP
and O
anticoagulants B-GROUP
, O
may O
cause O
bleeding O
complications O
. O
Therefore O
, O
careful O
monitoring O
is O
advised O
. O
In O
the O
treatment O
of O
acute O
MI O
, O
aspirin B-BRAND
, O
when O
not O
otherwise O
contraindicated O
, O
should O
be O
administered O
with O
Streptokinase B-DRUG
( O
see O
below O
) O
. O
Anticoagulation O
and O
Antiplatelets B-GROUP
After O
Treatment O
for O
Myocardial O
Infarction O
- O
- O
In O
the O
treatment O
of O
acute O
myocardial O
infarction O
, O
the O
use O
of O
aspirin B-BRAND
has O
been O
shown O
to O
reduce O
the O
incidence O
of O
reinfarction O
and O
stroke O
. O
The O
addition O
of O
aspirin B-BRAND
to O
Streptokinase B-DRUG
causes O
a O
minimal O
increase O
in O
the O
risk O
of O
minor O
bleeding O
( O
3 O
. O
9 O
% O
vs O
. O
3 O
. O
1 O
% O
) O
, O
but O
does O
not O
appear O
to O
increase O
the O
incidence O
of O
major O
bleeding O
( O
see O

ZANOSAR B-BRAND
may O
demonstrate O
additive O
toxicity O
when O
used O
in O
combination O
with O
other O
cytotoxic O
drugs O
. O
Streptozocin B-DRUG
has O
been O
reported O
to O
prolong O
the O
elimination O
half O
- O
life O
of O
doxorubicin B-DRUG
and O
may O
lead O
to O
severe O
bone O
marrow O
suppression O
; O
a O
reduction O
of O
the O
doxorubicin B-DRUG
dosage O
should O
be O
considered O
in O
patients O
receiving O
ZANOSAR B-BRAND
concurrently O
. O
The O
concurrent O
use O
of O
streptozocin B-DRUG
and O
phenytoin B-DRUG
has O
been O
reported O
in O
one O
case O
to O
result O
in O
reduced O
streptozocin B-DRUG
cytotoxicity O
. O

CHEMET B-BRAND
is O
not O
known O
to O
interact O
with O
other O
drugs O
including O
iron B-DRUG
supplements O
; O
interactions O
have O
not O
been O
systematically O
studied O
. O
Concomitant O
administration O
of O
CHEMET B-BRAND
with O
other O
chelation O
therapy O
, O
such O
as O
CaNa B-DRUG
2 I-DRUG
EDTA I-DRUG
is O
not O
recommended O
. O
Drug O
/ O
Laboratory O
Tests O
Interaction O
: O
Succimer B-DRUG
may O
interfere O
with O
serum O
and O
urinary O
laboratory O
tests O
. O
In O
vitro O
studies O
have O
shown O
succimer B-DRUG
to O
cause O
false O
positive O
results O
for O
ketones O
in O
urine O
using O
nitroprusside O
reagents O
such O
as O
Ketostix O
and O
falsely O
decreased O
measurements O
of O
serum O
uric O
acid O
and O
CPK O
. O

Sulfamethizole B-DRUG
may O
increase O
the O
effects O
of O
barbiturates B-GROUP
, O
tolbutamide B-DRUG
, O
and O
uricosurics B-GROUP
. O
It O
may O
also O
interact O
with O
thiazides B-GROUP
( O
increased O
thrombocytopenia O
) O
, O
cyclosporine B-DRUG
( O
increased O
nephrotoxicity O
) O
, O
sulfonylurea B-GROUP
agents I-GROUP
( O
increased O
hypoglycemic O
response O
) O
, O
warfarin B-DRUG
( O
increased O
anticoagulant O
effect O
) O
, O
methotrexate B-DRUG
( O
decreased O
renal O
excretion O
of O
methotrexate B-DRUG
) O
, O
phenytoin B-DRUG
( O
decreased O
hepatic O
clearance O
of O
phenytoin B-DRUG
) O
. O

In O
elderly O
patients O
concurrently O
receiving O
certain O
diuretics B-GROUP
, O
primarily O
thiazides B-GROUP
, O
an O
increased O
incidence O
of O
thrombopenia O
with O
purpura O
has O
been O
reported O
. O
It O
has O
been O
reported O
that O
sulfamethoxazole B-DRUG
may O
prolong O
the O
prothrombin O
time O
in O
patients O
who O
are O
receiving O
the O
anticoagulant B-GROUP
warfarin B-DRUG
. O
This O
interaction O
should O
be O
kept O
in O
mind O
when O
Gantanol B-BRAND
is O
given O
to O
patients O
already O
on O
anticoagulant O
therapy O
, O
and O
the O
coagulation O
time O
should O
be O
reassessed O
. O
Sulfamethoxazole B-DRUG
may O
inhibit O
the O
hepatic O
metabolism O
of O
phenytoin B-DRUG
. O
At O
a O
1 O
. O
6 O
- O
g O
dose O
, O
sulfamethoxazole B-DRUG
produced O
a O
slight O
but O
significant O
increase O
in O
the O
half O
- O
life O
of O
phenytoin B-DRUG
but O
did O
not O
produce O
a O
corresponding O
decrease O
in O
the O
metabolic O
clearance O
rate O
. O
When O
administering O
these O
drugs O
concurrently O
, O
one O
should O
be O
alert O
for O
possible O
excessive O
phenytoin B-DRUG
effect O
. O
Sulfonamides B-GROUP
can O
also O
displace O
methotrexate B-DRUG
from O
plasma O
protein O
- O
binding O
sites O
, O
thus O
increasing O
free O
methotrexate B-DRUG
concentrations O
. O
The O
presence O
of O
sulfamethoxazole B-DRUG
may O
interfere O
with O
the O
Jaff O
alkaline O
picrate O
reaction O
assay O
for O
creatinine O
, O
resulting O
in O
overestimations O
of O
about O
10 O
% O
in O
the O
range O
of O
normal O
values O
. O

This O
medicine O
is O
generally O
safe O
with O
other O
medications O
, O
but O
patient O
should O
consult O
doctor O
or O
pharmacist O
if O
patient O
is O
taking O
a O
blood O
thinner O
( O
anticoagulant B-GROUP
) O
, O
cyclosporin B-DRUG
, O
phenytoin B-DRUG
, O
or O
methotrexate B-DRUG
. O

Reduced O
absorption O
of O
folic B-DRUG
acid I-DRUG
and O
digoxin B-DRUG
have O
been O
reported O
when O
those O
agents O
were O
administered O
concomitantly O
with O
sulfasalazine B-DRUG
. O
When O
daily O
doses O
of O
sulfasalazine B-DRUG
2 O
g O
and O
weekly O
doses O
of O
methotrexate B-DRUG
7 O
. O
5 O
mg O
were O
coadministered O
to O
15 O
rheumatoid O
arthritis O
patients O
in O
a O
drug O
- O
drug O
interaction O
study O
, O
the O
pharmacokinetic O
disposition O
of O
the O
drugs O
was O
not O
altered O
. O
Daily O
doses O
of O
sulfasalazine B-DRUG
2 O
g O
( O
maximum O
3 O
g O
) O
and O
weekly O
doses O
of O
methotrexate B-DRUG
7 O
. O
5 O
mg O
( O
maximum O
15 O
mg O
) O
were O
administered O
alone O
or O
in O
combination O
to O
310 O
rheumatoid O
arthritis O
patients O
in O
two O
controlled O
52 O
- O
week O
clinical O
studies O
. O
The O
overall O
toxicity O
profile O
of O
the O
combination O
revealed O
an O
increased O
incidence O
of O
gastrointestinal O
adverse O
events O
, O
especially O
nausea O
, O
when O
compared O
to O
the O
incidence O
associated O
with O
either O
drug O
administered O
alone O
. O
Drug O
/ O
Laboratory O
Test O
Interactions O
: O
The O
presence O
of O
sulfasalazine B-DRUG
or O
its O
metabolites O
in O
body O
fluids O
has O
not O
been O
reported O
to O
interfere O
with O
laboratory O
test O
procedures O
. O
REFERENCES O
7 O
. O
Farr O
M O
, O
et O
al O
. O
Immunodeficiencies O
associated O
with O
sulphasalazine B-DRUG
therapy O
in O
inflammatory O
arthritis O
. O
British O
Jnl O
Rheum O
1991 O
; O
30 O
: O
413 O
- O
417 O
. O

Sulfoxone B-DRUG
may O
increase O
the O
effects O
of O
barbiturates B-GROUP
, O
tolbutamide B-DRUG
, O
and O
uricosurics B-GROUP
. O
It O
may O
also O
interact O
with O
thiazides B-GROUP
( O
increased O
thrombocytopenia O
) O
, O
cyclosporine B-DRUG
( O
increased O
nephrotoxicity O
) O
, O
sulfonylurea B-GROUP
agents I-GROUP
( O
increased O
hypoglycemic O
response O
) O
, O
warfarin B-DRUG
( O
increased O
anticoagulant O
effect O
) O
, O
methotrexate B-DRUG
( O
decreased O
renal O
excretion O
of O
methotrexate B-DRUG
) O
, O
phenytoin B-DRUG
( O
decreased O
hepatic O
clearance O
of O
phenytoin B-DRUG
) O
. O

Ergot B-GROUP
- O
containing O
drugs O
have O
been O
reported O
to O
cause O
prolonged O
vasospastic O
reactions O
. O
Because O
there O
is O
a O
theoretical O
basis O
that O
these O
effects O
may O
be O
additive O
, O
use O
of O
ergotamine B-DRUG
- O
containing O
or O
ergot B-GROUP
- I-GROUP
type I-GROUP
medications I-GROUP
( O
like O
dihydroergotamine B-DRUG
or O
methysergide B-DRUG
) O
and O
sumatriptan B-DRUG
within O
24 O
hours O
of O
each O
other O
should O
be O
avoided O
. O
MAO B-GROUP
- I-GROUP
A I-GROUP
inhibitors I-GROUP
reduce O
sumatriptan B-DRUG
clearance O
, O
significantly O
increasing O
systemic O
exposure O
. O
Therefore O
, O
the O
use O
of O
sumatriptan B-DRUG
succinate I-DRUG
tablets O
in O
patients O
receiving O
MAO B-GROUP
- I-GROUP
A I-GROUP
inhibitors I-GROUP
is O
contraindicated O
. O
Selective B-GROUP
serotonin I-GROUP
reuptake I-GROUP
inhibitors I-GROUP
( O
SSRIs B-GROUP
) O
( O
e O
. O
g O
. O
, O
fluoxetine B-DRUG
, O
fluvoxamine B-DRUG
, O
paroxetine B-DRUG
, O
sertraline B-DRUG
) O
have O
been O
reported O
, O
rarely O
, O
to O
cause O
weakness O
, O
hyperreflexia O
, O
and O
incoordination O
when O
coadministered O
with O
sumatriptan B-DRUG
. O
If O
concomitant O
treatment O
with O
sumatriptan B-DRUG
and O
an O
SSRI B-GROUP
is O
clinically O
warranted O
, O
appropriate O
observation O
of O
the O
patient O
is O
advised O
. O

Co O
- O
administration O
of O
SUTENT B-BRAND
with O
strong O
inhibitors O
of O
the O
CYP3A4 O
family O
( O
e O
. O
g O
. O
, O
ketoconazole B-DRUG
, O
itraconazole B-DRUG
, O
clarithromycin B-DRUG
, O
atazanavir B-DRUG
, O
indinavir B-DRUG
, O
nefazodone B-DRUG
, O
nelfinavir B-DRUG
, O
ritonavir B-DRUG
, O
saquinavir B-DRUG
, O
telithromycin B-DRUG
, O
voriconizole B-DRUG
) O
may O
increases O
sunitinib B-DRUG
concentrations O
. O
Grapefruit O
may O
also O
increase O
plasma O
concentrations O
of O
SUTENT B-BRAND
. O
Co O
- O
administration O
of O
SUTENT B-BRAND
with O
inducers O
of O
the O
CYP3A4 O
family O
( O
e O
. O
g O
. O
, O
dexamethasone B-DRUG
, O
phenytoin B-DRUG
, O
carbamazepine B-DRUG
, O
rifampin B-DRUG
, O
rifabutin B-DRUG
, O
rifapentin B-DRUG
, O
phenobarbital B-DRUG
, O
St O
. O
Johns O
Wort O
) O
may O
decrease O
sunitinib B-DRUG
concentrations O
. O
St O
. O
Johns O
Wort O
may O
decrease O
SUTENT B-BRAND
plasma O
concentrations O
unpredictably O
. O
Patients O
receiving O
SUTENT B-BRAND
should O
not O
take O
St O
. O
Johns O
Wort O
concomitantly O
. O
SUTENT B-BRAND
dose O
modification O
is O
recommended O
in O
patients O
using O
concomitant O
CYP3A4 O
inhibitors O
or O
inducers O
. O

Other O
eye O
drops O
or O
medications O
such O
as O
acetylcholine B-DRUG
chloride I-DRUG
( O
Miochol B-BRAND
) O
and O
carbachol B-DRUG
( O
Carboptic B-BRAND
, O
Isopto B-BRAND
Carbachol I-BRAND
) O
may O
decrease O
the O
effects O
of O
suprofen B-DRUG
ophthalmic O
. O

Formal O
topical O
drug O
interaction O
studies O
with O
PROTOPIC B-BRAND
Ointment O
have O
not O
been O
conducted O
. O
Based O
on O
its O
minimal O
extent O
of O
absorption O
, O
interactions O
of O
PROTOPIC B-BRAND
Ointment O
with O
systemically O
administered O
drugs O
are O
unlikely O
to O
occur O
but O
cannot O
be O
ruled O
out O
. O
The O
concomitant O
administration O
of O
known O
CYP3A4 O
inhibitors O
in O
patients O
with O
widespread O
and O
/ O
or O
erythrodermic O
disease O
should O
be O
done O
with O
caution O
. O
Some O
examples O
of O
such O
drugs O
are O
erythromycin B-DRUG
, O
itraconazole B-DRUG
, O
ketoconazole B-DRUG
, O
fluconazole B-DRUG
, O
calcium B-GROUP
channel I-GROUP
blockers I-GROUP
and O
cimetidine B-DRUG
. O

Drug O
- O
Drug O
Interactions O
: O
The O
pharmacokinetic O
and O
pharmacodynamic O
interactions O
between O
FLOMAX B-BRAND
capsules O
and O
other O
alpha B-GROUP
- I-GROUP
adrenergic I-GROUP
blocking I-GROUP
agents I-GROUP
have O
not O
been O
determined O
. O
However O
, O
interactions O
may O
be O
expected O
and O
FLOMAX B-BRAND
capsules O
should O
NOT O
be O
used O
in O
combination O
with O
other O
alpha B-GROUP
- I-GROUP
adrenergic I-GROUP
blocking I-GROUP
agents I-GROUP
. O
The O
pharmacokinetic O
interaction O
between O
cimetidine B-DRUG
and O
FLOMAX B-BRAND
capsules O
was O
investigated O
. O
The O
results O
indicate O
significant O
changes O
in O
tamsulosin B-DRUG
HCI I-DRUG
clearance O
( O
26 O
% O
decrease O
) O
and O
AUC O
( O
44 O
% O
increase O
) O
. O
Therefore O
, O
FLOMAX B-BRAND
capsules O
should O
be O
used O
with O
caution O
in O
combination O
with O
cimetidine B-DRUG
, O
particularly O
at O
doses O
higher O
than O
0 O
. O
4 O
mg O
. O
Results O
from O
limited O
in O
vitro O
and O
in O
vivo O
drug O
- O
drug O
interaction O
studies O
between O
tamsulosin B-DRUG
HCI I-DRUG
and O
warfarin B-DRUG
are O
inconclusive O
. O
Therefore O
, O
caution O
should O
be O
exercised O
with O
concomitant O
administration O
of O
warfarin B-DRUG
and O
FLOMAX B-BRAND
capsules O
. O

Telbivudine B-DRUG
is O
excreted O
mainly O
by O
passive O
diffusion O
so O
the O
potential O
for O
interactions O
between O
telbivudine B-DRUG
and O
other O
drugs O
eliminated O
by O
renal O
excretion O
is O
low O
. O
However O
, O
because O
telbivudine B-DRUG
is O
eliminated O
primarily O
by O
renal O
excretion O
, O
co O
administration O
of O
telbivudine B-DRUG
with O
drugs O
that O
alter O
renal O
function O
may O
alter O
plasma O
concentrations O
of O
telbivudine B-DRUG
. O

The O
pharmacokinetic O
profile O
of O
temazepam B-DRUG
does O
not O
appear O
to O
be O
altered O
by O
orally O
administered O
cimetidine B-DRUG
dosed O
according O
to O
labeling O
. O

Administration O
of O
valproic B-DRUG
acid I-DRUG
decreases O
oral O
clearance O
of O
temozolomide B-DRUG
by O
about O
5 O
% O
. O
The O
clinical O
implication O
of O
this O
effect O
is O
not O
known O
. O
Patients O
with O
Severe O
Hepatic O
or O
Renal O
Impairment O
Caution O
should O
be O
exercised O
when O
TEMODAR B-BRAND
Capsules O
are O
administered O
to O
patients O
with O
severe O
hepatic O
or O
renal O
impairment O
. O

Formal O
interaction O
studies O
of O
TNKase B-BRAND
with O
other O
drugs O
have O
not O
been O
performed O
. O
Patients O
studied O
in O
clinical O
trials O
of O
TNKase B-BRAND
were O
routinely O
treated O
with O
heparin B-DRUG
and O
aspirin B-BRAND
. O
Anticoagulants B-GROUP
( O
such O
as O
heparin B-DRUG
and O
vitamin B-GROUP
K I-GROUP
antagonists I-GROUP
) O
and O
drugs O
that O
alter O
platelet O
function O
( O
such O
as O
acetylsalicylic B-DRUG
acid I-DRUG
, O
dipyridamole B-DRUG
, O
and O
GP O
IIb O
/ O
IIIa O
inhibitors O
) O
may O
increase O
the O
risk O
of O
bleeding O
if O
administered O
prior O
to O
, O
during O
, O
or O
after O
TNKase B-BRAND
therapy O
. O
Drug O
/ O
Laboratory O
Test O
Interactions O
During O
TNKase B-BRAND
therapy O
, O
results O
of O
coagulation O
tests O
and O
/ O
or O
measures O
of O
fibrinolytic O
activity O
may O
be O
unreliable O
unless O
specific O
precautions O
are O
taken O
to O
prevent O
in O
vitro O
artifacts O
. O
Tenecteplase B-DRUG
is O
an O
enzyme O
that O
, O
when O
present O
in O
blood O
in O
pharmacologic O
concentrations O
, O
remains O
active O
under O
in O
vitro O
conditions O
. O
This O
can O
lead O
to O
degradation O
of O
fibrinogen O
in O
blood O
samples O
removed O
for O
analysis O
. O

In O
a O
study O
in O
which O
34 O
different O
drugs O
were O
tested O
, O
therapeutically O
relevant O
concentrations O
of O
tolbutamide B-DRUG
, O
sodium B-DRUG
salicylate I-DRUG
and O
sulfamethizole B-DRUG
displaced O
protein O
- O
bound O
teniposide B-DRUG
in O
fresh O
human O
serum O
to O
a O
small O
but O
significant O
extent O
. O
Because O
of O
the O
extremely O
high O
binding O
of O
teniposide B-DRUG
to O
plasma O
proteins O
, O
these O
small O
decreases O
in O
binding O
could O
cause O
substantial O
increases O
in O
free O
drug O
levels O
in O
plasma O
which O
could O
result O
in O
potentiation O
of O
drug O
toxicity O
. O
Therefore O
, O
caution O
should O
be O
used O
in O
administering O
VUMON B-BRAND
( O
teniposide B-DRUG
injection O
) O
to O
patients O
receiving O
these O
other O
agents O
. O
There O
was O
no O
change O
in O
the O
plasma O
kinetics O
of O
teniposide B-DRUG
when O
coadministered O
with O
methotrexate B-DRUG
. O
However O
, O
the O
plasma O
clearance O
of O
methotrexate B-DRUG
was O
slightly O
increased O
. O
An O
increase O
in O
intracellular O
levels O
of O
methotrexate B-DRUG
was O
observed O
in O
vitro O
in O
the O
presence O
of O
teniposide B-DRUG
. O

In O
vitro O
studies O
with O
human O
liver O
microsomes O
showed O
that O
terbinafine B-DRUG
does O
not O
inhibit O
the O
metabolism O
of O
tolbutamide B-DRUG
, O
ethinylestradiol B-DRUG
, O
ethoxycoumarin B-DRUG_N
, O
and O
cyclosporine B-DRUG
. O
In O
vitro O
studies O
have O
also O
shown O
that O
terbinafine B-DRUG
inhibits O
CYP2D6 O
- O
mediated O
metabolism O
. O
This O
may O
be O
of O
clinical O
relevance O
for O
compounds O
predominantly O
metabolized O
by O
this O
enzyme O
, O
such O
as O
tricyclic B-GROUP
antidepressants I-GROUP
, O
- O
blockers O
, O
selective B-GROUP
serotonin I-GROUP
reuptake I-GROUP
inhibitors I-GROUP
( O
SSRIs B-GROUP
) O
, O
and O
monoamine B-GROUP
oxidase I-GROUP
inhibitors I-GROUP
( I-GROUP
MAO I-GROUP
- I-GROUP
Is I-GROUP
) I-GROUP
Type I-GROUP
B I-GROUP
, O
if O
they O
have O
a O
narrow O
therapeutic O
window O
. O
In O
vivo O
drug O
- O
drug O
interaction O
studies O
conducted O
in O
normal O
volunteer O
subjects O
showed O
that O
terbinafine B-DRUG
does O
not O
affect O
the O
clearance O
of O
antipyrine B-DRUG
or O
digoxin B-DRUG
. O
Terbinafine B-DRUG
decreases O
the O
clearance O
of O
caffeine B-DRUG
by O
19 O
% O
. O
Terbinafine B-DRUG
increases O
the O
clearance O
of O
cyclosporine B-DRUG
by O
15 O
% O
. O
There O
have O
been O
spontaneous O
reports O
of O
increase O
or O
decrease O
in O
prothrombin O
times O
in O
patients O
concomitantly O
taking O
oral O
terbinafine B-DRUG
and O
warfarin B-DRUG
, O
however O
, O
a O
causal O
relationship O
between O
LAMISIL B-BRAND
Tablets O
and O
these O
changes O
has O
not O
been O
established O
. O
Terbinafine B-DRUG
clearance O
is O
increased O
100 O
% O
by O
rifampin B-DRUG
, O
a O
CyP450 O
enzyme O
inducer O
, O
and O
decreased O
33 O
% O
by O
cimetidine B-DRUG
, O
a O
CyP450 O
enzyme O
inhibitor O
. O
Terbinafine B-DRUG
clearance O
is O
unaffected O
by O
cyclosporine B-DRUG
. O
There O
is O
no O
information O
available O
from O
adequate O
drug O
- O
drug O
interaction O
studies O
with O
the O
following O
classes O
of O
drugs O
: O
oral O
contraceptives B-GROUP
, O
hormone O
replacement O
therapies O
, O
hypoglycemics B-GROUP
, O
theophyllines B-DRUG
, O
phenytoins B-DRUG
, O
thiazide B-GROUP
diuretics I-GROUP
, O
beta B-GROUP
blockers I-GROUP
, O
and O
calcium B-GROUP
channel I-GROUP
blockers I-GROUP
. O

TERAZOL B-BRAND
7 O
Vaginal O
Cream O
0 O
. O
4 O
% O
and O
TERAZOL B-BRAND
3 O
Vaginal O
Suppositories O
80 O
mg O
The O
therapeutic O
effect O
of O
these O
products O
is O
not O
affected O
by O
oral O
contraceptive B-GROUP
usage O
. O
TERAZOL B-BRAND
3 O
Vaginal O
Cream O
0 O
. O
8 O
% O
The O
levels O
of O
estradiol B-DRUG
( O
E2 O
) O
and O
progesterone B-DRUG
did O
not O
differ O
significantly O
when O
0 O
. O
8 O
% O
terconazole B-DRUG
vaginal O
cream O
was O
administered O
to O
healthy O
female O
volunteers O
established O
on O
a O
low O
dose O
oral O
contraceptive B-GROUP
. O

Ketoconazole B-DRUG
: O
Spontaneous O
adverse O
reaction O
reports O
of O
patients O
taking O
concomitant O
ketoconazole B-DRUG
with O
recommended O
doses O
of O
terfenadine B-DRUG
demonstrate O
QT O
interval O
prolongation O
and O
rare O
serious O
cardiac O
events O
, O
e O
. O
g O
. O
death O
, O
cardiac O
arrest O
, O
and O
ventricular O
arrhythmia O
including O
torsades O
de O
pointes O
. O
Pharmacokinetic O
data O
indicate O
that O
ketoconazole B-DRUG
markedly O
inhibits O
the O
metabolism O
of O
terfenadine B-DRUG
, O
resulting O
in O
elevated O
plasma O
terfenadine B-DRUG
levels O
. O
Presence O
of O
unchanged O
terfenadine B-DRUG
is O
associated O
with O
statistically O
significant O
prolongation O
of O
the O
QT O
and O
QTc O
intervals O
. O
Concomitant O
administration O
of O
ketoconazole B-DRUG
and O
terfenadine B-DRUG
is O
contraindicated O
. O
Itraconazole B-DRUG
: O
Torsades O
de O
pointes O
and O
elevated O
parent O
terfenadine B-DRUG
levels O
have O
been O
reported O
during O
concomitant O
use O
of O
terfenadine B-DRUG
and O
itraconazole B-DRUG
in O
clinical O
trials O
of O
itraconazole B-DRUG
and O
from O
foreign O
post O
- O
marketing O
sources O
. O
One O
death O
has O
also O
been O
reported O
from O
foreign O
post O
- O
marketing O
sources O
. O
Concomitant O
administration O
of O
itraconazole B-DRUG
and O
terfenadine B-DRUG
is O
contraindicated O
. O
Due O
to O
the O
chemical O
similarity O
of O
other O
azole B-GROUP
- I-GROUP
type I-GROUP
antifungal I-GROUP
agents I-GROUP
( O
including O
fluconazole B-DRUG
, O
metronidazole B-DRUG
, O
and O
miconazole B-DRUG
) O
to O
ketoconazole B-DRUG
, O
and O
itraconazole B-DRUG
, O
concomitant O
use O
of O
these O
products O
with O
terfenadine B-DRUG
is O
not O
recommended O
pending O
full O
examination O
of O
potential O
interactions O
. O
Macrolides B-GROUP
: O
Clinical O
drug O
interaction O
studies O
indicate O
that O
erythromycin B-DRUG
and O
clarithromycin B-DRUG
can O
exert O
an O
effect O
on O
terfenadine B-DRUG
metabolism O
by O
a O
mechanism O
which O
may O
be O
similar O
to O
that O
of O
ketoconazole B-DRUG
, O
but O
to O
a O
lesser O
extent O
. O
Although O
erythromycin O
measurably O
decreases O
the O
clearance O
of O
the O
terfenadine B-DRUG
acid O
metabolite O
, O
its O
influence O
on O
terfenadine O
plasma O
levels O
is O
still O
under O
investigation O
. O
A O
few O
spontaneous O
accounts O
of O
QT O
interval O
prolongation O
with O
ventricular O
arrhythmia O
including O
torsades O
de O
pointes O
, O
have O
been O
reported O
in O
patients O
receiving O
erythromycin B-DRUG
or O
troleandomycin B-DRUG
. O
Concomitant O
administration O
of O
terfenadine B-DRUG
with O
clarithromycin B-DRUG
, O
erythromycin B-DRUG
, O
or O
troleandomycin B-DRUG
is O
contraindicated O
: O
Pending O
full O
characterization O
of O
potential O
interactions O
, O

concomitant O
administration O
of O
terfenadine B-DRUG
with O
other O
macrolide B-GROUP
antibiotics I-GROUP
, O
including O
azithromycin B-DRUG
, O
is O
not O
recommended O
. O
Studies O
to O
evaluate O
potential O
interactions O
of O
terfenadine B-DRUG
with O
azithromycin B-DRUG
are O
in O
progress O
. O

When O
administered O
concurrently O
, O
testolactone B-DRUG
may O
increase O
the O
effects O
of O
oral O
anticoagulants B-GROUP
; O
monitor O
and O
adjust O
anticoagulant B-GROUP
dosage O
accordingly O
. O
Drug O
/ O
Laboratory O
Test O
Interactions O
: O
Physiologic O
effects O
of O
testolactone B-DRUG
may O
result O
in O
decreased O
estradiol O
concentrations O
with O
radioimmunoassays O
for O
estradiol O
, O
increased O
plasma O
calcium O
concentrations O
, O
and O
increased O
24 O
- O
hour O
urinary O
excretion O
of O
creatine O
and O
17 O
- O
ketosteroids O
. O

Interactions O
Interaction O
may O
occur O
with O
Antacids B-GROUP
, O
Calcium B-DRUG
supplements O
, O
Cholestyramine B-DRUG
, O
Choline B-DRUG
and I-DRUG
magnesium I-DRUG
salicylates I-DRUG
, O
Colestipol B-DRUG
, O
Iron B-DRUG
- O
containing O
drugs O
, O
Laxatives B-GROUP
, O
Magnesium B-DRUG
salicylate I-DRUG
: O
these O
drugs O
may O
decrease O
the O
potency O
of O
tetracyclines B-GROUP
. O
Oral O
contraceptives B-GROUP
containing O
estrogen B-DRUG
: O
tetracyclines B-GROUP
may O
decrease O
the O
contraceptive O
effect O
and O
increase O
the O
chance O
of O
unwanted O
pregnancy O
. O

Thalidomide B-DRUG
has O
been O
reported O
to O
enhance O
the O
sedative O
activity O
of O
barbiturates B-GROUP
, O
alcohol B-DRUG
, O
chlorpromazine B-DRUG
, O
and O
reserpine B-DRUG
. O
Peripheral O
Neuropathy O
: O
Medications O
known O
to O
be O
associated O
with O
peripheral O
neuropathy O
should O
be O
used O
with O
caution O
in O
patients O
receiving O
thalidomide B-DRUG
. O
Oral O
Contraceptives B-GROUP
: O
In O
10 O
healthy O
women O
, O
the O
pharmacokinetic O
profiles O
of O
norethindrone B-DRUG
and O
ethinyl B-DRUG
estradiol I-DRUG
following O
administration O
of O
a O
single O
dose O
containing O
1 O
. O
0 O
mg O
of O
norethindrone B-DRUG
acetate I-DRUG
and O
75 O
g O
of O
ethinyl B-DRUG
estradiol I-DRUG
were O
studied O
. O
The O
results O
were O
similar O
with O
and O
without O
coadministration O
of O
thalidomide B-DRUG
200 O
mg O
/ O
day O
to O
steady O
- O
state O
levels O
. O
Important O
Non O
- O
Thalidomide B-DRUG
Drug O
Interactions O
Drugs O
That O
Interfere O
with O
Hormonal B-GROUP
Contraceptives I-GROUP
: O
Concomitant O
use O
of O
HIV B-GROUP
- I-GROUP
protease I-GROUP
inhibitors I-GROUP
, O
griseofulvin B-DRUG
, O
modafinil B-DRUG
, O
penicillins B-GROUP
, O
rifampin B-DRUG
, O
rifabutin B-DRUG
, O
phenytoin B-DRUG
, O
carbamazepine B-DRUG
, O
or O
certain O
herbal O
supplements O
such O
as O
St O
. O
John B-DRUG_N
' I-DRUG_N
s I-DRUG_N
Wort I-DRUG_N
with O
hormonal B-GROUP
contraceptive I-GROUP
agents I-GROUP
may O
reduce O
the O
effectiveness O
of O
the O
contraception O
and O
up O
to O
one O
month O
after O
discontinuation O
of O
these O
concomitant O
therapies O
. O
Therefore O
, O
women O
requiring O
treatment O
with O
one O
or O
more O
of O
these O
drugs O
must O
use O
two O
OTHER O
effective O
or O
highly O
effective O
methods O
of O
contraception O
or O
abstain O
from O
heterosexual O
sexual O
contact O
while O
taking O
thalidomide B-DRUG
. O

Thiabendazole B-DRUG
may O
compete O
with O
other O
drugs O
, O
such O
as O
theophylline B-DRUG
, O
for O
sites O
of O
metabolism O
in O
the O
liver O
, O
thus O
elevating O
the O
serum O
levels O
of O
such O
compounds O
to O
potentially O
toxic O
levels O
. O
Therefore O
, O
when O
concomitant O
use O
of O
thiabendazole B-DRUG
and O
xanthine B-GROUP
derivatives I-GROUP
is O
anticipated O
, O
it O
may O
be O
necessary O
to O
monitor O
blood O
levels O
and O
/ O
or O
reduce O
the O
dosage O
of O
such O
compounds O
. O
Such O
concomitant O
use O
should O
be O
administered O
under O
careful O
medical O
supervision O
. O

Interactions O
for O
Vitamin B-DRUG
B1 I-DRUG
( O
Thiamine B-DRUG
) O
: O
Loop B-GROUP
Diuretics I-GROUP
, O
Oral O
Contraceptives B-GROUP
, O
Stavudine B-DRUG
, O
Tricyclic B-GROUP
Antidepressants I-GROUP

Phenothiazines B-GROUP
are O
capable O
of O
potentiating O
CNS B-GROUP
depressants I-GROUP
( O
e O
. O
g O
. O
, O
barbiturates B-GROUP
, O
anesthetics B-GROUP
, O
opiates B-GROUP
, O
alcohol B-DRUG
, O
etc O
. O
) O
as O
well O
as O
atropine B-DRUG
and O
phosphorous B-DRUG_N
insecticides I-DRUG_N
. O

There O
is O
usually O
complete O
cross O
- O
resistance O
between O
PURINETHOL B-BRAND
( O
mercaptopurine B-DRUG
) O
and O
TABLOID B-BRAND
brand O
Thioguanine B-DRUG
. O
As O
there O
is O
in O
vitro O
evidence O
that O
aminosalicylate B-GROUP
derivatives I-GROUP
( O
e O
. O
g O
. O
, O
olsalazine B-DRUG
, O
mesalazine B-DRUG
, O
or O
sulphasalazine B-DRUG
) O
inhibit O
the O
TPMT O
enzyme O
, O
they O
should O
be O
administered O
with O
caution O
to O
patients O
receiving O
concurrent O
thioguanine B-DRUG
therapy O
. O

Interactions O
between O
ZADAXIN B-BRAND
and O
other O
drugs O
have O
not O
been O
fully O
evaluated O
. O
Caution O
should O
be O
exercised O
when O
administering O
ZADAXIN B-BRAND
therapy O
in O
combination O
with O
other O
immunomodulating B-GROUP
drugs I-GROUP
. O
ZADAXIN B-BRAND
should O
not O
be O
mixed O
with O
any O
other O
drug O
. O

Prothrombin O
time O
or O
other O
suitable O
anticoagulation O
test O
should O
be O
monitored O
if O
tigecycline B-DRUG
is O
administered O
with O
warfarin B-DRUG
. O
Concurrent O
use O
of O
antibacterial B-GROUP
drugs I-GROUP
with O
oral O
contraceptives B-GROUP
may O
render O
oral O
contraceptives B-GROUP
less O
effective O
. O
Drug O
/ O
Laboratory O
Test O
Interactions O
There O
are O
no O
reported O
drug O
- O
laboratory O
test O
interactions O
. O

The O
bioavailability O
of O
SKELID B-BRAND
is O
decreased O
80 O
% O
by O
calcium B-DRUG
, O
when O
calcium B-DRUG
and O
SKELID B-BRAND
are O
administered O
at O
the O
same O
time O
, O
and O
60 O
% O
by O
some O
aluminum B-DRUG
- O
or O
magnesium B-DRUG
- O
containing O
antacids B-DRUG
, O
when O
administered O
1 O
hour O
before O
SKELID B-BRAND
. O
Aspirin B-BRAND
may O
decrease O
bioavailability O
of O
SKELID B-BRAND
by O
up O
to O
50 O
% O
when O
taken O
2 O
hours O
after O
SKELID B-BRAND
. O
The O
bioavailability O
of O
SKELID B-BRAND
is O
increased O
2 O
- O
4 O
fold O
by O
indomethacin B-DRUG
but O
is O
not O
significantly O
altered O
by O
coadministration O
of O
diclofenac B-DRUG
. O
The O
pharmacokinetic O
parameters O
of O
digoxin B-DRUG
are O
not O
significantly O
modified O
by O
SKELID B-BRAND
coadministration O
. O
In O
vitro O
studies O
show O
that O
tiludronate B-DRUG
does O
not O
displace O
warfarin B-DRUG
from O
its O
binding O
site O
on O
protein O
. O

SPIRIVA B-BRAND
has O
been O
used O
concomitantly O
with O
other O
drugs O
commonly O
used O
in O
COPD O
without O
increases O
in O
adverse O
drug O
reactions O
. O
These O
include O
sympathomimetic B-GROUP
bronchodilators I-GROUP
, O
methylxanthines B-GROUP
, O
and O
oral O
and O
inhaled O
steroids B-GROUP
. O
However O
, O
the O
co O
administration O
of O
SPIRIVA B-BRAND
with O
other O
anticholinergic B-GROUP
containing O
drugs O
( O
e O
. O
g O
. O
, O
ipratropium B-DRUG
) O
has O
not O
been O
studied O
and O
is O
therefore O
not O
recommended O
. O

AGGRASTAT B-BRAND
has O
been O
studied O
on O
a O
background O
of O
aspirin B-BRAND
and O
heparin B-DRUG
. O
The O
use O
of O
AGGRASTAT B-BRAND
, O
in O
combination O
with O
heparin B-DRUG
and O
aspirin B-BRAND
, O
has O
been O
associated O
with O
an O
increase O
in O
bleeding O
compared O
to O
heparin B-DRUG
and O
aspirin B-DRUG
alone O
( O
see O

In O
clinical O
studies O
of O
TOBI B-BRAND
, O
patients O
taking O
TOBI B-BRAND
concomitantly O
with O
dornase B-DRUG
alfa I-DRUG
( O
PULMOZYME B-BRAND
, O
Genentech O
) O
, O
( B-GROUP
beta I-GROUP
) I-GROUP
- I-GROUP
agonists I-GROUP
, O
inhaled O
corticosteroids B-GROUP
, O
other O
anti B-GROUP
- I-GROUP
pseudomonal I-GROUP
antibiotics I-GROUP
, O
or O
parenteral O
aminoglycosides B-GROUP
demonstrated O
adverse O
experience O
profiles O
similar O
to O
the O
study O
population O
as O
a O
whole O
. O
Concurrent O
and O
/ O
or O
sequential O
use O
of O
TOBI B-BRAND
with O
other O
drugs O
with O
neurotoxic O
or O
ototoxic O
potential O
should O
be O
avoided O
. O
Some O
diuretics B-GROUP
can O
enhance O
aminoglycoside B-GROUP
toxicity O
by O
altering O
antibiotic B-GROUP
concentrations O
in O
serum O
and O
tissue O
. O
TOBI B-BRAND
should O
not O
be O
administered O
concomitantly O
with O
ethacrynic B-DRUG
acid I-DRUG
, O
furosemide B-DRUG
, O
urea B-DRUG
, O
or O
mannitol B-DRUG
. O

The O
in O
vitro O
binding O
of O
warfarin B-DRUG
to O
human O
plasma O
proteins O
is O
unaffected O
by O
tolmetin B-DRUG
, O
and O
tolmetin B-DRUG
does O
not O
alter O
the O
prothrombin O
time O
of O
normal O
volunteers O
. O
However O
, O
increased O
prothrombin O
time O
and O
bleeding O
have O
been O
reported O
in O
patients O
on O
concomitant O
TOLECTIN B-BRAND
and O
warfarin B-DRUG
therapy O
. O
Therefore O
, O
caution O
should O
be O
exercised O
when O
administering O
TOLECTIN B-BRAND
to O
patients O
on O
anticoagulants B-GROUP
. O
In O
adult O
diabetic O
patients O
under O
treatment O
with O
either O
sulfonylureas B-GROUP
or O
insulin B-DRUG
there O
is O
no O
change O
in O
the O
clinical O
effects O
of O
either O
TOLECTIN B-BRAND
or O
the O
hypoglycemic B-GROUP
agents I-GROUP
. O
Caution O
should O
be O
used O
if O
TOLECTIN B-BRAND
is O
administered O
concomitantly O
with O
methotrexate B-DRUG
. O
TOLECTIN B-BRAND
and O
other O
nonsteroidal B-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
drugs I-GROUP
have O
been O
reported O
to O
reduce O
the O
tubular O
secretion O
of O
methotrexate B-DRUG
in O
an O
animal O
model O
, O
possibly O
enhancing O
the O
toxicity O
of O
methotrexate B-DRUG
. O
Laboratory O
Tests O
Because O
serious O
GI O
tract O
ulceration O
and O
bleeding O
can O
occur O
without O
warning O
symptoms O
, O
physicians O
should O
follow O
chronically O
treated O
patients O
for O
the O
signs O
and O
symptoms O
of O
ulceration O
and O
bleeding O
and O
should O
inform O
them O
of O
the O
importance O
of O
this O
follow O
- O
up O
. O

CYP3A4 O
Inhibitors O
: O
Ketoconazole B-DRUG
, O
an O
inhibitor O
of O
the O
drug O
metabolizing O
enzyme O
CYP3A4 O
, O
significantly O
increased O
plasma O
concentrations O
of O
tolterodine B-DRUG
when O
coadministered O
to O
subjects O
who O
were O
poor O
metabolizers O
( O
see O
CLINICAL O
PHARMACOLOGY O
, O
Variability O
in O
Metabolism O
and O
Drug O
- O
Drug O
Interactions O
) O
. O
For O
patients O
receiving O
ketoconazole B-DRUG
or O
other O
potent O
CYP3A4 O
inhibitors O
such O
as O
other O
azole B-GROUP
antifungals I-GROUP
( O
eg O
, O
itraconazole B-DRUG
, O
miconazole B-DRUG
) O
or O
macrolide B-GROUP
antibiotics I-GROUP
( O
eg O
, O
erythromycin B-DRUG
, O
clarithromycin B-DRUG
) O
or O
cyclosporine B-DRUG
or O
vinblastine B-DRUG
, O
the O
recommended O
dose O
of O
DETROL B-BRAND
LA I-BRAND
is O
2 O
mg O
daily O
. O
Drug O
- O
Laboratory O
- O
Test O
Interactions O
Interactions O
between O
tolterodine B-DRUG
and O
laboratory O
tests O
have O
not O
been O
studied O
. O

No O
formal O
drug O
interaction O
studies O
have O
been O
performed O
. O
Due O
to O
the O
frequent O
occurrence O
of O
severe O
and O
prolonged O
thrombocytopenia O
, O
the O
potential O
benefits O
of O
medications O
that O
interfere O
with O
platelet O
function O
and O
/ O
or O
anticoagulation O
should O
be O
weighed O
against O
the O
potential O
increased O
risk O
of O
bleeding O
and O
hemorrhage O
. O
Drug O
/ O
Laboratory O
Test O
Interactions O
Administration O
of O
the O
BEXXAR B-BRAND
therapeutic O
regimen O
may O
result O
in O
the O
development O
of O
human O
anti O
- O
murine O
antibodies O
( O
HAMA O
) O
. O
The O
presence O
of O
HAMA O
may O
affect O
the O
accuracy O
of O
the O
results O
of O
in O
vitro O
and O
in O
vivo O
diagnostic O
tests O
and O
may O
affect O
the O
toxicity O
profile O
and O
efficacy O
of O
therapeutic O
agents O
that O
rely O
on O
murine O
antibody O
technology O
. O
Patients O
who O
are O
HAMA O
positive O
may O
be O
at O
increased O
risk O
for O
serious O
allergic O
reactions O
and O
other O
side O
effects O
if O
they O
undergo O
in O
vivo O
diagnostic O
testing O
or O
treatment O
with O
murine B-GROUP
monoclonal I-GROUP
antibodies I-GROUP
. O

There O
have O
been O
no O
formal O
drug O
interaction O
studies O
performed O
with O
HERCEPTIN B-BRAND
in O
humans O
. O
Administration O
of O
paclitaxel B-DRUG
in O
combination O
with O
HERCEPTIN B-BRAND
resulted O
in O
a O
two O
- O
fold O
decrease O
in O
HERCEPTIN B-BRAND
clearance O
in O
a O
non O
- O
human O
primate O
study O
and O
in O
a O
1 O
. O
5 O
- O
fold O
increase O
in O
HERCEPTIN B-BRAND
serum O
levels O
in O
clinical O
studies O
. O

Trilostane B-DRUG
may O
interact O
with O
aminoglutethimide B-DRUG
or O
mitotane B-DRUG
( O
causing O
too O
great O
a O
decrease O
in O
adrenal O
function O
) O
. O

Trimethoprim B-DRUG
may O
inhibit O
the O
hepatic O
metabolism O
of O
phenytoin B-DRUG
. O
Trimethoprim B-DRUG
, O
given O
at O
a O
common O
clinical O
dosage O
, O
increased O
the O
phenytoin B-DRUG
half O
- O
life O
by O
51 O
% O
and O
decreased O
the O
phenytoin B-DRUG
metabolic O
clearance O
rate O
by O
30 O
% O
. O
When O
administering O
these O
drugs O
concurrently O
, O
one O
should O
be O
alert O
for O
possible O
excessive O
phenytoin B-DRUG
effect O
. O

Since O
trimetrexate B-DRUG
is O
metabolized O
by O
a O
P450 O
enzyme O
system O
, O
drugs O
that O
induce O
or O
inhibit O
this O
drug O
metabolizing O
enzyme O
system O
may O
elicit O
important O
drug O
- O
drug O
interactions O
that O
may O
alter O
trimetrexate B-DRUG
plasma O
concentrations O
. O
Agents O
that O
might O
be O
coadministered O
with O
trimetrexate B-DRUG
in O
AIDS O
patients O
for O
other O
indications O
that O
could O
elicit O
this O
activity O
include O
erythromycin B-DRUG
, O
rifampin B-DRUG
, O
rifabutin B-DRUG
, O
ketoconazole B-DRUG
, O
and O
fluconazole B-DRUG
. O
In O
vitro O
perfusion O
of O
isolated O
rat O
liver O
has O
shown O
that O
cimetidine B-DRUG
caused O
a O
significant O
reduction O
in O
trimetrexate B-DRUG
metabolism O
and O
that O
acetaminophen B-DRUG
altered O
the O
relative O
concentration O
of O
trimetrexate O
metabolites O
possibly O
by O
competing O
for O
sulfate O
metabolites O
. O
Based O
on O
an O
in O
vitro O
rat O
liver O
model O
, O
nitrogen O
substituted O
imidazole B-GROUP
drugs I-GROUP
( O
clotrimazole B-DRUG
, O
ketoconazole B-DRUG
, O
miconazole B-DRUG
) O
were O
potent O
, O
non O
- O
competitive O
inhibitors O
of O
trimetrexate B-DRUG
metabolism O
. O
Patients O
medicated O
with O
these O
drugs O
and O
trimetrexate B-DRUG
should O
be O
carefully O
monitored O
. O

Triprolidine B-DRUG
may O
enhance O
the O
sedative O
effects O
of O
central B-GROUP
nervous I-GROUP
system I-GROUP
depressants I-GROUP
including O
alcohol B-DRUG
, O
barbiturates B-GROUP
, O
hypnotics B-GROUP
, O
narcotic B-GROUP
analgesics I-GROUP
, O
sedatives B-GROUP
, O
and O
tranquillisers B-GROUP
. O
The O
effects O
of O
anticholinergic B-GROUP
drugs I-GROUP
, O
such O
as O
atropine B-DRUG
and O
tricyclic B-GROUP
antidepressants I-GROUP
may O
be O
enhanced O
by O
the O
concomitant O
administration O
of O
triprolidine B-DRUG
. O
Triprolidine B-DRUG
may O
effect O
the O
metabolism O
of O
drugs O
in O
the O
liver O
. O

The O
concomitant O
use O
of O
Sanctura B-BRAND
with O
other O
anticholinergic B-GROUP
agents I-GROUP
that O
produce O
dry O
mouth O
, O
constipation O
, O
and O
other O
anticholinergic O
pharmacological O
effects O
may O
increase O
the O
frequency O
and O
/ O
or O
severity O
of O
such O
effects O
. O
Anticholinergic B-GROUP
agents I-GROUP
may O
potentially O
alter O
the O
absorption O
of O
some O
concomitantly O
administered O
drugs O
due O
to O
anticholinergic O
effects O
on O
gastrointestinal O
motility O
. O
Drugs O
Eliminated O
by O
Active O
Tubular O
Secretion O
: O
Although O
studies O
to O
assess O
drug O
- O
drug O
interactions O
with O
Sanctura B-BRAND
have O
not O
been O
conducted O
, O
Sanctura B-BRAND
has O
the O
potential O
for O
pharmacokinetic O
interactions O
with O
other O
drugs O
that O
are O
eliminated O
by O
active O
tubular O
secretion O
( O
e O
. O
g O
. O
digoxin B-DRUG
, O
procainamide B-DRUG
, O
pancuronium B-DRUG
, O
morphine B-DRUG
, O
vancomycin B-DRUG
, O
metformin B-DRUG
and O
tenofovir B-DRUG
) O
. O
Coadministration O
of O
Sanctura B-BRAND
with O
drugs O
that O
are O
eliminated O
by O
active O
renal O
tubular O
secretion O
may O
increase O
the O
serum O
concentration O
of O
Sanctura B-BRAND
and O
/ O
or O
the O
coadministered O
drug O
due O
to O
competition O
for O
this O
elimination O
pathway O
. O
Careful O
patient O
monitoring O
is O
recommended O
in O
patients O
receiving O
such O
drugs O
. O
Drug O
- O
Laboratory O
- O
Test O
Interactions O
Interactions O
between O
Sanctura B-BRAND
and O
laboratory O
tests O
have O
not O
been O
studied O
. O

Because O
systemic O
exposure O
to O
Valstar B-BRAND
is O
negligible O
following O
intravesical O
administration O
, O
the O
potential O
for O
drug O
interactions O
is O
low O
. O
No O
drug O
interaction O
studies O
were O
conducted O
. O

Concomitant O
administration O
of O
vancomycin B-DRUG
and O
anesthetic B-GROUP
agents I-GROUP
has O
been O
associated O
with O
erythema O
and O
histamine O
- O
like O
flushing O
and O
anaphylactoid O
reactions O
. O
Concurrent O
and O
/ O
or O
sequential O
systemic O
or O
topical O
use O
of O
other O
potentially O
neurotoxic O
and O
/ O
or O
nephrotoxic O
drugs O
, O
such O
as O
amphotericin B-DRUG
B I-DRUG
, O
aminoglycosides B-GROUP
, O
bacitracin B-DRUG
, O
polymyxin B-DRUG
B I-DRUG
, O
colistin B-DRUG
, O
viomycin B-DRUG
, O
or O
cisplatin B-DRUG
, O
when O
indicated O
, O
requires O
careful O
monitoring O
. O

A O
study O
published O
in O
2002 O
found O
that O
vigabatrin B-DRUG
causes O
a O
statistically O
significant O
increase O
in O
plasma O
clearance O
of O
carbamazepine B-DRUG
. O
In O
1984 O
, O
Drs O
Rimmer O
and O
Richens O
at O
the O
University O
of O
Wales O
reported O
that O
administering O
vigabatrin B-DRUG
with O
phenytoin B-DRUG
lowered O
the O
serum O
phenytoin B-DRUG
concentration O
in O
patients O
with O
treatment O
- O
resistant O
epilepsy O
. O
The O
concentration O
of O
phenytoin B-DRUG
falls O
to O
23 O
% O
within O
five O
weeks O
, O
according O
to O
an O
experiment O
published O
in O
1989 O
by O
the O
same O
two O
scientists O
that O
tried O
and O
failed O
to O
elucidate O
the O
mechanism O
behind O
this O
interaction O
. O

Dosage O
adjustment O
should O
be O
based O
on O
serial O
blood O
level O
monitoring O
. O
The O
contribution O
of O
vincristine B-DRUG
sulfate I-DRUG
to O
this O
interaction O
is O
not O
certain O
. O
The O
interaction O
may O
result O
from O
reduced O
absorption O
of O
phenytoin B-DRUG
and O
an O
increase O
in O
the O
rate O
of O
its O
metabolism O
and O
elimination O
. O

Vindesine B-DRUG
can O
interact O
with O
the O
drugs O
of O
the O
following O
categories O
: O
- O
Blood O
dyscrasia O
: O
can O
cause O
unpredictable O
myelotoxicity O
- O
Bone O
marrow O
depressants O
: O
can O
cause O
a O
predictable O
dose O
- O
related O
myelotoxicity O
- O
Radiation O
therapy O
: O
may O
cause O
marrow O
depression O
- O
Neurotoxic O
medications O
: O
can O
cause O
neurologic O
toxicity O
- O
Phenytoin B-DRUG
: O
can O
increase O
seizure O
activity O
- O
Live B-GROUP
virus I-GROUP
vaccines I-GROUP
: O
may O
potentiate O
the O
replication O
of O
the O
vaccine B-DRUG
virus O
, O
may O
increase O
the O
side O
effects O
of O
the O
vaccination O
, O
and O
decrease O
patient O
' O
s O
response O
to O
the O
vaccine O
- O
Mitomycin B-DRUG
- I-DRUG
C I-DRUG
: O
may O
cause O
shortness O
of O
breath O
and O
bronchospasm O
- O
Killed B-GROUP
virus I-GROUP
vaccines I-GROUP
: O
may O
decrease O
patient O
' O
s O
response O
to O
the O
vaccine B-GROUP

Drug O
Interactions O
: O
Women O
on O
oral O
contraceptives B-GROUP
have O
shown O
a O
significant O
increase O
in O
plasma O
vitamin B-GROUP
A I-GROUP
levels O
. O

Limited O
evidence O
suggests O
that O
ascorbic B-DRUG
acid I-DRUG
may O
influence O
the O
intensity O
and O
duration O
of O
action O
of O
bishydroxycoumarin B-DRUG
. O

- O
Increased O
action O
of O
oral O
anticoagulants B-GROUP
. O
- O
Decreased O
absorption O
of O
colestipol B-DRUG
, O
cholestyramine B-DRUG
, O
mineral B-DRUG
oil I-DRUG
, O
and O
sucralfate B-DRUG
. O

Coumarin B-GROUP
- I-GROUP
Derivative I-GROUP
Anticoagulants I-GROUP
: O
Prolongation O
of O
prothrombin O
time O
( O
PT O
) O
and O
International O
Normalized O
Ratio O
( O
INR O
) O
were O
observed O
in O
patients O
receiving O
ZOLINZA B-BRAND
concomitantly O
with O
coumarin B-GROUP
- I-GROUP
derivative I-GROUP
anticoagulants I-GROUP
. O
Physicians O
should O
carefully O
monitor O
PT O
and O
INR O
in O
patients O
concurrently O
administered O
ZOLINZA B-BRAND
and O
coumarin B-GROUP
derivatives I-GROUP
. O
Other O
HDAC B-GROUP
Inhibitors I-GROUP
Severe O
thrombocytopenia O
and O
gastrointestinal O
bleeding O
have O
been O
reported O
with O
concomitant O
use O
of O
ZOLINZA B-BRAND
and O
other O
HDAC B-GROUP
inhibitors I-GROUP
( O
e O
. O
g O
. O
, O
valproic B-DRUG
acid I-DRUG
) O
. O
Monitor O
platelet O
count O
every O
2 O
weeks O
for O
the O
first O
2 O
months O
. O

